



## Clinical trial results:

### A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis

#### Summary

|                          |                                  |
|--------------------------|----------------------------------|
| EudraCT number           | 2014-005606-38                   |
| Trial protocol           | DE HU AT CZ DK NL SK BE BG PL IT |
| Global end of trial date | 30 November 2021                 |

#### Results information

|                                |  |
|--------------------------------|--|
| Result version number          | v2 (current)   |
| This version publication date  | 09 February 2023   |
| First version publication date | 16 December 2022   |
| Version creation reason        | <ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Changes done in Subject Disposition, Endpoints and Adverse Event Sections. |

#### Trial information

##### Trial identification

|                       |                 |
|-----------------------|-----------------|
| Sponsor protocol code | CNT01275UCO3001 |
|-----------------------|-----------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT02407236 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Janssen Research & Development, LLC  |
| Sponsor organisation address | 920 US Highway 202, Raritan, NJ, United States, 08869-1420                                 |
| Public contact               | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |
| Scientific contact           | Clinical Registry Group, Janssen Research & Development, LLC, ClinicalTrialsEU@its.jnj.com |

Notes:

#### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                  |
|--|------------------|
| Analysis stage                                       | Final            |
| Date of interim/final analysis                       | 30 November 2021 |
| Is this the analysis of the primary completion data? | No               |
| Global end of trial reached?                         | Yes              |
| Global end of trial date                             | 30 November 2021 |
| Was the trial ended prematurely?                     | Yes              |

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to evaluate the efficacy and safety of ustekinumab as intravenous (IV: into the vein) infusion in induction study in subjects with moderately to severely active Ulcerative Colitis (UC) and as subcutaneous (SC) administration in maintenance study in subjects with moderately to severely active Ulcerative Colitis (UC) who have demonstrated a clinical response to Induction treatment with IV ustekinumab.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

|   |              |
|---|--------------|
| Actual start date of recruitment                          | 10 July 2015 |
| Long term follow-up planned                               | No           |
| Independent data monitoring committee (IDMC) involvement? | Yes          |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Australia: 26          |
| Country: Number of subjects enrolled | Austria: 4             |
| Country: Number of subjects enrolled | Belgium: 39            |
| Country: Number of subjects enrolled | Bulgaria: 21           |
| Country: Number of subjects enrolled | Canada: 16             |
| Country: Number of subjects enrolled | Czechia: 30            |
| Country: Number of subjects enrolled | Germany: 45            |
| Country: Number of subjects enrolled | Denmark: 2             |
| Country: Number of subjects enrolled | France: 54             |
| Country: Number of subjects enrolled | United Kingdom: 21     |
| Country: Number of subjects enrolled | Hungary: 39            |
| Country: Number of subjects enrolled | Israel: 6              |
| Country: Number of subjects enrolled | Italy: 33              |
| Country: Number of subjects enrolled | Japan: 107             |
| Country: Number of subjects enrolled | Korea, Republic of: 26 |
| Country: Number of subjects enrolled | Netherlands: 16        |
| Country: Number of subjects enrolled | New Zealand: 19        |
| Country: Number of subjects enrolled | Poland: 71             |

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Romania: 24            |
| Country: Number of subjects enrolled | Russian Federation: 74 |
| Country: Number of subjects enrolled | Serbia: 10             |
| Country: Number of subjects enrolled | Slovakia: 10           |
| Country: Number of subjects enrolled | Ukraine: 89            |
| Country: Number of subjects enrolled | United States: 179     |
| Worldwide total number of subjects   | 961                    |
| EEA total number of subjects         | 388                    |

Notes:

---

### Subjects enrolled per age group

|   |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 910 |
| From 65 to 84 years                       | 51  |
| 85 years and over                         | 0   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 961 subjects enrolled in the Induction study. Out of 961 subjects, 783 subjects were further enrolled in the Maintenance study, out of which 588 subjects further entered the Long-term extension study.

### Period 1

|                              |                           |
|------------------------------|---------------------------|
| Period 1 title               | Induction Study (8 weeks) |
| Is this the baseline period? | Yes                       |
| Allocation method            | Randomised - controlled   |
| Blinding used                | Double blind              |
| Roles blinded                | Subject, Investigator     |

### Arms

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| <b>Arm title</b>             | Induction Study(IS): Placebo Intravenous (IV) |

Arm description:

Subjects received single dose of placebo as intravenous (IV) infusion at Week 0. Participants with clinical response at Week (W) 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received weight-range based dose of ustekinumab approximating 6 mg/kg IV + placebo SC at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|  |                 |
|--|-----------------|
| Arm type                               | Placebo         |
| Investigational medicinal product name | Placebo         |
| Investigational medicinal product code |                 |
| Other name                             |                 |
| Pharmaceutical forms                   | Injection       |
| Routes of administration               | Intravenous use |

Dosage and administration details:

Placebo was administered as an IV infusion.

|                  |                                       |
|------------------|---------------------------------------|
| <b>Arm title</b> | IS: Ustekinumab 130 milligram (mg) IV |
|------------------|---------------------------------------|

Arm description:

Subjects received single dose of ustekinumab 130 mg as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|  |                    |
|--|--------------------|
| Arm type                               | Experimental       |
| Investigational medicinal product name | Ustekinumab 130 mg |
| Investigational medicinal product code |                    |
| Other name                             |                    |
| Pharmaceutical forms                   | Injection          |
| Routes of administration               | Intravenous use    |

Dosage and administration details:

Ustekinumab 130 mg was administered as an IV infusion.

|                  |   |
|------------------|---|
| <b>Arm title</b> | IS: Ustekinumab approximately 6mg/kg IV |
|------------------|---|

**Arm description:**

Subjects received weight-range based dose of ustekinumab approximating 6 milligram per kilogram (mg/kg) (ustekinumab 260 mg [body weight ≤55 kg], 390 mg [body weight >55 kg ≤85 kg] and 520 mg [body weight >85 kg]), as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|  |                     |
|--|---------------------|
| Arm type                               | Experimental        |
| Investigational medicinal product name | Ustekinumab 6 mg/kg |
| Investigational medicinal product code |                     |
| Other name                             |                     |
| Pharmaceutical forms                   | Injection           |
| Routes of administration               | Intravenous use     |

**Dosage and administration details:**

Ustekinumab 6 mg/kg was administered as an IV infusion.

| <b>Number of subjects in period 1</b> | Induction Study(IS):<br>Placebo Intravenous<br>(IV) | IS: Ustekinumab<br>130 milligram (mg)<br>IV | IS: Ustekinumab<br>approximately<br>6mg/kg IV |
|---------------------------------------|---|---|---|
| Started                               | 319   | 320   | 322   |
| Completed                             | 296   | 309   | 307   |
| Not completed                         | 23  | 11  | 15  |
| Adverse event, serious fatal          | -   | -   | 1   |
| Consent withdrawn by subject          | 17  | 9   | 7   |
| Physician decision                    | 1   | 1   | -   |
| Adverse event, non-fatal              | 3   | -   | 1   |
| Unspecified                           | 2   | 1   | 5   |
| Lack of efficacy                      | -   | -   | 1   |

**Period 2**

|                              |                              |
|------------------------------|------------------------------|
| Period 2 title               | Maintenance Study (44 Weeks) |
| Is this the baseline period? | No                           |
| Allocation method            | Randomised - controlled      |
| Blinding used                | Double blind                 |
| Roles blinded                | Subject, Investigator        |

**Arms**

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|   |  |
|---|--|
| <b>Arm title</b>  | Maintenance study(MS): Placebo Subcutaneous (SC) |
| Arm description:  |  |
| Subjects in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab who were randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.  |  |
| Arm type  | Placebo  |
| Investigational medicinal product name  | Placebo  |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Injection  |
| Routes of administration  | Subcutaneous use                                 |
| Dosage and administration details:  |  |
| Placebo was administered as SC infusion.  |  |
| <b>Arm title</b>  | MS: Ustekinumab 90mg SC every 12 weeks (q12w)    |
| Arm description:  |  |
| Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) beginning at Week 0 of maintenance study through Week 44. |  |
| Arm type  | Experimental                                     |
| Investigational medicinal product name  | Ustekinumab 90 mg                                |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Injection  |
| Routes of administration  | Subcutaneous use                                 |
| Dosage and administration details:  |  |
| Ustekinumab 90 mg was administered as SC infusion every 12 weeks.   |  |
| <b>Arm title</b>  | MS: Ustekinumab 90mg SC every 8 weeks (q8w)      |
| Arm description:  |  |
| Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w), beginning at Week 0 of maintenance study through Week 44.  |  |
| Arm type  | Experimental                                     |
| Investigational medicinal product name  | Ustekinumab 90 mg                                |
| Investigational medicinal product code  |  |
| Other name  |  |
| Pharmaceutical forms  | Injection  |
| Routes of administration  | Subcutaneous use                                 |
| Dosage and administration details:  |  |
| Ustekinumab 90 mg was administered as SC infusion every 8 weeks.  |  |
| <b>Arm title</b>  | MS: Placebo IV (IS – Responders) to Placebo SC   |
| Arm description:  |  |
| Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects).  |  |
| Arm type  | Placebo  |

|   |   |
|---|---|
| Investigational medicinal product name  | Placebo   |
| Investigational medicinal product code  |   |
| Other name  |   |
| Pharmaceutical forms  | Injection   |
| Routes of administration  | Subcutaneous use  |
| Dosage and administration details:  |   |
| Placebo was administered as SC infusion (Responders who received Placebo IV during IS). |   |
| <b>Arm title</b>  | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w |

Arm description:

Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16, after receiving ustekinumab 90 mg SC at Week 8) received ustekinumab 90 mg SC every 8 weeks, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects).

|  |                   |
|--|-------------------|
| Arm type                               | Experimental      |
| Investigational medicinal product name | Ustekinumab 90 mg |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

Dosage and administration details:

Ustekinumab 90 mg was administered as SC infusion (delayed responders who received Ustekinumab during IS).

| <b>Number of subjects in period 2<sup>[1]</sup></b> | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
|---|--|---|---|
| Started   | 175  | 172   | 176   |
| Completed   | 132  | 148   | 158   |
| Not completed                                       | 43   | 24  | 18  |
| Adverse event, serious fatal                        | -  | -   | -   |
| Adverse event, non-fatal                            | 19   | 8   | 4   |
| Unspecified   | 5  | 7   | 8   |
| Lack of efficacy                                    | 19   | 9   | 6   |

| <b>Number of subjects in period 2<sup>[1]</sup></b> | MS: Placebo IV (IS – Responders) to Placebo SC | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w |
|---|--|---|
| Started   | 103  | 157   |
| Completed   | 76   | 128   |
| Not completed                                       | 27   | 29  |
| Adverse event, serious fatal                        | -  | 1   |
| Adverse event, non-fatal                            | 11   | 10  |
| Unspecified   | 4  | 6   |
| Lack of efficacy                                    | 12   | 12  |

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Out of the 912 subjects who were enrolled in Induction study, only 783 subjects entered the Maintenance study and of which 588 subjects entered the LTE study.

### Period 3

|                              |                                       |
|------------------------------|---------------------------------------|
| Period 3 title               | Long-term Extension Study (176 weeks) |
| Is this the baseline period? | No                                    |
| Allocation method            | Randomised - controlled               |
| Blinding used                | Double blind                          |
| Roles blinded                | Subject, Investigator                 |

### Arms

|                              |                                       |
|------------------------------|---------------------------------------|
| Are arms mutually exclusive? | Yes                                   |
| <b>Arm title</b>             | Long Term Extension (LTE): Placebo SC |

Arm description:

Subjects who were randomized to receive placebo SC in the maintenance study and received placebo SC at the first dosing visit (Week 48) of long term extension (LTE). After the Maintenance study was unblinded, subjects receiving placebo were discontinued.

|  |                  |
|--|------------------|
| Arm type                               | Placebo          |
| Investigational medicinal product name | Placebo SC       |
| Investigational medicinal product code |                  |
| Other name                             |                  |
| Pharmaceutical forms                   | Injection        |
| Routes of administration               | Subcutaneous use |

Dosage and administration details:

Placebo was continued as SC infusion in LTE phase

|                  |                                |
|------------------|--------------------------------|
| <b>Arm title</b> | LTE: Ustekinumab 90 mg SC q12w |
|------------------|--------------------------------|

Arm description:

Subjects who were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.

|  |                   |
|--|-------------------|
| Arm type                               | Experimental      |
| Investigational medicinal product name | Ustekinumab 90 mg |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

Dosage and administration details:

Ustekinumab 90 mg was continued as SC infusion in LTE phase for subjects who were benefited from this during MS study, every 12 weeks.

|                  |                               |
|------------------|-------------------------------|
| <b>Arm title</b> | LTE: Ustekinumab 90 mg SC q8w |
|------------------|-------------------------------|

Arm description:

Subjects who were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.

|  |                   |
|--|-------------------|
| Arm type                               | Experimental      |
| Investigational medicinal product name | Ustekinumab 90 mg |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

Dosage and administration details:

Ustekinumab 90 mg was continued as SC infusion in LTE phase for subjects who were benefited from this during MS study, every 8 weeks.



|   |   |
|---|---|
| <b>Arm title</b>  | LTE: Placebo IV (IS – Responders) to Placebo SC |
| Arm description:  |   |
| Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC in the maintenance study and the LTE through Week 200 (non-randomized subjects). After the Maintenance study was unblinded, subjects receiving placebo were discontinued. |   |
| Arm type  | Placebo   |
| Investigational medicinal product name  | Placebo SC                                      |
| Investigational medicinal product code  |   |
| Other name  |   |
| Pharmaceutical forms  | Injection                                       |
| Routes of administration  | Subcutaneous use                                |

**Dosage and administration details:**

Placebo was continued SC in LTE phase for subjects who were benefited from this during MS study (Responders who received Placebo IV during MS study).

|                  |   |
|------------------|---|
| <b>Arm title</b> | LTE: Ustekinumab Delayed Responders (IS) to UST 90mg SC q8w |
|------------------|---|

**Arm description:**

Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16, after receiving ustekinumab 90 mg SC at Week 8) received ustekinumab 90 mg SC q8w in the maintenance study and the LTE through Week 200 (non-randomized subjects).

|  |                   |
|--|-------------------|
| Arm type                               | Experimental      |
| Investigational medicinal product name | Ustekinumab 90 mg |
| Investigational medicinal product code |                   |
| Other name                             |                   |
| Pharmaceutical forms                   | Injection         |
| Routes of administration               | Subcutaneous use  |

**Dosage and administration details:**

Ustekinumab 90 mg was administered as SC infusion (delayed responders who received Ustekinumab during MS) during LTE phase.

| Number of subjects in period 3 <sup>[2]</sup> | Long Term Extension (LTE): Placebo SC | LTE: Ustekinumab 90 mg SC q12w | LTE: Ustekinumab 90 mg SC q8w |
|---|---------------------------------------|--------------------------------|-------------------------------|
|   |                                       |                                |                               |
| Started                                       | 115                                   | 141                            | 143                           |
| Completed                                     | 34                                    | 99                             | 101                           |
| Not completed                                 | 81                                    | 42                             | 42                            |
| Adverse event, non-fatal                      | 9                                     | 17                             | 10                            |
| Unspecified                                   | 63                                    | 19                             | 19                            |
| Lost to follow-up                             | -                                     | -                              | 1                             |
| Lack of efficacy                              | 9                                     | 6                              | 12                            |

| Number of subjects in period 3 <sup>[2]</sup> | LTE: Placebo IV (IS – Responders) to Placebo SC | LTE: Ustekinumab Delayed Responders (IS) to UST 90mg SC q8w |
|---|---|---|
|   |   |   |
| Started                                       | 73  | 116   |
| Completed                                     | 0   | 95  |
| Not completed                                 | 73  | 21  |
| Adverse event, non-fatal                      | 11  | 9   |

|                   |    |   |
|-------------------|----|---|
| Unspecified       | 55 | 6 |
| Lost to follow-up | -  | - |
| Lack of efficacy  | 7  | 6 |

---

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Out of the 912 subjects who were enrolled in Induction study, only 783 subjects entered the Maintenance study and of which 588 subjects entered the LTE study.

## Baseline characteristics

### Reporting groups

|  |   |
|--|---|
| Reporting group title  | Induction Study(IS): Placebo Intravenous (IV) |
| Reporting group description:   |   |
| Subjects received single dose of placebo as intravenous (IV) infusion at Week 0. Participants with clinical response at Week (W) 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received weight-range based dose of ustekinumab approximating 6 mg/kg IV + placebo SC at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.   |   |
| Reporting group title  | IS: Ustekinumab 130 milligram (mg) IV         |
| Reporting group description:   |   |
| Subjects received single dose of ustekinumab 130 mg as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.  |   |
| Reporting group title  | IS: Ustekinumab approximately 6mg/kg IV       |
| Reporting group description:   |   |
| Subjects received weight-range based dose of ustekinumab approximating 6 milligram per kilogram (mg/kg) (ustekinumab 260 mg [body weight ≤55 kg], 390 mg [body weight >55 kg ≤85 kg] and 520 mg [body weight >85 kg]), as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent. |   |

| Reporting group values                             | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |
|--|---|---------------------------------------|---|
| Number of subjects                                 | 319   | 320                                   | 322                                     |
| Age categorical<br>Units: Subjects                 |   |                                       |   |
| In utero   | 0   | 0                                     | 0                                       |
| Preterm newborn infants (gestational age < 37 wks) | 0   | 0                                     | 0                                       |
| Newborns (0-27 days)                               | 0   | 0                                     | 0                                       |
| Infants and toddlers (28 days-23 months)           | 0   | 0                                     | 0                                       |
| Children (2-11 years)                              | 0   | 0                                     | 0                                       |
| Adolescents (12-17 years)                          | 0   | 0                                     | 0                                       |
| Adults (18-64 years)                               | 303   | 302                                   | 305                                     |
| From 65-84 years                                   | 16  | 18                                    | 17                                      |
| 85 years and over                                  | 0   | 0                                     | 0                                       |
| Age continuous<br>Units: years                     |   |                                       |   |
| arithmetic mean                                    | 41.2  | 42.2                                  | 41.7                                    |
| standard deviation                                 | ± 13.50                                       | ± 13.94                               | ± 13.67                                 |

|   |       |     |     |
|---|-------|-----|-----|
| Sex: Female, Male                         |       |     |     |
| Units: participants                       |       |     |     |
| Female                                    | 122   | 130 | 127 |
| Male                                      | 197   | 190 | 195 |
| Race/Ethnicity, Customized                |       |     |     |
| Units: Subjects                           |       |     |     |
| American Indian or Alaska Native          | 0     | 0   | 1   |
| Asian                                     | 48    | 46  | 49  |
| Black or African American                 | 3     | 6   | 0   |
| Native Hawaiian or Other Pacific Islander | 0     | 0   | 0   |
| White                                     | 248   | 239 | 243 |
| More than one race                        | 0     | 0   | 0   |
| Unknown or Not Reported                   | 12    | 20  | 17  |
| Other                                     | 8     | 9   | 12  |
| Ethnicity (NIH/OMB)                       |       |     |     |
| Units: Subjects                           |       |     |     |
| Hispanic or Latino                        | 10    | 7   | 7   |
| Not Hispanic or Latino                    | 292   | 295 | 290 |
| Unknown or Not Reported                   | 17    | 18  | 25  |
| Region of enrollment                      |       |     |     |
| Units: Subjects                           |       |     |     |
| AUSTRALIA                                 | 7     | 8   | 11  |
| AUSTRIA                                   | 0     | 2   | 2   |
| BELGIUM                                   | 22    | 10  | 7   |
| BULGARIA                                  | 8     | 9   | 4   |
| CANADA                                    | 7     | 6   | 3   |
| CZECH REPUBLIC                            | 8     | 9   | 13  |
| DENMARK                                   | 0     | 0   | 2   |
| FRANCE                                    | 14    | 21  | 19  |
| GERMANY                                   | 19    | 14  | 12  |
| HUNGARY                                   | 11    | 12  | 16  |
| ISRAEL                                    | 0     | 3   | 3   |
| ITALY                                     | 10    | 11  | 12  |
| JAPAN                                     | 34    | 34  | 39  |
| NETHERLANDS                               | 5     | 8   | 3   |
| NEW ZEALAND                               | 4     | 4   | 11  |
| POLAND                                    | 25    | 26  | 20  |
| ROMANIA                                   | 7     | 9   | 8   |
| RUSSIAN FEDERATION                        | 26    | 22  | 26  |
| SERBIA                                    | 1     | 6   | 3   |
| SLOVAKIA                                  | 4     | 4   | 2   |
| SOUTH KOREA                               | 10    | 10  | 6   |
| UKRAINE                                   | 32    | 26  | 31  |
| UNITED KINGDOM                            | 5     | 3   | 13  |
| UNITED STATES                             | 60    | 63  | 56  |
| <b>Reporting group values</b>             | Total |     |     |
| Number of subjects                        | 961   |     |     |

|   |     |  |  |
|---|-----|--|--|
| Age categorical<br>Units: Subjects                    |     |  |  |
| In utero  | 0   |  |  |
| Preterm newborn infants<br>(gestational age < 37 wks) | 0   |  |  |
| Newborns (0-27 days)                                  | 0   |  |  |
| Infants and toddlers (28 days-23 months)              | 0   |  |  |
| Children (2-11 years)                                 | 0   |  |  |
| Adolescents (12-17 years)                             | 0   |  |  |
| Adults (18-64 years)                                  | 910 |  |  |
| From 65-84 years                                      | 51  |  |  |
| 85 years and over                                     | 0   |  |  |
| Age continuous<br>Units: years                        |     |  |  |
| arithmetic mean                                       |     |  |  |
| standard deviation                                    | -   |  |  |
| Sex: Female, Male<br>Units: participants              |     |  |  |
| Female  | 379 |  |  |
| Male  | 582 |  |  |
| Race/Ethnicity, Customized<br>Units: Subjects         |     |  |  |
| American Indian or Alaska Native                      | 1   |  |  |
| Asian   | 143 |  |  |
| Black or African American                             | 9   |  |  |
| Native Hawaiian or Other Pacific Islander             | 0   |  |  |
| White   | 730 |  |  |
| More than one race                                    | 0   |  |  |
| Unknown or Not Reported                               | 49  |  |  |
| Other   | 29  |  |  |
| Ethnicity (NIH/OMB)<br>Units: Subjects                |     |  |  |
| Hispanic or Latino                                    | 24  |  |  |
| Not Hispanic or Latino                                | 877 |  |  |
| Unknown or Not Reported                               | 60  |  |  |
| Region of enrollment<br>Units: Subjects               |     |  |  |
| AUSTRALIA   | 26  |  |  |
| AUSTRIA   | 4   |  |  |
| BELGIUM   | 39  |  |  |
| BULGARIA  | 21  |  |  |
| CANADA  | 16  |  |  |
| CZECH REPUBLIC  | 30  |  |  |
| DENMARK   | 2   |  |  |
| FRANCE  | 54  |  |  |
| GERMANY   | 45  |  |  |
| HUNGARY   | 39  |  |  |
| ISRAEL  | 6   |  |  |
| ITALY   | 33  |  |  |
| JAPAN   | 107 |  |  |

|                    |     |  |  |
|--------------------|-----|--|--|
| NETHERLANDS        | 16  |  |  |
| NEW ZEALAND        | 19  |  |  |
| POLAND             | 71  |  |  |
| ROMANIA            | 24  |  |  |
| RUSSIAN FEDERATION | 74  |  |  |
| SERBIA             | 10  |  |  |
| SLOVAKIA           | 10  |  |  |
| SOUTH KOREA        | 26  |  |  |
| UKRAINE            | 89  |  |  |
| UNITED KINGDOM     | 21  |  |  |
| UNITED STATES      | 179 |  |  |

## End points

### End points reporting groups

|  |  |
|--|--|
| Reporting group title  | Induction Study(IS): Placebo Intravenous (IV)    |
| Reporting group description:   |  |
| Subjects received single dose of placebo as intravenous (IV) infusion at Week 0. Participants with clinical response at Week (W) 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received weight-range based dose of ustekinumab approximating 6 mg/kg IV + placebo SC at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.   |  |
| Reporting group title  | IS: Ustekinumab 130 milligram (mg) IV            |
| Reporting group description:   |  |
| Subjects received single dose of ustekinumab 130 mg as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.  |  |
| Reporting group title  | IS: Ustekinumab approximately 6mg/kg IV          |
| Reporting group description:   |  |
| Subjects received weight-range based dose of ustekinumab approximating 6 milligram per kilogram (mg/kg) (ustekinumab 260 mg [body weight ≤55 kg], 390 mg [body weight >55 kg ≤85 kg] and 520 mg [body weight >85 kg]), as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent. |  |
| Reporting group title  | Maintenance study(MS): Placebo Subcutaneous (SC) |
| Reporting group description:   |  |
| Subjects in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab who were randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.   |  |
| Reporting group title  | MS: Ustekinumab 90mg SC every 12 weeks (q12w)    |
| Reporting group description:   |  |
| Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) beginning at Week 0 of maintenance study through Week 44.  |  |
| Reporting group title  | MS: Ustekinumab 90mg SC every 8 weeks (q8w)      |
| Reporting group description:   |  |
| Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w), beginning at Week 0 of maintenance study through Week 44.   |  |
| Reporting group title  | MS: Placebo IV (IS – Responders) to Placebo SC   |
| Reporting group description:   |  |
| Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects).   |  |

|   |   |
|---|---|
| Reporting group title   | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w   |
| Reporting group description:<br>Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16, after receiving ustekinumab 90 mg SC at Week 8) received ustekinumab 90 mg SC every 8 weeks, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects). |   |
| Reporting group title   | Long Term Extension (LTE): Placebo SC                       |
| Reporting group description:<br>Subjects who were randomized to receive placebo SC in the maintenance study and received placebo SC at the first dosing visit (Week 48) of long term extension (LTE). After the Maintenance study was unblinded, subjects receiving placebo were discontinued.  |   |
| Reporting group title   | LTE: Ustekinumab 90 mg SC q12w                              |
| Reporting group description:<br>Subjects who were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.   |   |
| Reporting group title   | LTE: Ustekinumab 90 mg SC q8w                               |
| Reporting group description:<br>Subjects who were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.   |   |
| Reporting group title   | LTE: Placebo IV (IS – Responders) to Placebo SC             |
| Reporting group description:<br>Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC in the maintenance study and the LTE through Week 200 (non-randomized subjects). After the Maintenance study was unblinded, subjects receiving placebo were discontinued.   |   |
| Reporting group title   | LTE: Ustekinumab Delayed Responders (IS) to UST 90mg SC q8w |
| Reporting group description:<br>Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16, after receiving ustekinumab 90 mg SC at Week 8) received ustekinumab 90 mg SC q8w in the maintenance study and the LTE through Week 200 (non-randomized subjects).               |   |

### **Primary: Induction Study - Percentage of Subjects with Clinical Remission at Week 8 (As per Global Definition)**

|  |   |
|--|---|
| End point title  | Induction Study - Percentage of Subjects with Clinical Remission at Week 8 (As per Global Definition) |
| End point description:<br>As per global definition, clinical remission is defined as a Mayo score less than or equal to ( $\leq$ )2 points, with no individual subscore greater than ( $>$ )1. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding [RB], endoscopy findings, and physician's global assessment [PGA]), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5 = mild; 6 to 10 = moderate; and 11 to 12 = severe disease. Subjects who had a prohibited change in concomitant ulcerative colitis (UC) medication or an ostomy or colectomy prior to the Week 8 or who had all 4 Mayo subscores missing at Week 8 were considered not to be in clinical remission. Endoscopy subscore as assessed during central review of video of endoscopy was used. The primary efficacy analysis set (PEAS) consisted of all subjects randomized in the induction study. |   |
| End point type   | Primary   |
| End point timeframe:<br>Week 8   |   |



| <b>End point values</b>       | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 5.3   | 15.6                                  | 15.5                                    |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
|---|---|
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 641   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           |   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Adjusted treatment difference   |
| Point estimate                          | 10.2  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 5.6   |
| upper limit                             | 14.8  |

| <b>Statistical analysis title</b>       | Statistical Analysis 1  |
|---|---|
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab 130 milligram (mg) IV |
| Number of subjects included in analysis | 639   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           |   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Adjusted treatment difference   |
| Point estimate                          | 10.3  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 5.7   |
| upper limit                             | 14.9  |

## Primary: Induction Study - Percentage of Subjects with Clinical Remission at Week 8 (As per US Definition)

|   |   |
|---|---|
| End point title   | Induction Study - Percentage of Subjects with Clinical Remission at Week 8 (As per US Definition) |
| End point description:<br>As per US definition, clinical remission was defined as absolute stool number $\leq 3$ , a Mayo rectal bleeding subscore of 0 (no blood seen), and a Mayo endoscopy subscore of 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]) without the physician's global assessment. Absolute stool number is average of daily stool number over 3 days. The Mayo rectal bleeding and endoscopy findings subscores were rated as 0 (normal) to 3 (severe). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who were missing all 3 of the Mayo components pertaining to this outcome measure (OM) (absolute stool number, rectal bleeding subscore, and Mayo endoscopy subscore) at Week 8 were considered not to be in clinical remission. Endoscopy subscore as assessed during central review of the video of the endoscopy was used. PEAS consisted of all subjects randomized in the induction study. |   |
| End point type  | Primary   |
| End point timeframe:<br>Week 8  |   |

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 6.3   | 16.6                                  | 18.9                                    |  |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 641   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           |   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Adjusted treatment difference   |
| Point estimate                          | 12.7  |
| Confidence interval                     |   |
| level                                   | Other: 97.5 %   |
| sides                                   | 2-sided   |
| lower limit                             | 7   |
| upper limit                             | 18.4  |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Statistical Analysis 1  |
| Comparison groups                 | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab 130 milligram (mg) IV |

|   |                               |
|---|-------------------------------|
| Number of subjects included in analysis | 639                           |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           |                               |
| P-value                                 | < 0.001                       |
| Method                                  | Cochran-Mantel-Haenszel       |
| Parameter estimate                      | Adjusted treatment difference |
| Point estimate                          | 10.3                          |
| Confidence interval                     |                               |
| level                                   | Other: 97.5 %                 |
| sides                                   | 2-sided                       |
| lower limit                             | 4.8                           |
| upper limit                             | 15.8                          |

### Primary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 (As per Global Definition)

|                        |   |
|------------------------|---|
| End point title        | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 (As per Global Definition)   |
| End point description: | As per global definition, clinical remission defined as Mayo score ≤2 points with no individual subscore >1. It consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment) rated as 0 (normal) to 3 (severe). Total score is sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5=mild; 6 to 10=moderate; 11 to 12=severe disease. Subjects who had a prohibited change in UC medication or an ostomy or colectomy or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 or who had all 4 Mayo subscores missing at Week 44 were considered not to be in clinical remission. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. |
| End point type         | Primary   |
| End point timeframe:   | Week 44   |

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 175  | 172   | 176   |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 24.0   | 38.4  | 43.8  |  |

### Statistical analyses

|                            |  |
|----------------------------|--|
| Statistical analysis title | Statistical Analysis 2   |
| Comparison groups          | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |

|   |                               |
|---|-------------------------------|
| Number of subjects included in analysis | 351                           |
| Analysis specification                  | Pre-specified                 |
| Analysis type                           |                               |
| P-value                                 | < 0.001                       |
| Method                                  | Cochran-Mantel-Haenszel       |
| Parameter estimate                      | Adjusted treatment difference |
| Point estimate                          | 19.7                          |
| Confidence interval                     |                               |
| level                                   | 95 %                          |
| sides                                   | 2-sided                       |
| lower limit                             | 10.3                          |
| upper limit                             | 29                            |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           |  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted treatment difference  |
| Point estimate                          | 14.5   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 5.5  |
| upper limit                             | 23.6   |

### **Primary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 (as per US Definition)**

|   |   |
|---|---|
| End point title   | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 (as per US Definition) |
| End point description:  |   |
| Per US definition, clinical remission: absolute stool number $\leq 3$ , a Mayo rectal bleeding subscore of 0 (no blood seen) and Mayo endoscopy subscore of 0 (normal/inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]), without the physician's global assessment. Absolute stool number is average of daily stool number over 3 days. The Mayo rectal bleeding and endoscopy findings subscores were rated as 0 (normal)-3 (severe). Subjects who had prohibited change in UC medication/ ostomy/ colectomy/used rescue medication after clinical flare/discontinued study agent due to lack of therapeutic effect/due to AE of worsening of UC prior to Week 44 and who were missing all 3 of Mayo components at Week 44 were considered not to be in clinical remission. PEAS consisted of all subjects who were in clinical response to IV UST induction and were randomized at Week 0 of the maintenance study to UST 90 mg SC q8w, UST 90 mg SC q12w, or placebo SC. |   |
| End point type  | Primary   |
| End point timeframe:  |   |
| Week 44   |   |

| <b>End point values</b>       | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks (q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group  | Reporting group                                      |  |
| Number of subjects analysed   | 175  | 172  | 176  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       | 24.6   | 39.5   | 42.6   |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 2   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 351  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           |  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted treatment difference  |
| Point estimate                          | 17.9   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 8.6  |
| upper limit                             | 27.2   |

| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           |  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Adjusted treatment difference  |
| Point estimate                          | 15.1   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 6  |
| upper limit                             | 24.2   |

## Secondary: Induction Study: Percentage of Subjects with Endoscopic Healing (EH) at Week 8

|   |  |
|---|--|
| End point title   | Induction Study: Percentage of Subjects with Endoscopic Healing (EH) at Week 8 |
| End point description:<br>Endoscopic healing is improvement in the endoscopic appearance of the mucosa. It is defined as Mayo endoscopic subscore = 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had a missing endoscopy score at Week 8 were considered not to have endoscopic healing. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 8  |  |

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 13.8  | 26.3                                  | 27.0                                    |  |

## Statistical analyses

|   |   |
|---|---|
| Statistical analysis title              | Statistical Analysis 2  |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 641   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Mean difference (final values)  |
| Point estimate                          | 13.3  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 7.3   |
| upper limit                             | 19.3  |

|  |                        |
|--|------------------------|
|  | Statistical Analysis 1 |
|--|------------------------|

|   |   |
|---|---|
| <b>Statistical analysis title</b>       |   |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab 130 milligram (mg) IV |
| Number of subjects included in analysis | 639   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Mean difference (final values)  |
| Point estimate                          | 12.4  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 6.5   |
| upper limit                             | 18.4  |

## Secondary: Induction Study: Percentage of Subjects with Clinical Response at Week 8

|   |  |
|---|--|
| End point title   | Induction Study: Percentage of Subjects with Clinical Response at Week 8 |
| End point description:  |  |
| Clinical response was defined as a decrease from induction baseline in the Mayo score by $\geq 30$ percent (%) and $\geq 3$ points, with either a decrease from baseline in the rectal bleeding subscore $\geq 1$ or a rectal bleeding subscore of 0 or 1. The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score was calculated as the sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5 = mild; 6 to 10 = moderate; and 11 to 12 = severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had all 4 Mayo subscores missing at Week 8 were considered not to be in clinical response. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Week 8  |  |

| <b>End point values</b>       | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 31.3  | 51.3                                  | 61.8                                    |  |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 1  |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab 130 milligram (mg) IV |
| Number of subjects included in analysis | 639   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Median difference (final values)  |
| Point estimate                          | 19.9  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 12.5  |
| upper limit                             | 27.3  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 641   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Median difference (final values)  |
| Point estimate                          | 30.5  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 23.2  |
| upper limit                             | 37.8  |

### **Secondary: Induction Study - Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8**

|   |   |
|---|---|
| End point title   | Induction Study - Change From Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8 |
| End point description:  |   |
| IBDQ is 32-item questionnaire used to evaluate disease-specific health-related quality of life. Each item score ranged from 1 (worst response) to 7 (best response) and were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. These domains scored as: 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); and 5 to 35 (social function) and higher score indicates better quality of life. Total score is sum of each item score and ranges from 32-224 with higher score indicates better quality of life. Subjects who had prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing IBDQ score at Week 8 had their last value carried forward. PEAS consisted of all subjects randomized in induction study. Here, N (number of subjects analyzed) signifies those subjects who were analyzed for this endpoint. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Baseline and Week 8   |   |



| <b>End point values</b>              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--------------------------------------|---|---------------------------------------|---|--|
| Subject group type                   | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed          | 317   | 316                                   | 321                                     |  |
| Units: Units on a scale              |   |                                       |   |  |
| arithmetic mean (standard deviation) | 16.1 (± 31.39)                                | 33.4 (± 32.53)                        | 35.0 (± 31.86)                          |  |

### Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 1  |
|---|---|
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab 130 milligram (mg) IV |
| Number of subjects included in analysis | 633   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | ANCOVA  |

| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
|---|---|
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 638   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | ANCOVA  |

### Secondary: Maintenance Study: Percentage of Subjects with Clinical Response up to Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Response up to Week 44 |
|-----------------|--|

#### End point description:

Clinical response: decrease from induction baseline in Mayo score by  $\geq 30\%$  and  $\geq 3$  points, with either decrease from induction baseline in rectal bleeding subscore  $\geq 1$  or rectal bleeding subscore of 0 or 1. It includes 4 subscores (stool frequency, rectal bleeding, endoscopy findings, physician's global assessment), rated as 0 (normal) to 3 (severe). Subjects who lost clinical response at any time before Week 44, had prohibited change in UC medication, ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 or who had all 4 Mayo subscores missing at Week 44 were considered not to be in clinical response. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 44        |           |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous<br>(SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|---|---|--|--|
| Subject group type            | Reporting group   | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 175   | 172   | 176  |  |
| Units: Percentage of Subjects |   |   |  |  |
| number (not applicable)       | 44.6  | 68.0  | 71.0   |  |

### Statistical analyses

| Statistical analysis title              | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 23.5   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 13.7   |
| upper limit                             | 33.3   |

| Statistical analysis title              | Statistical Analysis 2   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 351  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 26.4   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 16.6    |
| upper limit         | 36.1    |

## Secondary: Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44 |
|-----------------|--|

End point description:

Endoscopic healing is improvement in the endoscopic appearance of the mucosa. It was defined as Mayo endoscopic subscore = 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). Subjects who had prohibited change in UC medication, an ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC prior to Week 44 or who had missing endoscopy score at Week 44 were considered not to have endoscopic healing. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 44

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 175  | 172   | 176   |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 28.6   | 43.6  | 51.1  |  |

## Statistical analyses

|   |  |
|---|--|
| Statistical analysis title              | Statistical Analysis 1   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 15.2   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 5.8     |
| upper limit         | 24.6    |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 2   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 351  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 22.5   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 12.8   |
| upper limit                             | 32.2   |

### **Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission and not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission) at Week 44 (As per Global Definition)**

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Remission and not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission) at Week 44 (As per Global Definition) |
|-----------------|--|

#### End point description:

Per global definition, clinical remission was defined as Mayo score  $\leq 2$  points, with no individual subscore  $> 1$ . It consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Higher scores indicate more severe disease. Subjects who had prohibited change in UC medication/ ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 or had all 4 Mayo subscores missing at Week 44 were considered not to have achieved OM of clinical remission and not receiving corticosteroids at Week 44. Subjects who had missing value in corticosteroid use at Week 44 had their last value carried forward. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w/ placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### End point timeframe:

Week 44

| <b>End point values</b>       | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 175  | 172   | 176   |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 23.4   | 37.8  | 42.0  |  |

## Statistical analyses

| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 14.5   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 5.5  |
| upper limit                             | 23.6   |

| <b>Statistical analysis title</b>       | Statistical Analysis 2   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 351  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 18.5   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 9.3  |
| upper limit                             | 27.8   |

## Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission and not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission)

**at Week 44 (As per US Definition)**

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Remission and not Receiving Concomitant Corticosteroids (Corticosteroid-free Clinical Remission) at Week 44 (As per US Definition) |
|-----------------|--|

## End point description:

US definition of clinical remission: absolute stool number  $\leq 3$ , rectal bleeding subscore 0 (no blood seen), Mayo endoscopy subscore of 0 (normal or inactive disease)/ 1 (mild disease). Mayo rectal bleeding and endoscopy findings subscores rated: 0 (normal) to 3 (severe). Subjects with prohibited change in UC medication/ostomy/colectomy/used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 or were missing all 3 of Mayo components (absolute stool number, rectal bleeding, and Mayo endoscopy subscore) at Week 44 were considered not in corticosteroid-free clinical remission at Week 44. Subjects with missing value in corticosteroid use at Week 44 had last value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomised at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

## End point timeframe:

Week 44

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 175  | 172   | 176   |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 24.0   | 39.0  | 40.9  |  |

**Statistical analyses**

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 347  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 15.1   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 6.1  |
| upper limit                             | 24.2   |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 2   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 351  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | < 0.001  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 16.8   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 7.6  |
| upper limit                             | 26   |

**Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission up to Week 44 Among Subjects who Achieved Clinical Remission at Maintenance Study Baseline (As per Global Definition)**

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Remission up to Week 44 Among Subjects who Achieved Clinical Remission at Maintenance Study Baseline (As per Global Definition) |
|-----------------|---|

End point description:

Global definition of clinical remission: Mayo score  $\leq 2$  points, with no individual subscore  $>1$ . It includes 4 subscores (stool frequency, rectal bleeding, endoscopy findings, PGA), rated as 0 (normal) to 3 (severe). Total score: sum of 4 subscores and range: 0 to 12, where 3 to 5= mild, 6 to 10= moderate, and 11 to 12= severe disease. Subjects who had prohibited change in UC medication/ostomy/colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 or had all 4 subscores missing at Week 44 were considered not to be in clinical remission. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects who were in clinical remission at maintenance baseline.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 44        |           |

| <b>End point values</b>       | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 45   | 40  | 38  |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 37.8   | 65.0  | 57.9  |  |

## Statistical analyses

| Statistical analysis title              | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 85   |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.011  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 28.4   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 8  |
| upper limit                             | 48.9   |

| Statistical analysis title              | Statistical Analysis 2   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 83   |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.069  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 20.3   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0  |
| upper limit                             | 40.6   |

## Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission up to Week 44 Among Subjects who Achieved Clinical Remission at Maintenance Study Baseline (As per US Definition)

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Remission up to Week 44 Among Subjects who Achieved Clinical Remission at Maintenance Study Baseline (As per US Definition) |
|-----------------|---|

### End point description:

US definition of clinical remission: absolute stool number  $\leq 3$ , Mayo rectal bleeding subscore of 0 (no blood seen), Mayo endoscopy subscore of 0 (normal/ inactive disease) or 1 (mild disease). Absolute stool number: average of daily stool number over 3 days. Mayo rectal bleeding and endoscopy subscores: 0 (normal) to 3 (severe). Subjects with prohibited change in UC medication/ostomy/colectomy/used rescue medication after clinical flare/ discontinued study drug due to lack of therapeutic effect/ AE of worsening of UC before Week 44/ missing all 3 of Mayo components (absolute stool number, rectal bleeding, and Mayo endoscopy subscore) at Week 44 were considered not in clinical remission. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90



mg SC q12w, or placebo SC, with subjects who were in clinical remission at MS baseline.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 44        |           |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous<br>(SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|---|---|--|--|
| Subject group type            | Reporting group   | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 48  | 52  | 44   |  |
| Units: Percentage of Subjects |   |   |  |  |
| number (not applicable)       | 33.3  | 61.5  | 61.4   |  |

## Statistical analyses

| Statistical analysis title              | Statistical Analysis 1   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 100  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.003  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 30.4   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 11.9   |
| upper limit                             | 48.8   |

| Statistical analysis title              | Statistical Analysis 2   |
|---|--|
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
| Number of subjects included in analysis | 92   |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.006  |
| Method                                  | Cochran-Mantel-Haenszel  |
| Parameter estimate                      | Mean difference (final values)   |
| Point estimate                          | 21.9   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 10.4    |
| upper limit         | 47.9    |

## Secondary: Induction Study - Percentage of Subjects with Mucosal Healing at Week 8

|   |   |
|---|---|
| End point title   | Induction Study - Percentage of Subjects with Mucosal Healing at Week 8 |
| End point description:  |   |
| Mucosal healing is defined as having both EH and histologic healing (HH). EH: an endoscopy subscore of 0 (normal or inactive disease) or 1 mild disease ([erythema, decreased vascular pattern, mild friability]). Histologic healing: neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions or ulcerations or granulation tissue. Subjects who had prohibited change in concomitant UC medication/ ostomy/ colectomy before Week 8 or had missing endoscopy score/ were missing any component of histologic healing (that is assessment of neutrophils in crypts, crypt destruction/ erosions/ ulcerations/ granulations) at Week 8 or who had unevaluable biopsy (that is biopsy collected, but could not be assessed due to sample preparation or technical errors) at Week 8 but who did not achieve endoscopic healing, were considered not to have mucosal healing. PEAS consisted of all subjects randomised in the IS, with subjects whose mucosal healing status was determined at Week 8. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Week 8  |   |

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 316   | 316                                   | 315                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 20.3  | 8.9                                   | 18.4                                    |  |

## Statistical analyses

|   |   |
|---|---|
| Statistical analysis title              | Statistical analysis 1  |
| Comparison groups                       | IS: Ustekinumab 130 milligram (mg) IV v Induction Study(IS): Placebo Intravenous (IV) |
| Number of subjects included in analysis | 632   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Mean difference (final values)  |
| Point estimate                          | 11.3  |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 6       |
| upper limit         | 16.6    |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Statistical Analysis 2  |
| Comparison groups                       | Induction Study(IS): Placebo Intravenous (IV) v IS: Ustekinumab approximately 6mg/kg IV |
| Number of subjects included in analysis | 631   |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority   |
| P-value                                 | < 0.001   |
| Method                                  | Cochran-Mantel-Haenszel   |
| Parameter estimate                      | Mean difference (final values)  |
| Point estimate                          | 9.7   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 4.5   |
| upper limit                             | 14.9  |

### **Secondary: Induction Study -Percentage of Subjects in Clinical Remission with a Rectal Bleeding Subscore of 0 at Week 8 (As per Global Definition)**

|                 |   |
|-----------------|---|
| End point title | Induction Study -Percentage of Subjects in Clinical Remission with a Rectal Bleeding Subscore of 0 at Week 8 (As per Global Definition) |
|-----------------|---|

#### End point description:

As per global definition, clinical remission is defined as Mayo score  $\leq 2$  points, with no individual subscore  $> 1$ . The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score is calculated as sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5 = mild; 6 to 10 = moderate; and 11 to 12 = severe; higher scores indicate worsening of the disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 or who had missing rectal bleeding subscores at Week 8 were considered not to be in clinical remission with a rectal bleeding subscore of 0. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 319  | 320  | 322  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       | 5.3  | 15.3   | 15.2   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects in Symptomatic Remission at Week 8

|   |   |
|---|---|
| End point title   | Induction Study - Percentage of Subjects in Symptomatic Remission at Week 8 |
| End point description:<br>Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 and/or both stool frequency and rectal bleeding subscores missing at Week 8 were considered not to be in symptomatic remission. PEAS consisted of all subjects randomized in the induction study. |   |
| End point type  | Secondary   |
| End point timeframe:<br>Week 8  |   |

| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 319  | 320  | 322  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       | 22.6   | 41.3   | 44.7   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Normal or Inactive Mucosal Disease at Week 8

|  |  |
|--|--|
| End point title  | Induction Study - Percentage of Subjects with Normal or Inactive Mucosal Disease at Week 8 |
| End point description:<br>Normal or inactive mucosal disease is defined as an endoscopy score of 0. Subjects who had a |  |

prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 or who had a missing endoscopy score at Week 8 were considered not to have normal or inactive mucosal disease. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 3.8   | 10.3                                  | 7.8                                     |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Change from Baseline in Mayo score at Week 8

|                 |  |
|-----------------|--|
| End point title | Induction Study - Change from Baseline in Mayo score at Week 8 |
|-----------------|--|

End point description:

The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and physician's global assessment), rated as 0 (normal) to 3 (severe). Total score is calculated as the sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5 = mild; 6 to 10 = moderate; and 11 to 12 = severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline Mayo score carried forward to Week 8 or who had all 4 Mayo subscores missing at Week 8 had their last available individual Mayo subscores carried forward. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies those subjects who were analyzed for this OM.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Baseline and Week 8  |           |

| End point values                     | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--------------------------------------|---|---------------------------------------|---|--|
| Subject group type                   | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed          | 319   | 320                                   | 322                                     |  |
| Units: Units on a scale              |   |                                       |   |  |
| arithmetic mean (standard deviation) | -1.8 (± 2.40)                                 | -3.2 (± 2.81)                         | -3.5 (± 2.67)                           |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in Partial Mayo Score Through Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Change from Baseline in Partial Mayo Score Through Week 8 |
|-----------------|---|

End point description:

The partial Mayo score, which is sum of 3 subscores of the Mayo score without the endoscopy subscore (stool frequency, rectal bleeding, and physician's global assessment subscores; rated as 0 [normal] to 3 [severe]). The partial Mayo score is calculated as the sum of the 3 subscores and values range from 0 to 9; higher scores indicates more severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline value carried forward from the time of the event onward. Subjects with the partial Mayo score missing at a timepoint had their last available individual partial Mayo subscore carried forward to that timepoint. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies those subjects who were analyzed for this OM.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 8

| End point values                     | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|--------------------------------------|--|--|--|--|
| Subject group type                   | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed          | 319  | 320  | 321  |  |
| Units: Units on a scale              |  |  |  |  |
| arithmetic mean (standard deviation) |  |  |  |  |
| Change at Week 2                     | -1.0 (± 1.63)  | -1.5 (± 1.74)                                  | -1.6 (± 1.69)                                    |  |
| Change at Week 4                     | -1.4 (± 1.86)  | -2.1 (± 1.86)                                  | -2.5 (± 1.93)                                    |  |
| Change at Week 8                     | -1.5 (± 2.07)  | -2.6 (± 2.31)                                  | -2.9 (± 2.20)                                    |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with individual Mayo Subscore (Stool Frequency) up to Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with individual Mayo Subscore (Stool Frequency) up to Week 8 |
|-----------------|---|

**End point description:**

The stool frequency subscore of Mayo score is rated as 0 (normal) to 3 (severe). Stool frequency scores: 0 = normal number of stools, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing Mayo stool frequency subscore at the designated analysis timepoint had the last available value for that subscore carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies those subjects who were analyzed for this OM.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 8         |           |

| End point values                          | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|---|---|---------------------------------------|---|--|
| Subject group type                        | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed               | 319   | 320                                   | 321                                     |  |
| Units: Percentage of Subjects             |   |                                       |   |  |
| number (not applicable)                   |   |                                       |   |  |
| Week 2: Normal number of stools           | 5.0   | 10.0                                  | 8.1                                     |  |
| Week 2: 1-2 stools more than normal       | 25.7  | 30.9                                  | 29.3                                    |  |
| Week 2: 3-4 stools more than normal       | 26.6  | 27.5                                  | 28.0                                    |  |
| Week 2: 5 or more stools more than normal | 42.6  | 31.6                                  | 34.6                                    |  |
| Week 4: Normal number of stools           | 9.4   | 11.3                                  | 15.6                                    |  |
| Week 4: 1-2 stools more than normal       | 26.6  | 38.1                                  | 39.3                                    |  |
| Week 4: 3-4 stools more than normal       | 25.4  | 24.4                                  | 22.4                                    |  |
| Week 4: 5 or more stools more than normal | 38.6  | 26.3                                  | 22.7                                    |  |
| Week 8: Normal number of stools           | 8.8   | 20.6                                  | 22.1                                    |  |
| Week 8: 1-2 stools more than normal       | 29.2  | 35.0                                  | 34.3                                    |  |
| Week 8: 3-4 stools more than normal       | 23.8  | 19.1                                  | 26.5                                    |  |
| Week 8: 5 or more stools more than normal | 38.2  | 25.3                                  | 17.1                                    |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Induction Study - Percentage of Subjects with individual Mayo Subscore (Rectal Bleeding) up to Week 8**

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with individual Mayo Subscore (Rectal Bleeding) up to Week 8 |
|-----------------|---|

**End point description:**

The rectal bleeding subscore of the Mayo Score is rated as 0 (normal) to 3 (severe). Rectal bleeding scores: 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 = blood alone passed. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing Mayo rectal bleeding

subscore at the designated analysis timepoint had the last available value for that subscore carried forward. PEAS consisted of all subjects randomized in the induction study.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 8         |           |

| End point values                                    | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|---|---|---------------------------------------|---|--|
| Subject group type                                  | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed                         | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects                       |   |                                       |   |  |
| number (not applicable)                             |   |                                       |   |  |
| Week 2: No blood seen                               | 26.0  | 32.5                                  | 37.3                                    |  |
| Week 2: Streaks of blood with stool < half time     | 37.3  | 38.1                                  | 40.7                                    |  |
| Week 2: Obvious blood with stool most of the time   | 29.5  | 25.9                                  | 19.6                                    |  |
| Week 2: Blood alone passed                          | 7.2   | 3.4                                   | 2.5                                     |  |
| Week 4: No blood seen                               | 36.7  | 43.1                                  | 50.0                                    |  |
| Week 4: Streaks of blood with stool < half time     | 32.3  | 36.6                                  | 35.7                                    |  |
| Week 4: Obvious blood with stool most of time       | 23.5  | 16.9                                  | 12.4                                    |  |
| Week 4: Blood alone passed                          | 7.5   | 3.4                                   | 1.9                                     |  |
| Week 8: No blood seen                               | 37.3  | 54.1                                  | 63.4                                    |  |
| Week 8: Streaks of blood with stool < half the time | 33.2  | 26.6                                  | 25.2                                    |  |
| Week 8: Obvious blood with stool most of the time   | 22.9  | 16.9                                  | 9.6                                     |  |
| Week 8: Blood alone passed                          | 6.6   | 2.5                                   | 1.9                                     |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Percentage of Subjects with individual Mayo Subscore (Endoscopy Findings) at Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with individual Mayo Subscore (Endoscopy Findings) at Week 8 |
|-----------------|---|

End point description:

The endoscopy findings subscore of the Mayo score is rated as 0 (normal) to 3 (severe). Endoscopy finding scores: 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern, mild friability), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = Severe disease (spontaneous bleeding, ulceration). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing Mayo endoscopy subscore at Week 8 had the last available value for that subscore carried forward. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study.



|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values                   | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|------------------------------------|--|--|--|--|
| Subject group type                 | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed        | 319  | 320  | 322  |  |
| Units: Percentage of Subjects      |  |  |  |  |
| number (not applicable)            |  |  |  |  |
| Week 8: Normal or inactive disease | 3.8  | 10.3   | 7.8  |  |
| Week 8:Mild disease                | 10.0   | 15.9   | 19.3   |  |
| Week 8: Moderate disease           | 31.0   | 30.0   | 26.1   |  |
| Week 8: Severe disease             | 55.2   | 43.8   | 46.9   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Individual Mayo Subscore (Physician's Global Assessment) up to Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Individual Mayo Subscore (Physician's Global Assessment) up to Week 8 |
|-----------------|---|

End point description:

The physician's global assessment subscore of the Mayo score is rated as 0 (normal) to 3 (severe). Physician's global assessment scores: 0 = normal, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing Mayo physician's global assessment subscore at the designated analysis timepoint had the last available value for that subscore carried forward. PEAS consisted of all subjects randomized in the induction study.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 8         |           |

| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 319  | 320  | 322  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       |  |  |  |  |
| Week 2: Normal                | 0.9  | 1.3  | 3.1  |  |

|                          |      |      |      |  |
|--------------------------|------|------|------|--|
| Week 2:Mild disease      | 20.7 | 25.6 | 25.2 |  |
| Week 2: Moderate disease | 60.8 | 60.3 | 56.2 |  |
| Week 2: Severe disease   | 17.6 | 12.8 | 15.5 |  |
| Week 4:Normal            | 4.1  | 4.4  | 6.8  |  |
| Week 4:Mild disease      | 25.7 | 36.9 | 42.5 |  |
| Week 4: Moderate disease | 56.7 | 51.2 | 42.9 |  |
| Week 4: Severe disease   | 13.5 | 7.5  | 7.8  |  |
| Week 8:Normal            | 6.6  | 11.6 | 15.2 |  |
| Week 8:Mild disease      | 26.0 | 42.5 | 41.9 |  |
| Week 8: Moderate disease | 48.0 | 35.9 | 32.9 |  |
| Week 8: Severe disease   | 19.4 | 10.0 | 9.9  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Percentage of Subjects with Clinical Remission at Week 8 by Biologic Failure (BF) Status (As per Global Definition)

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Clinical Remission at Week 8 by Biologic Failure (BF) Status (As per Global Definition) |
|-----------------|---|

End point description:

Global definition of clinical remission: Mayo score  $\leq 2$  points, with no individual subscore  $> 1$ . It included 4 subscores (stool frequency, rectal bleeding, endoscopy findings, PGA), rated as 0 (normal) to 3 (severe). Total score = sum of 4 subscores and range from 0 to 12, where 3 to 5 = mild; 6 to 10 = moderate; 11 to 12 = severe disease. BF: subjects received treatment with 1 or more tumor necrosis factor (TNF) antagonists and/or vedolizumab at dose approved for treatment of UC and did not respond initially or responded initially but lost response or were intolerant of medication. Subjects with prohibited change in concomitant UC medication/ ostomy/colectomy before Week 8 or who had all 4 Mayo subscores missing at Week 8 considered not in clinical remission. PEAS included all subjects randomized in the IS. Here, n (number of subjects analyzed) refer subjects analyzed for this OM with specified category.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values                       | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--|---|---------------------------------------|---|--|
| Subject group type                     | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed            | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects          |   |                                       |   |  |
| number (not applicable)                |   |                                       |   |  |
| Subjects with BF (n= 161, 164, 166)    | 1.2   | 11.6                                  | 12.7                                    |  |
| Subjects without BF (n= 158, 156, 156) | 9.5   | 19.9                                  | 18.6                                    |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Clinical Remission at Week 8 by Biologic Failure (BF) Status (As per US Definition)

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Clinical Remission at Week 8 by Biologic Failure (BF) Status (As per US Definition) |
|-----------------|---|

End point description:

US definition of clinical remission: absolute stool number  $\leq 3$ , a Mayo rectal bleeding subscore of 0 (no blood seen), Mayo endoscopy subscore of (normal/ inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]), without PGA. Mayo rectal bleeding and endoscopy subscores rated 0 (normal) to 3 (severe). BF: subjects received treatment with 1/ more TNF antagonists/ vedolizumab at dose approved for treatment of UC, and did not respond initially or responded initially but lost response/ intolerant of medication. Subjects with prohibited change in concomitant UC medication/ ostomy/ colectomy before Week 8/ missing all 3 of Mayo components (absolute stool number, rectal bleeding, Mayo endoscopy subscore) at Week 8 considered not in clinical remission. PEAS consisted of all subjects randomized in the induction study. Here, n (number of subjects analyzed) refer subjects analyzed for this OM with specified category.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values                       | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--|---|---------------------------------------|---|--|
| Subject group type                     | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed            | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects          |   |                                       |   |  |
| number (not applicable)                |   |                                       |   |  |
| Subjects with BF (n= 161, 164, 166)    | 2.5   | 11.6                                  | 13.3                                    |  |
| Subjects without BF (n= 158, 156, 156) | 10.1  | 21.8                                  | 25.0                                    |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Endoscopic Healing at Week 8 by Biologic Failure Status

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Endoscopic Healing at Week 8 by Biologic Failure Status |
|-----------------|---|

End point description:

Endoscopic healing is improvement in the endoscopic appearance of the mucosa. It is defined as Mayo endoscopic subscore = 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). BF: Subjects received treatment with 1/ more TNF antagonists and/or vedolizumab at dose approved for treatment of UC, and either did not respond initially, responded initially but then lost response/ were intolerant of medication. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 or who had a missing endoscopy score at Week 8 were considered not to have endoscopic healing. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the

induction study. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM with specified category.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values                      | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|---------------------------------------|---|---------------------------------------|---|--|
| Subject group type                    | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed           | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects         |   |                                       |   |  |
| number (not applicable)               |   |                                       |   |  |
| Subjects with BF (n= 161,164, 166)    | 6.8   | 18.3                                  | 21.1                                    |  |
| Subjects without BF (n= 158,156, 156) | 20.9  | 34.6                                  | 33.3                                    |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Percentage of Subjects with Clinical Response at Week 8 by Biologic Failure Status

|                 |  |
|-----------------|--|
| End point title | Induction Study - Percentage of Subjects with Clinical Response at Week 8 by Biologic Failure Status |
|-----------------|--|

End point description:

Clinical response: decrease from IS baseline in Mayo score by  $\geq 30\%$  and  $\geq 3$  points, with either decrease from baseline in rectal bleeding subscore  $\geq 1$ /rectal bleeding subscore=0/1. Mayo score included 4 subscores (stool frequency, rectal bleeding, endoscopy findings, PGA), rated as 0 (normal) to 3 (severe). Total score=sum of 4 subscores; range: 0 to 12, where 3 to 5=mild; 6 to 10=moderate; 11 to 12=severe; higher scores=worsening of disease. BF: subjects received treatment with 1/more TNF antagonists and/or vedolizumab at dose approved for treatment of UC and did not respond initially or responded initially but lost response/were intolerant of medication. Subjects with prohibited change in concomitant UC medication/ ostomy/ colectomy before Week 8 or who had all 4 Mayo subscores missing at Week 8 were considered not in clinical response. PEAS included all subjects randomized in IS. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM with specified category.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 8               |           |

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |

|                                       |      |      |      |  |
|---------------------------------------|------|------|------|--|
| number (not applicable)               |      |      |      |  |
| Subjects with BF (n= 161,164, 166)    | 27.3 | 45.1 | 57.2 |  |
| Subjects without BF (n= 158,156, 156) | 35.4 | 57.7 | 66.7 |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific)

|   |   |
|---|---|
| End point title   | Induction Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific) |
| End point description:<br>Percentage of subjects in remission based on stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal), rectal bleeding subscore of 0 (no blood seen), and endoscopy subscore of 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]) at Week 8 were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who were missing all 3 of the Mayo components related to this OM (stool frequency, rectal bleeding subscore, and Mayo endoscopy subscore) at Week 8 were considered not to be in remission. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study. |   |
| End point type  | Secondary   |
| End point timeframe:<br>Week 8  |   |

| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 319  | 320  | 322  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       | 7.8  | 18.8   | 20.8   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific)

|                 |  |
|-----------------|--|
| End point title | Induction Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 8 (US Specific) |
|-----------------|--|

**End point description:**

Percentage of subjects in remission based on stool frequency subscore of 0 (normal number of stools), rectal bleeding subscore of 0 (no blood seen), and endoscopy subscore of 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]) at Week 8 were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who were missing all 3 of the Mayo components related to this OM (stool frequency, rectal bleeding subscore, and Mayo endoscopy subscore) at Week 8 were considered not to be in remission. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects randomized in the induction study.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 8

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 3.1   | 10.9                                  | 9.0                                     |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Induction Study - Change from Baseline in C-reactive Protein (CRP) Concentration Through Week 8**

|                 |   |
|-----------------|---|
| End point title | Induction Study - Change from Baseline in C-reactive Protein (CRP) Concentration Through Week 8 |
|-----------------|---|

**End point description:**

Change from baseline in CRP concentration through Week 8 was reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing CRP value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects who were analyzed for this OM.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 8

| End point values                  | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-----------------------------------|---|---------------------------------------|---|--|
| Subject group type                | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed       | 316   | 315                                   | 320                                     |  |
| Units: milligram per liter (mg/L) |   |                                       |   |  |

|                                       |                       |                       |                        |  |
|---------------------------------------|-----------------------|-----------------------|------------------------|--|
| median (inter-quartile range (Q1-Q3)) |                       |                       |                        |  |
| Change at Week 2                      | -0.01 (-2.79 to 1.21) | -0.75 (-4.53 to 0.00) | -0.92 (-6.24 to 0.05)  |  |
| Change at Week 4                      | -0.18 (-3.12 to 0.71) | -1.08 (-5.86 to 0.00) | -1.94 (-7.16 to -0.06) |  |
| Change at Week 8                      | 0.00 (-2.47 to 2.61)  | -1.30 (-5.04 to 0.30) | -1.43 (-7.36 to 0.00)  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Normalized CRP ( $\leq 3$ mg/L) up to Week 8 Among Subjects with Abnormal CRP ( $> 3$ mg/L) at Baseline

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Normalized CRP ( $\leq 3$ mg/L) up to Week 8 Among Subjects with Abnormal CRP ( $> 3$ mg/L) at Baseline |
|-----------------|---|

End point description:

Percentage of subjects with normalized CRP ( $\leq 3$  mg/L) up to Week 8 among subjects with abnormal CRP ( $> 3$  mg/L) at baseline were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had a missing CRP value at the designated analysis timepoint were considered not to have normalized CRP. PEAS consisted of all subjects randomized in the induction study, with those subjects who were having abnormal CRP at baseline.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 8

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 185   | 185                                   | 199                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       |   |                                       |   |  |
| Week 2                        | 19.5  | 29.2                                  | 29.1                                    |  |
| Week 4                        | 22.2  | 37.8                                  | 37.7                                    |  |
| Week 8                        | 21.1  | 34.1                                  | 38.7                                    |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in Fecal Lactoferrin Concentration Through Week 8

|                 |  |
|-----------------|--|
| End point title | Induction Study - Change from Baseline in Fecal Lactoferrin Concentration Through Week 8 |
|-----------------|--|

End point description:

Change from baseline in fecal lactoferrin concentration through Week 8 was reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing fecal lactoferrin value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects who were analyzed for this OM.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 8

| End point values                      | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|---------------------------------------|---|---------------------------------------|---|--|
| Subject group type                    | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed           | 294   | 302                                   | 306                                     |  |
| Units: microgram per gram (mcg/g)     |   |                                       |   |  |
| median (inter-quartile range (Q1-Q3)) |   |                                       |   |  |
| Change at Week 2                      | 0.00 (-103.22 to 120.67)                      | -4.67 (-140.04 to 75.46)              | -24.06 (-202.88 to 60.23)               |  |
| Change at Week 4                      | 0.00 (-117.67 to 133.67)                      | -29.26 (-203.79 to 46.29)             | -69.51 (-240.62 to 24.90)               |  |
| Change at Week 8                      | -4.71 (-149.28 to 92.90)                      | -43.41 (-220.99 to 29.10)             | -101.46 (-301.23 to 0.00)               |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Normalized Fecal Lactoferrin ( $\leq 7.24$ mcg/g) up to Week 8 Among Subjects with Abnormal fecal lactoferrin ( $> 7.24$ mcg/g) at Baseline

|                 |   |
|-----------------|---|
| End point title | Induction Study - Percentage of Subjects with Normalized Fecal Lactoferrin ( $\leq 7.24$ mcg/g) up to Week 8 Among Subjects with Abnormal fecal lactoferrin ( $> 7.24$ mcg/g) at Baseline |
|-----------------|---|

End point description:

Percentage of subjects with normalized fecal lactoferrin ( $\leq 7.24$  mcg/g) up to Week 8 among subjects with abnormal fecal lactoferrin ( $> 7.24$  mcg/g) at baseline were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had a missing fecal lactoferrin value at the designated analysis timepoint were considered not to have normalized fecal lactoferrin. PEAS consisted of all subjects randomized in the induction study, with those subjects who had abnormal fecal lactoferrin at baseline.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 8



| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 280  | 291  | 294  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       |  |  |  |  |
| Week 2                        | 5.7  | 5.8  | 5.1  |  |
| Week 4                        | 5.7  | 12.7   | 11.2   |  |
| Week 8                        | 9.3  | 17.2   | 14.6   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in Fecal Calprotectin Concentration Through Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Change from Baseline in Fecal Calprotectin Concentration Through Week 8 |
|-----------------|---|

End point description:

Change from baseline in fecal calprotectin concentration through Week 8 was reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from the time of the event onward. Subjects who had a missing fecal calprotectin value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects who were analyzed for this OM.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 8

| End point values                      | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|---------------------------------------|--|--|--|--|
| Subject group type                    | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed           | 289  | 296  | 300  |  |
| Units: milligram per kilogram (mg/kg) |  |  |  |  |
| median (inter-quartile range (Q1-Q3)) |  |  |  |  |
| Change at Week 2                      | 0.00 (-702.00<br>to 631.00)                            | -29.00 (-<br>933.50 to<br>492.00)              | -127.00 (-<br>1029.50 to<br>433.50)              |  |
| Change at Week 4                      | -2.00 (-961.00<br>to 894.00)                           | -223.00 (-<br>1200.50 to<br>266.50)            | -485.50 (-<br>1536.50 to<br>158.50)              |  |

|                  |                            |                              |                            |  |
|------------------|----------------------------|------------------------------|----------------------------|--|
| Change at Week 8 | -59.00 (-996.00 to 751.00) | -431.50 (-1635.50 to 175.00) | -715.50 (-1913.50 to 0.00) |  |
|------------------|----------------------------|------------------------------|----------------------------|--|

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with Normalized Fecal Calprotectin ( $\leq 250$ mg/kg) up to Week 8 Among Subjects with Abnormal Fecal Calprotectin ( $> 250$ mg/kg) at Baseline

|  |   |
|--|---|
| End point title  | Induction Study - Percentage of Subjects with Normalized Fecal Calprotectin ( $\leq 250$ mg/kg) up to Week 8 Among Subjects with Abnormal Fecal Calprotectin ( $> 250$ mg/kg) at Baseline |
| End point description:<br>Percentage of subjects with normalized fecal calprotectin ( $\leq 250$ milligram per kilogram [mg/kg]) up to Week 8 among subjects with abnormal fecal calprotectin ( $> 250$ mg/kg) at baseline were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had a missing fecal calprotectin value at the designated analysis timepoint were considered not to have normalized fecal calprotectin. PEAS consisted of all randomized subjects in the induction study, with abnormal fecal calprotectin ( $> 250$ mg/kg) at baseline. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Up to Week 8   |   |

| End point values              | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|-------------------------------|--|--|--|--|
| Subject group type            | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed   | 250  | 264  | 274  |  |
| Units: Percentage of Subjects |  |  |  |  |
| number (not applicable)       |  |  |  |  |
| Week 2                        | 8.0  | 14.0   | 13.5   |  |
| Week 4                        | 10.0   | 17.0   | 17.2   |  |
| Week 8                        | 20.4   | 24.2   | 25.5   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Percentage of Subjects with a $> 20$ -point Improvement from Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8

|                 |  |
|-----------------|--|
| End point title | Induction Study - Percentage of Subjects with a $> 20$ -point Improvement from Baseline in Total Inflammatory Bowel Disease Questionnaire (IBDQ) Score at Week 8 |
|-----------------|--|

---

**End point description:**

The IBDQ is 32-item questionnaire for subjects with IBD used to evaluate disease-specific health-related quality of life. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains were scored as follows: 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); and 5 to 35 (social function). For each domain, higher score indicated better quality of life. Total score is sum of each item score and ranges from 32 to 224 with higher score means better quality of life. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy prior to the Week 8 or who had a missing IBDQ score at either baseline or Week 8 were considered not to have achieved a greater than 20-point improvement. PEAS consisted of all subjects randomized in the induction study.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

End point timeframe:

Baseline and Week 8

---

| End point values              | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|-------------------------------|---|---------------------------------------|---|--|
| Subject group type            | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed   | 319   | 320                                   | 322                                     |  |
| Units: Percentage of Subjects |   |                                       |   |  |
| number (not applicable)       | 37.0  | 61.3                                  | 62.1                                    |  |

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Induction Study - Change from Baseline in IBDQ Dimension Scores at Week 8**

---

|                 |   |
|-----------------|---|
| End point title | Induction Study - Change from Baseline in IBDQ Dimension Scores at Week 8 |
|-----------------|---|

---

End point description:

IBDQ questionnaire used to evaluate disease-specific health-related quality of life (QoL), consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response), which were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. These domains were scored as 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); and 5 to 35 (social function). Each domain, higher score means better QoL. Total score is sum of each item score; ranges: 32 to 224; higher score means better QoL. Subjects who had prohibited change in concomitant UC medication/ostomy/colectomy prior to Week 8 had their baseline value carried forward from time of event onward and subjects who had missing score at designated analysis timepoint had their last value carried forward. PEAS included all subjects randomized in IS. Here, n (number of subjects analyzed) refers subjects analyzed for this OM at specified category.

---

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

---

End point timeframe:

Baseline and Week 8

---

| End point values                               | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|--|--|--|--|--|
| Subject group type                             | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed                    | 317  | 319  | 321  |  |
| Units: Units on a scale                        |  |  |  |  |
| arithmetic mean (standard deviation)           |  |  |  |  |
| Bowel: Change at Week 8 (n= 317, 319, 321)     | 5.9 (± 10.34)  | 12.5 (± 11.27)                                 | 12.7 (± 11.11)                                   |  |
| Emotional: Change at Week 8 (n= 317, 317, 321) | 5.3 (± 12.33)  | 10.1 (± 12.39)                                 | 11.2 (± 12.33)                                   |  |
| Systemic: Change at Week 8 (n= 317, 319, 321)  | 2.3 (± 5.59)   | 5.1 (± 5.59)                                   | 5.2 (± 5.65)                                     |  |
| Social: Change at Week 8 (n= 317, 318, 321)    | 2.7 (± 6.55)   | 5.7 (± 7.41)                                   | 5.9 (± 6.44)                                     |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Week 8

|                 |  |
|-----------------|--|
| End point title | Induction Study - Change from Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Week 8 |
|-----------------|--|

End point description:

SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each scales scored from 0 to 100 with higher scores= better health. Based on scale scores, physical component summary (PCS: calculated from subscales physical functioning, role-physical, bodily pain, and general health) and mental component summary (MCS: calculated from subscales vitality, social functioning, role-emotional and mental health) scores were derived. Subjects who had prohibited change in concomitant UC medication/ostomy/colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing component summary score at Week 8 had their last value carried forward. PEAS included all subjects randomized in the IS. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 8

| End point values                     | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|--------------------------------------|--|--|--|--|
| Subject group type                   | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed          | 319  | 318  | 322  |  |
| Units: Units on a scale              |  |  |  |  |
| arithmetic mean (standard deviation) |  |  |  |  |
| PCS: Change at Week 8                | 2.1 (± 6.39)   | 4.7 (± 6.49)                                   | 5.2 (± 6.16)                                     |  |
| MCS: Change at Week 8                | 2.2 (± 10.20)  | 5.3 (± 9.63)                                   | 5.1 (± 9.72)                                     |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Week 8

|                 |  |
|-----------------|--|
| End point title | Induction Study - Change from Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Week 8 |
|-----------------|--|

End point description:

SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. Subjects who had prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing individual scale at a designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects who were analyzed for this OM.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and Week 8

| End point values                       | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|--|--|--|--|--|
| Subject group type                     | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed            | 319  | 318  | 322  |  |
| Units: Units on a scale                |  |  |  |  |
| arithmetic mean (standard deviation)   |  |  |  |  |
| Physical functioning: Change at Week 8 | 1.7 (± 6.46)   | 3.0 (± 6.46)                                   | 3.4 (± 6.51)                                     |  |
| Role-physical: Change at Week 8        | 2.4 (± 9.51)   | 5.9 (± 9.34)                                   | 6.1 (± 8.53)                                     |  |
| Bodily pain: Change at Week 8          | 2.6 (± 9.71)   | 6.0 (± 9.45)                                   | 6.8 (± 9.08)                                     |  |
| General health: Change at Week 8       | 1.5 (± 7.36)   | 4.7 (± 7.74)                                   | 4.5 (± 7.10)                                     |  |
| Vitality: Change at Week 8             | 2.7 (± 9.93)   | 6.1 (± 9.35)                                   | 6.8 (± 9.78)                                     |  |
| Social functioning: Change at Week 8   | 3.0 (± 10.52)  | 6.6 (± 10.25)                                  | 6.4 (± 9.84)                                     |  |
| Role-emotional: Change at Week 8       | 1.6 (± 11.04)  | 4.4 (± 11.04)                                  | 3.6 (± 10.53)                                    |  |
| Mental health: Change at Week 8        | 2.0 (± 9.86)   | 4.7 (± 9.14)                                   | 5.1 (± 9.27)                                     |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Induction Study - Change from Baseline in EuroQOL-5 Dimensions (EQ-

## 5D) Health Questionnaire index Score at Week 8

|  |   |
|--|---|
| End point title  | Induction Study - Change from Baseline in EuroQOL-5 Dimensions (EQ-5D) Health Questionnaire index Score at Week 8 |
| End point description:<br>EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 (death) to 1 (full health). Subjects who had prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing score at a designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects analyzed for this OM. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Baseline and Week 8  |   |

| End point values                     | Induction Study(IS):<br>Placebo<br>Intravenous<br>(IV) | IS:<br>Ustekinumab<br>130 milligram<br>(mg) IV | IS:<br>Ustekinumab<br>approximately<br>6mg/kg IV |  |
|--------------------------------------|--|--|--|--|
| Subject group type                   | Reporting group  | Reporting group                                | Reporting group                                  |  |
| Number of subjects analysed          | 317  | 319  | 322  |  |
| Units: Units on a scale              |  |  |  |  |
| arithmetic mean (standard deviation) | 0.04 (± 0.182)   | 0.09 (± 0.182)                                 | 0.11 (± 0.172)                                   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Change from Baseline in EuroQOL-5 Dimensions (EQ-5D) Health State Visual Analog Scale (VAS) Score at Week 8

|                 |   |
|-----------------|---|
| End point title | Induction Study - Change from Baseline in EuroQOL-5 Dimensions (EQ-5D) Health State Visual Analog Scale (VAS) Score at Week 8 |
|-----------------|---|

End point description:

The EQ-5D VAS records the subject's self-rated health on a vertical, VAS, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual subjects. Subjects who had prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing score at a designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects randomized in the induction study. Here, N (number of subjects analyzed) signifies subjects analyzed for this OM.

|   |           |
|---|-----------|
| End point type                              | Secondary |
| End point timeframe:<br>Baseline and Week 8 |           |

| End point values                     | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--------------------------------------|---|---------------------------------------|---|--|
| Subject group type                   | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed          | 317   | 319                                   | 322                                     |  |
| Units: Units on a scale              |   |                                       |   |  |
| arithmetic mean (standard deviation) | 5.71 ( $\pm$ 19.584)                          | 13.64 ( $\pm$ 20.394)                 | 13.51 ( $\pm$ 18.447)                   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Induction Study - Percentage of Subjects with Change from Baseline in EuroQOL-5 Dimensions (EQ-5D) Score at Week 8

|  |  |
|--|--|
| End point title  | Induction Study - Percentage of Subjects with Change from Baseline in EuroQOL-5 Dimensions (EQ-5D) Score at Week 8 |
| End point description:   |  |
| EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 (death) to 1 (full health). Subjects who had prohibited change in concomitant UC medication or an ostomy or colectomy prior to Week 8 had their baseline value carried forward from time of event onward or subjects who had missing score at a designated analysis timepoint had their last value carried forward. Percentage of subjects with various responses to the 5 dimensions were reported. PEAS consisted of all subjects randomized in the induction study. Here, n (number of subjects analyzed) signifies subjects who were analyzed for this OM at specified category. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| Baseline and Week 8  |  |

| End point values                                 | Induction Study(IS): Placebo Intravenous (IV) | IS: Ustekinumab 130 milligram (mg) IV | IS: Ustekinumab approximately 6mg/kg IV |  |
|--|---|---------------------------------------|---|--|
| Subject group type                               | Reporting group                               | Reporting group                       | Reporting group                         |  |
| Number of subjects analysed                      | 319   | 320                                   | 322                                     |  |
| Units: Percentage of subjects                    |   |                                       |   |  |
| number (not applicable)                          |   |                                       |   |  |
| Mobility:Improved at Week 8 (n= 317, 319, 322)   | 18.0  | 16.3                                  | 24.2                                    |  |
| Mobility:No change at Week 8 (n= 317, 319, 322)  | 71.9  | 71.8                                  | 66.8                                    |  |
| Mobility:Worsened at Week 8 (n= 317, 319, 322)   | 10.1  | 11.9                                  | 9.0                                     |  |
| Self-care:Improved at Week 8 (n= 317, 319, 322)  | 5.4   | 6.9                                   | 7.5                                     |  |
| Self-care:No change at Week 8 (n= 317, 319, 322) | 89.6  | 88.4                                  | 90.4                                    |  |

|  |      |      |      |  |
|--|------|------|------|--|
| Self-care:Worsened at Week 8 (n= 317, 319, 322)    | 5.0  | 4.7  | 2.2  |  |
| Usual activities:Improved Week 8(n=317,319,322)    | 34.1 | 49.5 | 45.0 |  |
| Usual activities:No Change Week 8(n=317,319,322)   | 51.1 | 40.4 | 44.1 |  |
| Usual activities:Worsened Week 8(n=317,319,322)    | 14.8 | 10.0 | 10.9 |  |
| Pain/discomfort:Improved Week 8(n=319,320,322)     | 34.4 | 44.2 | 43.5 |  |
| Pain/discomfort:No Change Week 8(n= 317,319,322)   | 49.8 | 48.3 | 48.1 |  |
| Pain/discomfort:Worsened Week 8(n=317,319,322)     | 15.8 | 7.5  | 8.4  |  |
| Anxiety/depression:Improved Week 8(n=317,319,322)  | 26.8 | 33.5 | 37.6 |  |
| Anxiety/depression:No Change Week 8(n=317,319,322) | 55.5 | 54.2 | 51.6 |  |
| Anxiety/depression:Worsened Week 8(n=317,319,322)  | 17.7 | 12.2 | 10.9 |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study - Change from Maintenance Baseline in Mayo score at Week 44

|  |   |
|--|---|
| End point title  | Maintenance Study - Change from Maintenance Baseline in Mayo score at Week 44 |
| End point description:<br>The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and PGA), rated as 0 (normal) to 3 (severe). Total score is calculated as sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5=mild; 6 to 10=moderate; and 11 to 12=severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy , or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to Week 44 had their Week 0 value of the induction study carried forward or who had all 4 Mayo subscores missing at Week 44 had their last available individual Mayo subscores carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Baseline and Week 44   |   |

| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 175  | 172   | 176  |  |
| Units: Units on a scale              |  |   |  |  |
| arithmetic mean (standard deviation) | 1.6 (± 3.45)   | 0.1 (± 3.02)  | -0.5 (± 2.88)  |  |



## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study - Change from Induction Baseline in Mayo Score at Week 44

|                 |   |
|-----------------|---|
| End point title | Maintenance Study - Change from Induction Baseline in Mayo Score at Week 44 |
|-----------------|---|

End point description:

The Mayo score consists of 4 subscores (stool frequency, rectal bleeding, endoscopy findings, and PGA), rated as 0 (normal) to 3 (severe). Total Mayo score is calculated as sum of 4 subscores and values range from 0 to 12 scores, where 3 to 5=mild; 6 to 10=moderate; and 11 to 12=severe disease. Subjects who had a prohibited change in concomitant UC medication/ostomy/colectomy or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward or who had all 4 Mayo subscores missing at Week 44 had their last available individual Mayo subscores carried forward. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Induction Baseline and Week 44

| End point values                     | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed          | 175  | 172   | 176   |  |
| Units: Units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) | -3.3 (± 3.34)                                    | -5.0 (± 3.27)                                 | -5.6 (± 3.17)                               |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study - Percentage of Subjects with Individual Mayo Subscore (Stool Frequency) up to Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study - Percentage of Subjects with Individual Mayo Subscore (Stool Frequency) up to Week 44 |
|-----------------|--|

End point description:

Stool frequency subscore of Mayo score is rated as 0 (normal) to 3 (severe). Stool frequency scores: 0 =normal number of stools, 1 = 1-2 stools more than normal, 2 = 3-4 stools more than normal, 3 = 5 or more stools more than normal. Subjects who had a prohibited change in concomitant UC medication or

an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward or who had a missing Mayo subscores at a timepoint had the last available value for that subscore carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Up to Week 44        |           |

| End point values                           | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--|--|---|--|--|
| Subject group type                         | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed                | 175  | 172   | 176  |  |
| Units: Percentage of Subjects              |  |   |  |  |
| number (not applicable)                    |  |   |  |  |
| Week 4:Normal number of stools             | 32.0   | 35.5  | 33.0   |  |
| Week 4:1-2 stools more than normal         | 52.0   | 44.2  | 48.9   |  |
| Week 4: 3-4 stools more than normal        | 12.0   | 15.1  | 16.5   |  |
| Week 4: 5 or more stools more than normal  | 4.0  | 5.2   | 1.7  |  |
| Week 8:Normal number of stools             | 40.0   | 36.0  | 34.7   |  |
| Week 8:1-2 stools more than normal         | 39.4   | 43.6  | 47.7   |  |
| Week 8: 3-4 stools more than normal        | 12.6   | 14.5  | 14.8   |  |
| Week 8: 5 or more stools more than normal  | 8.0  | 5.8   | 2.8  |  |
| Week 12:Normal number of stools            | 35.4   | 32.0  | 36.4   |  |
| Week 12:1-2 stools more than normal        | 41.1   | 43.6  | 48.3   |  |
| Week 12: 3-4 stools more than normal       | 11.4   | 16.3  | 11.9   |  |
| Week 12: 5 or more stools more than normal | 12.0   | 8.1   | 3.4  |  |
| Week 16:Normal number of stools            | 36.0   | 29.7  | 41.5   |  |
| Week 16:1-2 stools more than normal        | 37.7   | 45.3  | 43.8   |  |
| Week 16: 3-4 stools more than normal       | 14.3   | 15.7  | 8.5  |  |
| Week 16: 5 or more stools more than normal | 12.0   | 9.3   | 6.3  |  |
| Week 20:Normal number of stools            | 33.7   | 36.6  | 38.1   |  |
| Week 20:1-2 stools more than normal        | 31.4   | 37.8  | 48.3   |  |
| Week 20: 3-4 stools more than normal       | 19.4   | 15.1  | 8.5  |  |
| Week 20: 5 or more stools more than normal | 15.4   | 10.5  | 5.1  |  |
| Week 24:Normal number of stools            | 28.6   | 37.2  | 40.9   |  |
| Week 24:1-2 stools more than normal        | 36.0   | 35.5  | 41.5   |  |
| Week 24: 3-4 stools more than normal       | 17.7   | 18.0  | 11.4   |  |
| Week 24: 5 or more stools more than normal | 17.7   | 9.3   | 6.3  |  |
| Week 28:Normal number of stools            | 29.7   | 37.2  | 38.1   |  |
| Week 28:1-2 stools more than normal        | 30.3   | 37.2  | 43.2   |  |
| Week 28: 3-4 stools more than normal       | 19.4   | 14.0  | 12.5   |  |

|  |      |      |      |  |
|--|------|------|------|--|
| Week 28: 5 or more stools more than normal | 20.6 | 11.6 | 6.3  |  |
| Week 32: Normal number of stools           | 29.1 | 34.3 | 40.9 |  |
| Week 32: 1-2 stools more than normal       | 31.4 | 38.4 | 41.5 |  |
| Week 32: 3-4 stools more than normal       | 20.0 | 14.5 | 10.2 |  |
| Week 32: 5 or more stools more than normal | 19.4 | 12.8 | 7.4  |  |
| Week 36: Normal number of stools           | 28.0 | 34.3 | 43.8 |  |
| Week 36: 1-2 stools more than normal       | 29.7 | 34.9 | 37.5 |  |
| Week 36: 3-4 stools more than normal       | 20.6 | 16.9 | 10.2 |  |
| Week 36: 5 or more stools more than normal | 21.7 | 14.0 | 8.5  |  |
| Week 40: Normal number of stools           | 28.0 | 32.0 | 46.0 |  |
| Week 40: 1-2 stools more than normal       | 28.6 | 37.8 | 33.0 |  |
| Week 40: 3-4 stools more than normal       | 20.6 | 15.1 | 11.9 |  |
| Week 40: 5 or more stools more than normal | 22.9 | 15.1 | 9.1  |  |
| Week 44: Normal number of stools           | 26.3 | 36.0 | 40.3 |  |
| Week 44: 1-2 stools more than normal       | 30.3 | 33.1 | 40.9 |  |
| Week 44: 3-4 stools more than normal       | 20.0 | 16.3 | 9.1  |  |
| Week 44: 5 or more stools more than normal | 23.4 | 14.5 | 9.7  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study - Percentage of Subjects with individual Mayo Subscore (Rectal Bleeding) up to Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study - Percentage of Subjects with individual Mayo Subscore (Rectal Bleeding) up to Week 44 |
|-----------------|--|

End point description:

The rectal bleeding subscore of the Mayo Score is rated as 0 (normal) to 3 (severe). Rectal bleeding scores: 0 = no blood seen, 1 = streaks of blood with stool <half time, 2 = obvious blood with stool most of time, and 3 = blood alone passed. Higher scores = worsening of disease. Subjects who had prohibited change in concomitant UC medication/ ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ due to AE of worsening of UC before Week 44 had their Week 0 value of induction study carried forward from time of event onward and who had missing Mayo subscores at timepoint had last available value for that subscore carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 44

| End point values                                   | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--|--|---|--|--|
| Subject group type                                 | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed                        | 175  | 172   | 176  |  |
| Units: Percentage of Subjects                      |  |   |  |  |
| number (not applicable)                            |  |   |  |  |
| Week 4:No blood seen                               | 85.1   | 86.0  | 81.3   |  |
| Week 4:Streaks of blood with stool < half time     | 11.4   | 13.4  | 16.5   |  |
| Week 4: Obvious blood with stool most of the time  | 2.3  | 0.6   | 13.6   |  |
| Week 4: Blood alone passed                         | 1.1  | 0.0   | 0.0  |  |
| Week 8:No blood seen                               | 79.4   | 87.8  | 80.1   |  |
| Week 8:Streaks of blood with stool < half time     | 15.4   | 9.9   | 17.6   |  |
| Week 8: Obvious blood with stool most of time      | 3.4  | 1.7   | 2.3  |  |
| Week 8:Blood alone passed                          | 1.7  | 0.6   | 0.0  |  |
| Week 12:No blood seen                              | 80.6   | 83.7  | 84.7   |  |
| Week 12:Streaks of blood with stool <half time     | 12.0   | 11.0  | 10.2   |  |
| Week 12: Obvious blood with stool most of the time | 5.7  | 4.7   | 3.4  |  |
| Week 12: Blood alone passed                        | 1.7  | 0.6   | 1.7  |  |
| Week 16:No blood seen                              | 80.6   | 83.7  | 84.7   |  |
| Week 16:Streaks of blood with stool < half time    | 12.0   | 11.0  | 10.2   |  |
| Week 16: Obvious blood with stool most of the time | 5.7  | 4.7   | 3.4  |  |
| Week 16: Blood alone passed                        | 1.7  | 0.6   | 1.7  |  |
| Week 20:No blood seen                              | 76.6   | 84.3  | 85.2   |  |
| Week 20:Streaks of blood with stool <half time     | 13.7   | 9.9   | 9.7  |  |
| Week 20: Obvious blood with stool most of the time | 7.4  | 4.7   | 4.5  |  |
| Week 20: Blood alone passed                        | 2.3  | 1.2   | 0.6  |  |
| Week 24:No blood seen                              | 68.6   | 82.0  | 81.8   |  |
| Week 24:Streaks of blood with stool <half time     | 17.7   | 9.9   | 11.4   |  |
| Week 24: Obvious blood with stool most of the time | 10.9   | 7.0   | 6.3  |  |
| Week 24: Blood alone passed                        | 2.9  | 1.2   | 0.6  |  |
| Week 28:No blood seen                              | 65.1   | 82.0  | 83.5   |  |
| Week 28:Streaks of blood with stool <half time     | 14.9   | 10.5  | 6.8  |  |
| Week 28: Obvious blood with stool most of the time | 16.0   | 5.8   | 8.0  |  |
| Week 28: Blood alone passed                        | 4.0  | 1.7   | 1.7  |  |
| Week 32:No blood seen                              | 62.3   | 80.2  | 83.5   |  |
| Week 32:Streaks of blood with stool <half time     | 18.3   | 9.3   | 7.4  |  |
| Week 32: Obvious blood with stool most of the time | 14.3   | 8.1   | 8.0  |  |
| Week 32: Blood alone passed                        | 5.1  | 2.3   | 1.1  |  |
| Week 36:No blood seen                              | 61.7   | 79.1  | 85.2   |  |

|  |      |      |      |  |
|--|------|------|------|--|
| Week 36:Streaks of blood with stool <half time     | 17.1 | 10.5 | 5.1  |  |
| Week 36: Obvious blood with stool most of the time | 16.0 | 8.7  | 8.5  |  |
| Week 36: Blood alone passed                        | 5.1  | 1.7  | 1.1  |  |
| Week 40:No blood seen                              | 60.0 | 76.7 | 83.5 |  |
| Week 40:Streaks of blood with stool <half time     | 18.9 | 12.8 | 5.7  |  |
| Week 40: Obvious blood with stool most of the time | 16.0 | 7.6  | 9.7  |  |
| Week 40: Blood alone passed                        | 5.1  | 2.9  | 1.1  |  |
| Week 44:No blood seen                              | 57.7 | 79.7 | 79.0 |  |
| Week 44::Streaks of blood with stool <half time    | 20.0 | 8.7  | 9.1  |  |
| Week 44: Obvious blood with stool most of the time | 17.1 | 8.7  | 10.8 |  |
| Week 44: Blood alone passed                        | 5.1  | 2.9  | 1.1  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study - Percentage of Subjects with Individual Mayo Subscore (Endoscopy Findings) at Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study - Percentage of Subjects with Individual Mayo Subscore (Endoscopy Findings) at Week 44 |
|-----------------|--|

End point description:

The endoscopy findings subscore of the Mayo score is rated as 0 (normal) to 3 (severe). Endoscopy finding scores: 0=normal/ inactive disease, 1=mild disease (erythema, decreased vascular pattern, mild friability), 2 =moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 =severe disease (spontaneous bleeding, ulceration). Higher scores=worse disease. Subjects who had prohibited change in concomitant UC medication/ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 had Week 0 value of induction study carried forward from time of event onward and who had missing endoscopy subscores at timepoint had last available value for that subscore carried forward. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 44

| End point values                    | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------------|--|---|---|--|
| Subject group type                  | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed         | 175  | 172   | 176   |  |
| Units: Percentage of Subjects       |  |   |   |  |
| number (not applicable)             |  |   |   |  |
| Week 44: Normal or inactive disease | 18.9   | 25.0  | 29.5  |  |
| Week 44:Mild disease                | 12.0   | 21.5  | 23.9  |  |

|                           |      |      |      |  |
|---------------------------|------|------|------|--|
| Week 44: Moderate disease | 22.9 | 24.4 | 28.4 |  |
| Week 44: Severe disease   | 46.3 | 29.1 | 18.2 |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study - Percentage of Subjects with individual Mayo Subscore (Physician's Global Assessment) up to Week 44

|   |  |
|---|--|
| End point title   | Maintenance Study - Percentage of Subjects with individual Mayo Subscore (Physician's Global Assessment) up to Week 44 |
| End point description:  |  |
| <p>The physician's global assessment subscore of the Mayo score is rated as 0 (normal) to 3 (severe). Physician's global assessment scores: 0 = normal, 1 = mild disease, 2 = moderate disease, and 3 = severe disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward and who had a missing Mayo subscores at a timepoint had the last available value for that subscore carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.</p> |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Up to Week 44   |  |

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 175  | 172   | 176   |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       |  |   |   |  |
| Week 4: Normal                | 35.4   | 35.5  | 33.5  |  |
| Week 4: Mild disease          | 57.1   | 57.6  | 59.7  |  |
| Week 4: Moderate disease      | 6.9  | 7.0   | 6.3   |  |
| Week 4: Severe disease        | 0.6  | 0.0   | 0.6   |  |
| Week 8: Normal                | 37.1   | 40.7  | 43.2  |  |
| Week 8: Mild disease          | 51.4   | 51.7  | 50.0  |  |
| Week 8: Moderate disease      | 9.7  | 7.6   | 6.3   |  |
| Week 8: Severe disease        | 1.7  | 0.0   | 0.6   |  |
| Week 12: Normal               | 37.7   | 39.5  | 41.5  |  |
| Week 12: Mild disease         | 45.1   | 47.1  | 50.0  |  |
| Week 12: Moderate disease     | 14.9   | 9.3   | 8.0   |  |
| Week 12: Severe disease       | 2.3  | 4.1   | 0.6   |  |
| Week 16: Normal               | 38.3   | 47.7  | 47.2  |  |
| Week 16: Mild disease         | 38.9   | 40.1  | 44.3  |  |

|                           |      |      |      |  |
|---------------------------|------|------|------|--|
| Week 16: Moderate disease | 18.3 | 8.1  | 7.4  |  |
| Week 16: Severe disease   | 4.6  | 4.1  | 1.1  |  |
| Week 20: Normal           | 37.1 | 49.4 | 47.7 |  |
| Week 20: Mild disease     | 32.6 | 36.6 | 41.5 |  |
| Week 20: Moderate disease | 23.4 | 9.3  | 9.1  |  |
| Week 20: Severe disease   | 6.9  | 4.7  | 1.7  |  |
| Week 24: Normal           | 30.9 | 48.8 | 51.7 |  |
| Week 24: Mild disease     | 34.9 | 37.8 | 38.6 |  |
| Week 24: Moderate disease | 25.1 | 8.1  | 8.5  |  |
| Week 24: Severe disease   | 9.1  | 5.2  | 1.1  |  |
| Week 28: Normal           | 33.1 | 50.0 | 50.6 |  |
| Week 28: Mild disease     | 29.7 | 36.6 | 36.9 |  |
| Week 28: Moderate disease | 26.9 | 8.1  | 11.4 |  |
| Week 28: Severe disease   | 10.3 | 5.2  | 1.1  |  |
| Week 32: Normal           | 31.4 | 48.8 | 52.3 |  |
| Week 32: Mild disease     | 29.7 | 32.6 | 35.2 |  |
| Week 32: Moderate disease | 26.3 | 13.4 | 10.8 |  |
| Week 32: Severe disease   | 12.6 | 5.2  | 1.7  |  |
| Week 36: Normal           | 33.7 | 45.3 | 52.8 |  |
| Week 36: Mild disease     | 25.7 | 34.9 | 34.1 |  |
| Week 36: Moderate disease | 26.9 | 14.0 | 10.8 |  |
| Week 36: Severe disease   | 13.7 | 5.8  | 2.3  |  |
| Week 40: Normal           | 32.6 | 48.3 | 51.7 |  |
| Week 40: Mild disease     | 27.4 | 29.1 | 34.1 |  |
| Week 40: Moderate disease | 25.1 | 14.0 | 11.9 |  |
| Week 40: Severe disease   | 14.9 | 8.7  | 2.3  |  |
| Week 44: Normal           | 26.9 | 45.3 | 48.3 |  |
| Week 44: Mild disease     | 25.1 | 31.4 | 35.2 |  |
| Week 44: Moderate disease | 32.6 | 14.0 | 14.2 |  |
| Week 44: Severe disease   | 15.4 | 9.3  | 2.3  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study - Change from Maintenance Baseline in Partial Mayo Score Through Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study - Change from Maintenance Baseline in Partial Mayo Score Through Week 44 |
|-----------------|--|

End point description:

The partial Mayo score, which is sum of 3 subscores of the Mayo score without the endoscopy subscore (stool frequency, rectal bleeding, and PGA subscores), rated as 0 (normal) to 3 (severe). Total score is sum of 3 subscores and values range from 0 to 9; higher scores means worse disease. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the IS carried forward from the time of the event onward. Subjects who had a missing partial Mayo score at a time point had their last available individual partial Mayo subscore carried forward to that time point. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:  
Baseline through Week 44

| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 175  | 172   | 176  |  |
| Units: Units on a scale              |  |   |  |  |
| arithmetic mean (standard deviation) |  |   |  |  |
| Change at Week 4                     | -0.2 (± 1.24)  | -0.3 (± 1.23)   | -0.1 (± 1.26)  |  |
| Change at Week 8                     | -0.1 (± 1.59)  | -0.3 (± 1.15)   | -0.2 (± 1.44)  |  |
| Change at Week 12                    | 0.1 (± 1.82)   | 0.0 (± 1.66)  | -0.2 (± 1.63)  |  |
| Change at Week 16                    | 0.3 (± 2.07)   | -0.1 (± 1.76)   | -0.3 (± 1.76)  |  |
| Change at Week 20                    | 0.6 (± 2.36)   | -0.1 (± 1.91)   | -0.2 (± 1.92)  |  |
| Change at Week 24                    | 0.9 (± 2.34)   | 0.0 (± 2.02)  | -0.3 (± 1.88)  |  |
| Change at Week 28                    | 1.0 (± 2.53)   | -0.1 (± 1.95)   | -0.2 (± 1.94)  |  |
| Change at Week 32                    | 1.1 (± 2.60)   | 0.1 (± 2.12)  | -0.2 (± 1.96)  |  |
| Change at Week 36                    | 1.2 (± 2.62)   | 0.2 (± 2.13)  | -0.2 (± 2.08)  |  |
| Change at Week 40                    | 1.3 (± 2.64)   | 0.3 (± 2.27)  | -0.2 (± 1.97)  |  |
| Change at Week 44                    | 1.5 (± 2.63)   | 0.3 (± 2.29)  | 0.0 (± 2.09)   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study - Change from Induction Baseline in Partial Mayo Score Through Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study - Change from Induction Baseline in Partial Mayo Score Through Week 44 |
|-----------------|--|

End point description:

The partial Mayo score, which is sum of 3 subscores of the Mayo score without the endoscopy subscore (stool frequency, rectal bleeding, and PGA subscores; rated as 0 [normal] to 3 [severe]). Total score is sum of the 3 subscores and values range from 0 to 9; higher scores means worse disease. Subjects who had a prohibited change in concomitant UC medication/ostomy/colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the IS carried forward from the time of the event onward. Subjects who had a missing partial Mayo score at a time point had their last available individual partial Mayo subscore carried forward to that time point. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline through Week 44



| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 175  | 172   | 176  |  |
| Units: Units on a scale              |  |   |  |  |
| arithmetic mean (standard deviation) |  |   |  |  |
| Change at Week 4                     | -4.2 (± 1.70)  | -4.5 (± 1.76)   | -4.4 (± 1.72)  |  |
| Change at Week 8                     | -4.1 (± 1.80)  | -4.5 (± 1.68)   | -4.5 (± 1.85)  |  |
| Change at Week 12                    | -3.9 (± 2.07)  | -4.2 (± 2.02)   | -4.5 (± 2.02)  |  |
| Change at Week 16                    | -3.7 (± 2.17)  | -4.3 (± 2.07)   | -4.6 (± 2.08)  |  |
| Change at Week 20                    | -3.4 (± 2.26)  | -4.3 (± 2.13)   | -4.5 (± 2.13)  |  |
| Change at Week 24                    | -3.1 (± 2.36)  | -4.2 (± 2.26)   | -4.5 (± 2.18)  |  |
| Change at Week 28                    | -3.0 (± 2.49)  | -4.3 (± 2.26)   | -4.4 (± 2.27)  |  |
| Change at Week 32                    | -2.9 (± 2.51)  | -4.1 (± 2.40)   | -4.5 (± 2.30)  |  |
| Change at Week 36                    | -2.8 (± 2.43)  | -4.0 (± 2.43)   | -4.5 (± 2.40)  |  |
| Change at Week 40                    | -2.7 (± 2.51)  | -3.9 (± 2.46)   | -4.5 (± 2.39)  |  |
| Change at Week 44                    | -2.5 (± 2.52)  | -3.9 (± 2.49)   | -4.3 (± 2.48)  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0 or 1, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44 |
|-----------------|--|

End point description:

Percentage of subjects in remission based on stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal), rectal bleeding subscore of 0 (no blood seen), and endoscopy subscore of 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]) at Week 44 were reported. Subjects who had a prohibited change in concomitant UC medication/ostomy/colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 and who were missing all 3 of the Mayo subscores related to this OM (stool frequency, rectal bleeding subscore, and Mayo endoscopy subscore) at Week 44 were considered not to be in remission. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 44

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 175  | 172   | 176  |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 28.0   | 40.7  | 47.7   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects in Remission Based on Stool Frequency Subscore of 0, Rectal Bleeding Subscore of 0, and Endoscopy Subscore of 0 or 1 at Week 44 |
|-----------------|---|

End point description:

Percentage of subjects in remission based on stool frequency subscore of 0 (normal number of stools), rectal bleeding subscore of 0 (no blood seen), and endoscopy subscore of 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]) at Week 44 were reported. Subjects who had a prohibited change in concomitant UC medication/ostomy/colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 or who were missing all 3 of the Mayo subscores related to this OM (stool frequency, rectal bleeding subscore, and Mayo endoscopy subscore) at Week 44 were considered not to be in remission. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 44

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 175  | 172   | 176  |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 17.1   | 24.4  | 27.3   |  |

## Statistical analyses

No statistical analyses for this end point

**Secondary: Maintenance Study: Percentage of Subjects in Symptomatic Remission at Week 44**

|  |   |
|--|---|
| End point title  | Maintenance Study: Percentage of Subjects in Symptomatic Remission at Week 44 |
| End point description:<br>Symptomatic remission was defined as a Mayo stool frequency subscore of 0 (normal number of stools) or 1 (1-2 stools more than normal) and a rectal bleeding subscore of 0 (no blood seen). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 were considered not to be in symptomatic remission from the time of the event onward. Subjects who had both stool frequency and rectal bleeding subscores missing at Week 44 were considered not to be in symptomatic remission for that visit. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 44  |   |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 175  | 172   | 176  |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 45.1   | 62.2  | 67.6   |  |

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 by Biologic Failure Status (As per Global Definition)**

|   |  |
|---|--|
| End point title   | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 by Biologic Failure Status (As per Global Definition) |
| End point description:<br>Global definition of clinical remission: Mayo score $\leq 2$ points, with no individual subscore $> 1$ . Mayo score included 4 subscores (stool frequency, rectal bleeding, endoscopy findings, physician's global assessment), rated as 0 (normal) to 3 (severe). Total score =sum of 4 subscores and range from 0 to 12, where 3 to 5=mild; 6 to 10=moderate; 11 to 12=severe disease. BF: participants received treatment with 1/ more TNF antagonists/ vedolizumab at dose approved for treatment of UC, and did not respond initially or responded initially but lost response/ were intolerant of medication. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) refers subjects who were analyzed for this OM with specified category. |  |
| End point type  | Secondary  |
| End point timeframe:<br>Week 44   |  |

| End point values                         | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--|--|---|--|--|
| Subject group type                       | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed              | 175  | 172   | 176  |  |
| Units: Percentage of Subjects            |  |   |  |  |
| number (not applicable)                  |  |   |  |  |
| Participants with BF (n=88, 70, 91)      | 17.0   | 22.9  | 39.6   |  |
| Participants without BF (n= 87, 102, 85) | 31.0   | 49.0  | 48.2   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 by Biologic Failure Status (As per US Definition)

|  |  |
|--|--|
| End point title  | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 by Biologic Failure Status (As per US Definition) |
| End point description:   |  |
| US definition of clinical remission: absolute stool number $\leq 3$ , Mayo rectal bleeding subscore: 0 (no blood seen), Mayo endoscopy subscore: 0(normal/ inactive disease) or 1(mild disease [erythema, decreased vascular pattern, mild friability]). Absolute stool number: average of daily stool number over 3 days. Mayo rectal bleeding and endoscopy subscores: 0(normal) to 3(severe). BF: subjects received 1/ more TNF antagonists/ vedolizumab for treatment of UC, not responded initially/ responded initially but lost response/ were intolerant of medicines. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM with specified category. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| Week 44  |  |

| End point values                    | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------------|--|---|--|--|
| Subject group type                  | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed         | 175  | 172   | 176  |  |
| Units: Percentage of Subjects       |  |   |  |  |
| number (not applicable)             |  |   |  |  |
| Subjects with BF (n=88, 70, 91)     | 17.0   | 24.3  | 37.4   |  |
| Subjects without BF (n=87, 102, 85) | 32.2   | 50.0  | 48.2   |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects with Clinical Response up to Week 44 by Biologic Failure Status

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects with Clinical Response up to Week 44 by Biologic Failure Status |
|-----------------|---|

End point description:

Clinical response: decrease from IS baseline in Mayo score by  $\geq 30\%$  and  $\geq 3$  points, with either decrease from baseline in RB subscore  $\geq 1$ / RB subscore of 0/ 1. Mayo score have 4 subscores (SF, RB, endoscopy findings, PGA), rated 0(normal) to 3(severe). Total score=sum of 4 subscores and range from 0 to 12, where 3 to 5=mild; 6 to 10=moderate; 11 to 12=severe disease. BF: subjects received treatment: 1/ more TNF antagonists/ vedolizumab for treating UC, no respond initially/responded initially but lost response/ medication intolerant. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM with specified category.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 44

| End point values                  | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-----------------------------------|--|---|---|--|
| Subject group type                | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed       | 175  | 172   | 176   |  |
| Units: Percentage of Subjects     |  |   |   |  |
| number (not applicable)           |  |   |   |  |
| Subjects with BF (n= 88, 70, 91)  | 38.6   | 55.7  | 64.8  |  |
| Subjects without BF (87, 102, 85) | 50.6   | 76.5  | 77.6  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44 by Biologic Failure Status

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44 by Biologic Failure Status |
|-----------------|---|

End point description:

Percentage of subjects with endoscopic healing at week 44 by BF status were reported. Endoscopic

healing is improvement in endoscopic appearance of mucosa. It is defined as Mayo endoscopic subscore = 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). BF: subjects received treatment with 1 or more tumor necrosis factor (TNF) antagonists or vedolizumab at dose approved for treatment of UC, and either did not respond initially, responded initially but then lost response, or were intolerant of medication. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM with specified category.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 44              |           |

| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 175  | 172   | 176  |  |
| Units: Percentage of Subjects        |  |   |  |  |
| number (not applicable)              |  |   |  |  |
| Subjects with BF (n=88, 70, 91)      | 22.7   | 25.7  | 45.1   |  |
| Subjects without BF (n= 87, 102, 85) | 34.5   | 55.9  | 57.6   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44 Among Subjects who had Achieved Endoscopic Healing at Maintenance Baseline

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Percentage of Subjects with Endoscopic Healing at Week 44 Among Subjects who had Achieved Endoscopic Healing at Maintenance Baseline |
|-----------------|---|

End point description:

Endoscopic healing is improvement in the endoscopic appearance of the mucosa. It is defined as Mayo endoscopic subscore = 0 (normal or inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 or who had a missing endoscopy score at Week 44 were considered not to have endoscopic healing. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects who had achieved endoscopic healing at maintenance baseline.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Week 44              |           |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 71   | 68  | 57   |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 35.2   | 60.3  | 64.9   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects with Normal or Inactive Mucosal Disease at Week 44

|  |  |
|--|--|
| End point title  | Maintenance Study: Percentage of Subjects with Normal or Inactive Mucosal Disease at Week 44 |
| End point description:   |  |
| Normal or inactive mucosal disease is defined as an endoscopy score of 0. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 or who had a missing endoscopy score at Week 44 were considered not to have endoscopic healing. Endoscopy subscore as assessed during central review of video of endoscopy was used. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| Week 44  |  |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 175  | 172   | 176  |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 18.3   | 23.8  | 29.0   |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 and not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline (per Global Definition)

|   |   |
|---|---|
| End point title   | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 and not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline (per Global Definition) |
| End point description:  |   |
| Global definition of clinical remission: Mayo score $\leq 2$ points, with no individual subscore $> 1$ . Mayo score includes 4 subscores (stool frequency, rectal bleeding, endoscopy findings, physician's global assessment), rated 0(normal) to 3(severe). Total score=sum of 4 subscores, range: 0 to 12, where 3 to 5=mild; 6 to 10=moderate; 11 to 12=severe disease. Subjects with all 4 Mayo subscores missing at Week 44 considered not in clinical remission. subjects missing value in corticosteroid use had their last value carried forward. PEAS consisted of all Subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC with, subjects who were receiving concomitant corticosteroids at maintenance baseline. |   |
| End point type  | Secondary   |
| End point timeframe:  |   |
| Week 44   |   |

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 91   | 82  | 92  |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 18.7   | 30.5  | 39.1  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 and not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline (per US Definition)

|  |   |
|--|---|
| End point title  | Maintenance Study: Percentage of Subjects with Clinical Remission at Week 44 and not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline (per US Definition) |
| End point description:   |   |
| US definition of clinical remission: absolute stool number $\leq 3$ , a Mayo rectal bleeding subscore of 0 (no blood seen), and Mayo endoscopy subscore of 0(normal/ inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]), without PGA. Absolute stool number is average of daily stool number over 3 days. Mayo rectal bleeding and endoscopy findings subscores rated as 0 (normal) to 3 (severe). Subjects with missing value in corticosteroid use had last value carried forward. Endoscopy subscore assessed during central review of video of endoscopy was used. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects who were receiving concomitant corticosteroids at maintenance baseline. |   |
| End point type   | Secondary   |
| End point timeframe:   |   |
| Week 44  |   |



| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 91   | 82  | 92   |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 19.8   | 32.9  | 37.0   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: MS: Change from Maintenance Baseline in Average Daily P.Eq Corticosteroid Dose Through Week 44 Among Subjects who Received Corticosteroids Other Than Budesonide and Beclomethasone Dipropionate at Maintenance Baseline

|                 |  |
|-----------------|--|
| End point title | MS: Change from Maintenance Baseline in Average Daily P.Eq Corticosteroid Dose Through Week 44 Among Subjects who Received Corticosteroids Other Than Budesonide and Beclomethasone Dipropionate at Maintenance Baseline |
|-----------------|--|

End point description:

The change from maintenance baseline in average daily prednisone-equivalent (P.Eq) corticosteroid dose through Week 44 among the subjects receiving concomitant corticosteroids other than budesonide and beclomethasone dipropionate at maintenance baseline was reported. Subjects who had prohibited change in UC medication/ ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward. Subjects who had a missing value in corticosteroid use at a timepoint had their last available value carried forward to that timepoint. PEAS consisted of all subjects who were in clinical response to IV ustekinumab IS and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects who were receiving concomitant corticosteroids at maintenance baseline.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline Through Week 44

| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 75   | 69  | 82   |  |
| Units: milligram per day (mg/day)    |  |   |  |  |
| arithmetic mean (standard deviation) |  |   |  |  |
| Change at Week 4                     | -7.4 (± 5.73)  | -7.8 (± 5.48)   | -7.2 (± 5.42)  |  |
| Change at Week 8                     | -10.8 (± 6.77)   | -11.7 (± 8.17)  | -12.1 (± 6.81)                                       |  |
| Change at Week 12                    | -10.1 (± 8.7)  | -11.6 (± 9.16)  | -12.6 (± 7.00)                                       |  |

|                   |                |                |                |  |
|-------------------|----------------|----------------|----------------|--|
| Change at Week 16 | -10.1 (± 7.73) | -12.1 (± 8.37) | -12.8 (± 6.98) |  |
| Change at Week 20 | -9.5 (± 7.85)  | -12.0 (± 8.44) | -12.6 (± 7.27) |  |
| Change at Week 24 | -8.9 (± 7.96)  | -11.9 (± 8.62) | -12.5 (± 7.88) |  |
| Change at Week 28 | -7.8 (± 8.72)  | -11.5 (± 9.23) | -12.4 (± 7.56) |  |
| Change at Week 32 | -7.7 (± 8.18)  | -11.4 (± 8.98) | -12.1 (± 8.21) |  |
| Change at Week 36 | -7.6 (± 8.28)  | -11.3 (± 8.80) | -11.7 (± 8.34) |  |
| Change at Week 40 | -7.2 (± 8.04)  | -11.5 (± 8.62) | -11.5 (± 8.37) |  |
| Change at Week 44 | -6.8 (± 7.98)  | -11.0 (± 8.87) | -11.5 (± 8.37) |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline

|                        |  |
|------------------------|--|
| End point title        | Maintenance Study: Percentage of Subjects not Receiving Concomitant Corticosteroids at Week 44 Among Subjects who Received Concomitant Corticosteroids at Maintenance Baseline   |
| End point description: | Percentage of subjects not receiving concomitant corticosteroids at Week 44 among subjects who received concomitant corticosteroids at maintenance Baseline were reported. Subjects who had prohibited change in UC medication/ ostomy/ colectomy/ used rescue medication after clinical flare/ discontinued study agent due to lack of therapeutic effect/ AE of worsening of UC before Week 44 considered to be receiving concomitant corticosteroids at Week 44. Subjects who had a missing value in corticosteroid use at Week 44 had their last value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC with, subjects who were receiving concomitant corticosteroids at maintenance baseline. |
| End point type         | Secondary  |
| End point timeframe:   |  |
| Week 44                |  |

| End point values              | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|-------------------------------|--|---|---|--|
| Subject group type            | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed   | 91   | 82  | 92  |  |
| Units: Percentage of Subjects |  |   |   |  |
| number (not applicable)       | 47.3   | 68.3  | 79.3  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects who Maintained 20-point

## Improvement from Induction Baseline in IBDQ up to Week 44 Among Subjects with a >20-point Improvement in IBDQ at Maintenance Baseline

|   |   |
|---|---|
| End point title   | Maintenance Study: Percentage of Subjects who Maintained 20-point Improvement from Induction Baseline in IBDQ up to Week 44 Among Subjects with a >20-point Improvement in IBDQ at Maintenance Baseline |
| End point description:<br>IBDQ consists of 32 items questionnaire, each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains were scored as: 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); and 5 to 35 (social function). For each domain, higher score indicates better quality of life. Total score is sum of each item score and ranges from 32 to 224 with higher score indicates better quality of life UC. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects with >20-point Improvement in IBDQ at the maintenance baseline. |   |
| End point type  | Secondary   |
| End point timeframe:<br>Up to Week 44   |   |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous<br>(SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|---|---|--|--|
| Subject group type            | Reporting group   | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 129   | 144   | 143  |  |
| Units: Percentage of Subjects |   |   |  |  |
| number (not applicable)       | 49.6  | 66.0  | 71.3   |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Change from Maintenance Baseline in the IBDQ Score at Week 20 and 44

|   |   |
|---|---|
| End point title   | Maintenance Study: Change from Maintenance Baseline in the IBDQ Score at Week 20 and 44 |
| End point description:<br>IBDQ consists of 32 items questionnaire , each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains were scored as follows: 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); and 5 to 35 (social function). For each domain, higher score indicates better quality of life. Total score is sum of each item score and ranges from 32 to 224 with higher score indicates better quality of life. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the MS to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint. |   |
| End point type  | Secondary   |
| End point timeframe:<br>Baseline, Week 20, and 44   |   |

| End point values                     | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--------------------------------------|--|---|--|--|
| Subject group type                   | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed          | 173  | 172   | 174  |  |
| Units: Units on a scale              |  |   |  |  |
| arithmetic mean (standard deviation) |  |   |  |  |
| Change at Week 20 (n= 174, 172, 174) | -7.0 (± 31.37)   | 0.8 (± 29.05)   | 5.5 (± 27.40)  |  |
| Change at Week 44 (n= 173, 172, 174) | -15.1 (± 35.43)  | -3.0 (± 32.89)  | 3.9 (± 31.54)  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Change from Maintenance Baseline in the IBDQ Dimension Scores at Week 20 and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Change from Maintenance Baseline in the IBDQ Dimension Scores at Week 20 and 44 |
|-----------------|--|

End point description:

IBDQ consists of 32 items questionnaire , each item score ranged from 1 (worst possible response) to 7 (best possible response). The 32 items were grouped into 4 domains: bowel function, emotional status, systemic symptoms and social function. The 4 domains were scored as: 10 to 70 (bowel symptoms); 5 to 35 (systemic symptoms); 12 to 84 (emotional function); 5 to 35 (social function). For each domain, higher score indicated better quality of life. Total score is sum of each item score and ranges from 32 to 224 with higher score indicates better quality of life. PEAS included all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM for specified categories at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Week 20, and 44

| End point values                           | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--|--|---|--|--|
| Subject group type                         | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed                | 174  | 172   | 174  |  |
| Units: Units on a scale                    |  |   |  |  |
| arithmetic mean (standard deviation)       |  |   |  |  |
| Bowel:Change at Week 20 (n= 174, 172, 174) | -3.2 (± 10.88)   | -0.5 (± 9.16)   | 1.3 (± 9.56)   |  |
| Bowel:Change at Week 44 (n= 173, 172, 174) | -5.7 (± 12.34)   | -1.6 (± 10.99)  | 0.8 (± 10.49)  |  |

|   |                |                |               |  |
|---|----------------|----------------|---------------|--|
| Emotional: Change at Week 20 (n= 174, 172, 174) | -1.9 (± 12.16) | 0.9 (± 11.12)  | 2.2 (± 10.56) |  |
| Emotional: Change at Week 44 (n= 173, 172, 174) | -4.7 (± 13.84) | -0.5 (± 12.17) | 1.4 (± 12.22) |  |
| Systemic: Change at Week 20 (n= 174, 172, 174)  | -1.1 (± 5.54)  | 0.0 (± 5.31)   | 0.7 (± 5.24)  |  |
| Systemic: Change at Week 44 (n= 173, 172, 174)  | -2.2 (± 5.52)  | -0.5 (± 5.97)  | 0.5 (± 5.83)  |  |
| Social: Change at Week 20 (n= 174, 172, 174)    | -0.7 (± 5.93)  | 0.3 (± 6.59)   | 1.4 (± 5.44)  |  |
| Social: Change at Week 44 (n= 173, 172, 174)    | -2.5 (± 6.72)  | -0.5 (± 7.10)  | 1.1 (± 6.29)  |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Change from Maintenance Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Weeks 20 and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Change from Maintenance Baseline in 36-Item Short-Form (SF-36) Physical Component Score (PCS) and Mental Component Score (MCS) at Weeks 20 and 44 |
|-----------------|--|

End point description:

SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. Based on scale scores, PCS (calculated from subscales physical functioning, role-physical, bodily pain, and general health) and MCS (calculated from subscales vitality, social functioning, role-emotional and mental health) scores were derived. Summary MCS and PCS score is also scaled from 0 to 100 with higher scores= better health. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 20, and 44

| End point values                     | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed          | 173  | 172   | 175   |  |
| Units: Units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| PCS: Change at Week 20               | -1.2 (± 6.20)                                    | -0.2 (± 6.15)                                 | 0.8 (± 5.55)                                |  |
| PCS: Change at Week 44               | -1.7 (± 6.45)                                    | -0.4 (± 7.14)                                 | 1.3 (± 5.68)                                |  |
| MCS: Change at Week 20               | -1.1 (± 8.90)                                    | 1.0 (± 8.91)                                  | 0.4 (± 9.10)                                |  |
| MCS: Change at Week 44               | -2.4 (± 9.89)                                    | 0.3 (± 8.41)                                  | 0.3 (± 9.51)                                |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Change from Maintenance Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Weeks 20 and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Change from Maintenance Baseline in Individual Subscales of 36-Item Short-Form (SF-36) at Weeks 20 and 44 |
|-----------------|--|

End point description:

SF-36 evaluates 8 individual subscales (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health). Each 8 scales scored from 0 to 100 with higher scores= better health. Subjects who had prohibited change in concomitant UC medication/ ostomy/ colectomy/ used rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to AE of worsening of UC prior to Week 44 had Week 0 value of induction study carried forward from time of event onward and subjects with missing individual scale score at timepoint had last available value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 20, and 44

| End point values                        | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|---|--|---|---|--|
| Subject group type                      | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed             | 175  | 172   | 176   |  |
| Units: Units on a scale                 |  |   |   |  |
| arithmetic mean (standard deviation)    |  |   |   |  |
| Physical functioning: Change at Week 20 | -0.61 (± 6.140)                                  | -0.01 (± 5.506)                               | 0.51 (± 4.809)                              |  |
| Physical functioning: Change at Week 44 | -1.40 (± 5.932)                                  | -0.44 (± 5.624)                               | 0.66 (± 4.819)                              |  |
| Role-physical: Change at Week 20        | -0.61 (± 8.630)                                  | 0.17 (± 7.996)                                | 0.23 (± 8.144)                              |  |
| Role-physical: Change at Week 44        | -2.27 (± 9.400)                                  | -0.84 (± 8.293)                               | 1.08 (± 8.096)                              |  |
| Bodily pain:Change at Week 20           | -2.80 (± 9.081)                                  | -0.30 (± 8.556)                               | 1.06 (± 8.971)                              |  |
| Bodily pain:Change at Week 44           | -2.33 (± 9.245)                                  | 0.23 (± 9.340)                                | 0.94 (± 8.350)                              |  |
| General health:Change at Week 20        | -0.95 (± 7.468)                                  | 0.67 (± 7.802)                                | 1.14 (± 7.133)                              |  |
| General health:Change at Week 44        | -1.62 (± 7.449)                                  | 0.24 (± 8.722)                                | 1.92 (± 7.955)                              |  |

|                                       |                  |                |                |  |
|---------------------------------------|------------------|----------------|----------------|--|
| Vitality:Change at Week 20            | -1.71 (± 8.876)  | 0.74 (± 8.917) | 0.39 (± 9.209) |  |
| Vitality:Change at Week 44            | -3.18 (± 10.389) | 0.11 (± 9.152) | 0.53 (± 9.743) |  |
| Social functioning: Change at Week 20 | -0.87 (± 9.245)  | 0.47 (± 8.979) | 0.72 (± 9.907) |  |
| Social functioning: Change at Week 44 | -1.83 (± 10.186) | 0.06 (± 9.515) | 1.12 (± 9.678) |  |
| Role-emotional: Change at Week 20     | -0.93 (± 9.586)  | 0.47 (± 9.338) | 0.14 (± 8.637) |  |
| Role-emotional: Change at Week 44     | -2.21 (± 10.187) | 0.04 (± 9.324) | 0.10 (± 8.199) |  |
| Mental health:Change at Week 20       | -1.07 (± 9.085)  | 1.08 (± 8.631) | 0.61 (± 8.467) |  |
| Mental health:Change at Week 44       | -2.15 (± 9.992)  | 0.06 (± 8.042) | 0.53 (± 8.915) |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Change from Maintenance Baseline in EuroQOL-5 Dimensions (EQ-5D) Health Questionnaire index Score at Weeks 20 and 44

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Change from Maintenance Baseline in EuroQOL-5 Dimensions (EQ-5D) Health Questionnaire index Score at Weeks 20 and 44 |
|-----------------|---|

End point description:

EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 (death) to 1 (full health). PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 20, and 44

| End point values                     | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed          | 173  | 172   | 175   |  |
| Units: Units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| Change at Week 20                    | -0.036 (± 0.1535)                                | -0.002 (± 0.1694)                             | 0.016 (± 0.1471)                            |  |
| Change at Week 44                    | -0.048 (± 0.1587)                                | 0.008 (± 0.1656)                              | 0.025 (± 0.1674)                            |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Change from Maintenance Baseline in EuroQOL-5 (EQ-5D) Health State Visual Analog Scale (VAS) Score at Weeks 20 and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Change from Maintenance Baseline in EuroQOL-5 (EQ-5D) Health State Visual Analog Scale (VAS) Score at Weeks 20 and 44 |
|-----------------|--|

#### End point description:

The EQ-5D VAS records the participant's self-rated health on a vertical, VAS, with 0 representing the worst imaginable health state and 100 representing the best imaginable health state. The EQ VAS is used as a quantitative measure of health outcome as judged by the individual subjects. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### End point timeframe:

Baseline, Weeks 20 and 44

| End point values                     | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|--------------------------------------|--|---|---|--|
| Subject group type                   | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed          | 173  | 172   | 175   |  |
| Units: Units on a scale              |  |   |   |  |
| arithmetic mean (standard deviation) |  |   |   |  |
| Change at Week 20                    | -4.0 (± 16.70)                                   | -0.3 (± 17.29)                                | 2.6 (± 17.80)                               |  |
| Change at Week 44                    | -7.7 (± 18.75)                                   | -2.2 (± 19.87)                                | 2.4 (± 17.28)                               |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Percentage of Subjects with Change from Maintenance Baseline in EuroQOL-5 (EQ-5D) Dimensions Score at Weeks 20 and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Percentage of Subjects with Change from Maintenance Baseline in EuroQOL-5 (EQ-5D) Dimensions Score at Weeks 20 and 44 |
|-----------------|--|

#### End point description:

EQ-5D descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no



problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 (death) to 1 (full health). Percentage of subjects with various responses to the 5 dimensions were reported. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects who were analyzed for this OM at specified timepoint.

|                            |           |
|----------------------------|-----------|
| End point type             | Secondary |
| End point timeframe:       |           |
| Baseline, Weeks 20, and 44 |           |

| End point values                             | Maintenance study (MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|--|---|---|--|--|
| Subject group type                           | Reporting group   | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed                  | 175   | 172   | 176  |  |
| Units: Percentage of Subjects                |   |   |  |  |
| number (not applicable)                      |   |   |  |  |
| Change at Week (W) 20:<br>Mobility:Improved  | 12.7  | 10.5  | 13.7   |  |
| Change at W 20:Mobility:No change            | 75.7  | 79.1  | 78.9   |  |
| Change at W 20:Mobility:Worsened             | 11.6  | 10.5  | 7.4  |  |
| Change at W 44:Mobility:Improved             | 9.8   | 11.6  | 12.0   |  |
| Change at W 44:Mobility:No change            | 75.1  | 76.2  | 79.4   |  |
| Change at W 44:Mobility:Worsened             | 15.0  | 12.2  | 8.6  |  |
| Change at W 20:Self-care:Improved            | 1.7   | 1.7   | 4.0  |  |
| Change at W 20:Self-care:No change           | 91.9  | 93.6  | 93.7   |  |
| Change at W 20:Self-care:Worsened            | 6.4   | 4.7   | 2.3  |  |
| Change at W 44:Self-care:Improved            | 1.7   | 2.3   | 4.0  |  |
| Change at W 44:Self-care:No change           | 95.4  | 93.0  | 93.1   |  |
| Change at W 44:Self-care:Worsened            | 2.9   | 4.7   | 2.9  |  |
| Change at W 20:Usual<br>activities:Improved  | 12.7  | 17.4  | 22.3   |  |
| Change at W 20:Usual activities:No<br>Change | 64.2  | 66.9  | 64.0   |  |
| Change at W 20:Usual<br>activities:Worsened  | 23.1  | 15.7  | 13.7   |  |
| Change at W 44: Usual<br>activities:Improved | 14.5  | 24.4  | 25.1   |  |
| Change at W 44:Usual activities:No<br>Change | 52.6  | 55.2  | 62.9   |  |
| Change at W 44:Usual<br>activities:Worsened  | 32.9  | 20.3  | 12.0   |  |
| Change at W 20:Pain/discomfort:<br>Improved  | 16.8  | 22.1  | 23.4   |  |
| Change at W 20:Pain/discomfort: No<br>Change | 54.9  | 58.7  | 58.9   |  |
| Change at W 20:Pain/discomfort:<br>Worsened  | 28.3  | 19.2  | 17.7   |  |
| Change at W 44:Pain/discomfort:<br>Improved  | 17.9  | 25.0  | 30.3   |  |
| Change at W 44:Pain/discomfort: No<br>Change | 46.2  | 55.8  | 50.9   |  |

|   |      |      |      |  |
|---|------|------|------|--|
| Change at W 44:Pain/discomfort:<br>Worsened     | 35.8 | 19.2 | 18.9 |  |
| Change at W 20:Anxiety/depression:<br>Improved  | 16.2 | 20.3 | 24.6 |  |
| Change at W 20:Anxiety/depression: No<br>Change | 62.4 | 61.6 | 58.3 |  |
| Change at W 20:Anxiety/depression:<br>Worsened  | 21.4 | 18.0 | 17.1 |  |
| Change at W 44:Anxiety/depression:<br>Improved  | 17.9 | 20.3 | 26.9 |  |
| Change at W 44:Anxiety/depression: No<br>Change | 56.1 | 58.7 | 58.9 |  |
| Change at W 44:Anxiety/depression:<br>Worsened  | 26.0 | 20.9 | 14.3 |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Maintenance Study: Percentage of Subjects with Mucosal Healing at Week 44

|  |   |
|--|---|
| End point title  | Maintenance Study: Percentage of Subjects with Mucosal Healing at Week 44 |
| End point description:<br>Mucosal healing included EH and HH. EH: endoscopy subscore of 0 (normal/ inactive disease) or 1 (mild disease [erythema, decreased vascular pattern, mild friability]). HH: neutrophil infiltration in <5% of crypts, no crypt destruction, no erosions/ ulcerations/ granulation tissue. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC, with subjects whose mucosal healing status was determined at Week 44 with evaluable biopsy. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Week 44  |   |

| End point values              | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|-------------------------------|--|---|--|--|
| Subject group type            | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed   | 170  | 170   | 172  |  |
| Units: Percentage of Subjects |  |   |  |  |
| number (not applicable)       | 24.1   | 38.8  | 45.9   |  |

## Statistical analyses

|                            |  |
|----------------------------|--|
| Statistical analysis title | Statistical Analysis 2   |
| Comparison groups          | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 8 weeks (q8w) |

|   |                         |
|---|-------------------------|
| Number of subjects included in analysis | 342                     |
| Analysis specification                  | Pre-specified           |
| Analysis type                           | superiority             |
| P-value                                 | < 0.001                 |
| Method                                  | Cochran-Mantel-Haenszel |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Statistical Analysis 1   |
| Comparison groups                       | Maintenance study(MS): Placebo Subcutaneous (SC) v MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
| Number of subjects included in analysis | 340  |
| Analysis specification                  | Pre-specified  |
| Analysis type                           | superiority  |
| P-value                                 | = 0.002  |
| Method                                  | Cochran-Mantel-Haenszel  |

### Secondary: Maintenance Study: Change from Maintenance Baseline in C-reactive Protein (CRP) Concentration at Weeks 8, 24, and 44

|                 |  |
|-----------------|--|
| End point title | Maintenance Study: Change from Maintenance Baseline in C-reactive Protein (CRP) Concentration at Weeks 8, 24, and 44 |
|-----------------|--|

End point description:

Change from Maintenance baseline in CRP concentration at Weeks 8, 24, and 44 were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward. Subjects who had a missing CRP value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects who were analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 8, 24, and 44

| <b>End point values</b>               | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|---------------------------------------|--|---|---|--|
| Subject group type                    | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed           | 174  | 170   | 176   |  |
| Units: milligram per liter (mg/L)     |  |   |   |  |
| median (inter-quartile range (Q1-Q3)) |  |   |   |  |
| Change at Week 8 (n= 174, 170, 176)   | 0.05 (-0.67 to 0.81)                             | -0.03 (-0.92 to 0.37)                         | -0.04 (-1.50 to 0.92)                       |  |
| Change at Week 24 (n= 174, 170, 176)  | 0.68 (-0.28 to 2.34)                             | 0.13 (-0.75 to 1.16)                          | -0.03 (-1.53 to 0.59)                       |  |
| Change at Week 44 (n= 174, 170, 175)  | 1.07 (0.00 to 5.18)                              | 0.38 (-0.35 to 1.53)                          | -0.07 (-1.73 to 0.79)                       |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Change from Maintenance Baseline in Fecal Lactoferrin Concentration at Weeks 8, 24, and 44

|                 |   |
|-----------------|---|
| End point title | Maintenance Study: Change from Maintenance Baseline in Fecal Lactoferrin Concentration at Weeks 8, 24, and 44 |
|-----------------|---|

End point description:

Change from Maintenance baseline in fecal lactoferrin concentration at Weeks 8, 24, and 44 were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward. Subjects who had a missing fecal lactoferrin value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects who were analyzed for this OM at specified timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, Weeks 8, 24, and 44

| End point values                      | Maintenance study(MS): Placebo Subcutaneous (SC) | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |  |
|---------------------------------------|--|---|---|--|
| Subject group type                    | Reporting group                                  | Reporting group                               | Reporting group                             |  |
| Number of subjects analysed           | 167  | 161   | 163   |  |
| Units: microgram per gram (mcg/g)     |  |   |   |  |
| median (inter-quartile range (Q1-Q3)) |  |   |   |  |
| Change at Week 8 (n= 167, 161, 163)   | 0.0 (-44.8 to 72.0)                              | 0.0 (-35.0 to 48.5)                           | -1.4 (-52.0 to 30.9)                        |  |
| Change at Week 24 (n= 166 161, 161)   | 2.2 (-45.3 to 139.9)                             | -0.8 (-47.9 to 35.1)                          | -2.3 (-65.5 to 25.5)                        |  |
| Change at Week 44 (n= 166, 159, 160)  | 0.8 (-34.2 to 177.4)                             | -1.9 (-54.4 to 35.1)                          | -9.1 (-101.6 to 7.8)                        |  |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Maintenance Study: Change from Maintenance Baseline in Fecal Calprotectin Concentration at Weeks 8, 24, and 44

|   |  |
|---|--|
| End point title   | Maintenance Study: Change from Maintenance Baseline in Fecal Calprotectin Concentration at Weeks 8, 24, and 44 |
| End point description:  |  |
| Change from Maintenance baseline in fecal calprotectin concentration at Weeks 8, 24, and 44 were reported. Subjects who had a prohibited change in concomitant UC medication or an ostomy or colectomy, or used a rescue medication after clinical flare, or discontinued study agent due to lack of therapeutic effect or due to an AE of worsening of UC prior to the Week 44 had their Week 0 value of the induction study carried forward from the time of the event onward. Subjects who had a missing fecal calprotectin value at the designated analysis timepoint had their last value carried forward. PEAS consisted of all subjects who were in clinical response to IV ustekinumab induction and were randomized at Week 0 of the maintenance study to ustekinumab 90 mg SC q8w, ustekinumab 90 mg SC q12w, or placebo SC. Here, n (number of subjects analyzed) signifies subjects who were analyzed for this OM at specified timepoint. |  |
| End point type  | Secondary  |
| End point timeframe:  |  |
| Baseline, Weeks 8, 24, and 44   |  |

| End point values                      | Maintenance study(MS):<br>Placebo<br>Subcutaneous (SC) | MS:<br>Ustekinumab<br>90mg SC every<br>12 weeks<br>(q12w) | MS:<br>Ustekinumab<br>90mg SC every<br>8 weeks (q8w) |  |
|---------------------------------------|--|---|--|--|
| Subject group type                    | Reporting group  | Reporting group   | Reporting group                                      |  |
| Number of subjects analysed           | 168  | 160   | 161  |  |
| Units: milligram per kilogram (mg/kg) |  |   |  |  |
| median (inter-quartile range (Q1-Q3)) |  |   |  |  |
| Change at Week 8 (n= 168, 160, 161)   | 0.0 (-0.158 to 557.0)                                  | -18.5 (-368.5 to 225.5)                                   | -31.0 (-380.0 to 205.0)                              |  |
| Change at Week 24 (n= 165, 160, 159)  | 125.0 (-97.0 to 1223.0)                                | -31.5 (-413.5 to 385.0)                                   | -46.0 (-530.0 to 318.0)                              |  |
| Change at Week 44 (n= 164, 158, 159)  | 229.5 (-102.5 to 1387.0)                               | -37.5 (-476.0 to 274.0)                                   | -85.0 (-742.0 to 166.0)                              |  |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to Week 220

Adverse event reporting additional description:

The safety analysis set included subjects who received at least 1 dose of studyagent, including partial dose, according to actual treatment received.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.1 |
|--------------------|------|

### Reporting groups

|                       |                                       |
|-----------------------|---------------------------------------|
| Reporting group title | IS: Ustekinumab 130 milligram (mg) IV |
|-----------------------|---------------------------------------|

Reporting group description:

Subjects received single dose of ustekinumab 130 mg as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|                       |   |
|-----------------------|---|
| Reporting group title | Induction Study(IS): Placebo Intravenous (IV) |
|-----------------------|---|

Reporting group description:

Subjects received single dose of placebo as intravenous (IV) infusion at Week 0. Participants with clinical response at Week (W) 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received weight-range based dose of ustekinumab approximating 6 mg/kg IV + placebo SC at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|                       |   |
|-----------------------|---|
| Reporting group title | IS: Ustekinumab approximately 6mg/kg IV |
|-----------------------|---|

Reporting group description:

Subjects received weight-range based dose of ustekinumab approximating 6 milligram per kilogram (mg/kg) (ustekinumab 260 mg [body weight ≤55 kg], 390 mg [body weight >55 kg but ≤85 kg] and 520 mg [body weight >85 kg]), as IV infusion at Week 0. Subjects with clinical response at Week 8 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 8 received 1 dose of ustekinumab 90 mg SC+ placebo IV at Week 8. At Week 16, subjects who did not achieve clinical response at Week 8 were re-evaluated for clinical response. Subjects with clinical response at Week 16 were eligible to enter the maintenance study. Subjects who did not achieve clinical response at Week 16 were not eligible to enter the maintenance study and had a safety follow-up visit up to 20 weeks after their last dose of study agent.

|                       |   |
|-----------------------|---|
| Reporting group title | MS: Ustekinumab 90mg SC every 12 weeks (q12w) |
|-----------------------|---|

Reporting group description:

Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) beginning at Week 0 of maintenance study through Week 44.

|                       |   |
|-----------------------|---|
| Reporting group title | MS: Ustekinumab 90mg SC every 8 weeks (q8w) |
|-----------------------|---|

Reporting group description:

Subjects who were randomized to receive ustekinumab (ie, 130 mg IV or approximately 6 mg/kg IV) at Week 0 of the induction study and were in clinical response at induction Week 8 and subjects who were randomized to receive placebo at Week 0 of the induction study and were not in clinical response at induction Week 8 but were in clinical response at induction Week 16 after receiving a dose of IV ustekinumab (approximately 6 mg/kg) at induction Week 8 (placebo to ustekinumab 6 mg/kg IV) were

randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w), beginning at Week 0 of maintenance study through Week 44.

|                       |  |
|-----------------------|--|
| Reporting group title | Maintenance study(MS): Placebo Subcutaneous (SC) |
|-----------------------|--|

Reporting group description:

Subjects in clinical response (at Week 8 or Week 16) to Induction treatment with single IV infusion of Ustekinumab who were randomized to receive placebo subcutaneously, beginning Week 0 of Maintenance study through Week 44.

|                       |   |
|-----------------------|---|
| Reporting group title | IS: Ustekinumab Nonresponders at Week 8 |
|-----------------------|---|

Reporting group description:

Subjects who did not achieve clinical response to ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 and received a single dose of ustekinumab 90 mg SC along with matching placebo IV (to maintain the blind). Subjects with clinical response at Week 16 (that is, delayed responders) were eligible to enter Maintenance study, but were not be randomized. Included data from Week 8 onward through the final safety visit.

|                       |                                     |
|-----------------------|-------------------------------------|
| Reporting group title | IS: Placebo-Nonresponders at Week 8 |
|-----------------------|-------------------------------------|

Reporting group description:

Subjects who did not achieve clinical response to placebo IV at Week 8 and received a single IV infusion of ustekinumab approximating 6 mg/kg at Week 8. Included data from Week 8 onward through the final safety visit.

|                       |  |
|-----------------------|--|
| Reporting group title | MS: Placebo IV (IS – Responders) to Placebo SC |
|-----------------------|--|

Reporting group description:

Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects).

|                       |   |
|-----------------------|---|
| Reporting group title | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w |
|-----------------------|---|

Reporting group description:

Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16) received ustekinumab 90 mg SC every 8 weeks, beginning at Week 0 of maintenance study through Week 44 (non-randomized subjects).

|                       |                                       |
|-----------------------|---------------------------------------|
| Reporting group title | Long Term Extension (LTE): Placebo SC |
|-----------------------|---------------------------------------|

Reporting group description:

Subjects who were randomized to receive placebo SC in the maintenance study and received placebo SC at the first dosing visit (Week 48) of long term extension (LTE). After the Maintenance study was unblinded, subjects receiving placebo were discontinued.

|                       |   |
|-----------------------|---|
| Reporting group title | LTE: Placebo SC to Ustekinumab SC 90 mg q8w |
|-----------------------|---|

Reporting group description:

Subjects who were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.

|                       |  |
|-----------------------|--|
| Reporting group title | LTE: Ustekinumab 90 mg SC q12w to 90 mg SC q8w |
|-----------------------|--|

Reporting group description:

Subjects who were randomized to receive ustekinumab 90 mg SC q12w in the maintenance study and had a dose adjustment to ustekinumab 90 mg SC q8w during the LTE.

|                       |                                |
|-----------------------|--------------------------------|
| Reporting group title | LTE: Ustekinumab 90 mg SC q12w |
|-----------------------|--------------------------------|

Reporting group description:

Subjects who were randomized to receive ustekinumab 90 mg SC every 12 weeks (q12w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.

|                       |   |
|-----------------------|---|
| Reporting group title | LTE: Ustekinumab 90 mg SC q8w to 90 mg SC q8w |
|-----------------------|---|

Reporting group description:

Subjects who were randomized to receive ustekinumab 90 mg SC q8w in the maintenance study and had a sham dose adjustment to ustekinumab 90 mg SC q8w during the LTE.

|                       |                               |
|-----------------------|-------------------------------|
| Reporting group title | LTE: Ustekinumab 90 mg SC q8w |
|-----------------------|-------------------------------|

Reporting group description:

Subjects who were randomized to receive ustekinumab 90 mg SC every 8 weeks (q8w) in the maintenance study and received ustekinumab 90 mg SC at the first dosing visit (Week 48) of the LTE.

|                       |   |
|-----------------------|---|
| Reporting group title | LTE: Ustekinumab Delayed Responders (IS) to UST 90mg SC q8w |
|-----------------------|---|

Reporting group description:

Subjects who were delayed responders to ustekinumab induction (were not in clinical response to induction treatment ustekinumab (130 mg or approximately 6 mg/kg [IV]) at Week 8 but were in clinical response at Week 16) received ustekinumab 90 mg SC q8w in the maintenance study and the LTE through Week 200 (non-randomized subjects ).

|                       |   |
|-----------------------|---|
| Reporting group title | LTE: Placebo IV (IS – Responders) to Placebo SC |
|-----------------------|---|

Reporting group description:

Subjects with clinical response to Induction Week 0 treatment with placebo IV received placebo SC in the maintenance study and the LTE through Week 200 (non-randomized subjects). After the Maintenance study was unblinded, subjects receiving placebo were discontinued.

| <b>Serious adverse events</b>                                       | IS: Ustekinumab<br>130 milligram (mg)<br>IV | Induction Study(IS):<br>Placebo Intravenous<br>(IV) | IS: Ustekinumab<br>approximately<br>6mg/kg IV |
|---|---|---|---|
| Total subjects affected by serious adverse events                   |   |   |   |
| subjects affected / exposed   | 12 / 321 (3.74%)                            | 22 / 319 (6.90%)                                    | 11 / 320 (3.44%)                              |
| number of deaths (all causes)                                       | 0   | 0   | 1   |
| number of deaths resulting from adverse events                      |   |   |   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |   |   |
| Basal Cell Carcinoma  |   |   |   |
| subjects affected / exposed   | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0   | 0 / 0   |
| Bowen's Disease   |   |   |   |
| subjects affected / exposed   | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0   | 0 / 0   |
| Colon Adenoma   |   |   |   |
| subjects affected / exposed   | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0   | 0 / 0   |
| Colon Cancer  |   |   |   |
| subjects affected / exposed   | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0   | 0 / 0   |
| Colorectal Cancer   |   |   |   |
| subjects affected / exposed   | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences causally related to treatment / all                     | 0 / 0                                       | 0 / 0   | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                                       | 0 / 0   | 0 / 0   |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Hepatic Adenoma                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intraductal Papilloma of Breast                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lentigo Maligna                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Adenoma                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pituitary Tumour Benign                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate Cancer                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenocarcinoma                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenoma                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Cancer                                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin Papilloma                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Testis Cancer                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                              |                 |                 |                 |
| Deep Vein Thrombosis                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 2 / 320 (0.63%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Extremity Necrosis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhage                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vasculitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pregnancy, puerperium and perinatal conditions  |                 |                 |                 |
| Abortion Spontaneous                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| General disorders and administration site conditions |                 |                 |                 |
| Non-Cardiac Chest Pain                               |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyrexia  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                              |                 |                 |                 |
| Anaphylactic Reaction                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders             |                 |                 |                 |
| Benign Prostatic Hyperplasia                         |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Cyst   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostatitis  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                 |
| Acute Respiratory Failure                            |                 |                 |                 |
| subjects affected / exposed                          | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchiectasis                                       |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hyperventilation                                |                 |                 |                 |
| subjects affected / exposed                     | 2 / 321 (0.62%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pleurisy  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Embolism                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Eosinophilia                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Confusional State                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mental Status Changes                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Suicidal Ideation                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Ankle Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bladder Injury                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Clavicle Fracture                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Fibula Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hip Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Jaw Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lumbar Vertebral Fracture                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Meniscus Injury                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Procedural Intestinal Perforation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radius Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rib Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Spinal Compression Fracture                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tibia Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Traumatic Fracture                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Congenital, familial and genetic disorders      |                 |                 |                 |
| Hydrocele                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Acute Myocardial Infarction                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial Fibrillation                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac Arrest                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Coronary Artery Disease                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myocardial Infarction                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pericarditis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Aphasia   |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cognitive Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Epilepsy  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Generalised Tonic-Clonic Seizure                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ischaemic Stroke                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Migraine  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Motor Dysfunction                               |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Optic Neuritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Presyncope                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Anaemia   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Autoimmune Haemolytic Anaemia                   |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Iron Deficiency Anaemia                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                 |                 |                 |
| Deafness Neurosensory                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Deafness Unilateral                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                 |                 |                 |
| Cataract  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Retinal Detachment                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Abdominal Pain                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Abdominal Pain Upper                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                  |                 |
|---|-----------------|------------------|-----------------|
| Anal Fissure                                    |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Anorectal Disorder                              |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Colitis Ulcerative                              |                 |                  |                 |
| subjects affected / exposed                     | 4 / 321 (1.25%) | 11 / 319 (3.45%) | 4 / 320 (1.25%) |
| occurrences causally related to treatment / all | 1 / 4           | 0 / 12           | 0 / 4           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Colon Dysplasia                                 |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Diarrhoea Haemorrhagic                          |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Duodenal Ulcer                                  |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Enteritis                                       |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Enterovesical Fistula                           |                 |                  |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%)  | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0            | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0            | 0 / 0           |
| Gastrointestinal Haemorrhage                    |                 |                  |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Inguinal Hernia                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Perforation                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Polyp                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mesenteric Fibrosis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oesophageal Varices Haemorrhage                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| Pancreatitis Acute                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pseudopolyposis                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Small Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subileus  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Umbilical Hernia                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vomiting  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholecystitis Acute                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Drug-Induced Liver Injury                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Liver Disorder                                  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |
| Dermatitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyoderma Gangrenosum                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rash  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Acute Kidney Injury                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Calculus Bladder                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic Kidney Disease                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Glomerulonephritis Chronic                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nephrolithiasis                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal Colic                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ureterolithiasis                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urinary Incontinence                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Enthesopathy                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intervertebral Disc Protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteoarthritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rotator Cuff Syndrome                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sacroiliitis                                    |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Infections and infestations</b>              |                 |                 |                 |
| <b>Anal Abscess</b>                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Appendicitis</b>                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cellulitis</b>                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Clostridium Difficile Infection</b>          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Complicated Appendicitis</b>                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cystitis</b>                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cytomegalovirus Colitis</b>                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cytomegalovirus Infection</b>                |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diverticulitis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis Salmonella                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis C                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Herpes Zoster                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Human Herpesvirus 6 Infection                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Influenza                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Listeriosis                                     |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Neutropenic Sepsis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oral Herpes                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pelvic Inflammatory Disease                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Periorbital Cellulitis                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Perirectal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pharyngeal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 321 (0.31%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Legionella                            |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Viral                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingitis                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingo-Oophoritis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subcutaneous Abscess                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tooth Abscess                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Diabetic Metabolic Decompensation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Failure to Thrive                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | MS: Ustekinumab 90mg SC every 12 weeks (q12w) | MS: Ustekinumab 90mg SC every 8 weeks (q8w) | Maintenance study(MS): Placebo Subcutaneous (SC) |
|---|---|---|--|
| Total subjects affected by serious adverse events                   |   |   |  |
| subjects affected / exposed   | 13 / 172 (7.56%)                              | 15 / 176 (8.52%)                            | 17 / 175 (9.71%)                                 |
| number of deaths (all causes)                                       | 0   | 0   | 0  |
| number of deaths resulting from adverse events                      |   |   |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |   |  |
| Basal Cell Carcinoma  |   |   |  |
| subjects affected / exposed   | 0 / 172 (0.00%)                               | 0 / 176 (0.00%)                             | 0 / 175 (0.00%)                                  |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                       | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                       | 0 / 0  |
| Bowen's Disease   |   |   |  |
| subjects affected / exposed   | 0 / 172 (0.00%)                               | 0 / 176 (0.00%)                             | 0 / 175 (0.00%)                                  |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                       | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                       | 0 / 0  |
| Colon Adenoma   |   |   |  |
| subjects affected / exposed   | 0 / 172 (0.00%)                               | 0 / 176 (0.00%)                             | 0 / 175 (0.00%)                                  |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                       | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                       | 0 / 0  |
| Colon Cancer  |   |   |  |
| subjects affected / exposed   | 0 / 172 (0.00%)                               | 1 / 176 (0.57%)                             | 0 / 175 (0.00%)                                  |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 1                                       | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                       | 0 / 0  |
| Colorectal Cancer   |   |   |  |
| subjects affected / exposed   | 0 / 172 (0.00%)                               | 0 / 176 (0.00%)                             | 0 / 175 (0.00%)                                  |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                       | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                       | 0 / 0  |
| Hepatic Adenoma   |   |   |  |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intraductal Papilloma of Breast                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lentigo Maligna                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Adenoma                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pituitary Tumour Benign                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate Cancer                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenocarcinoma                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenoma                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Cancer                                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin Papilloma                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 3           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Testis Cancer                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                              |                 |                 |                 |
| Deep Vein Thrombosis                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Extremity Necrosis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhage                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vasculitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pregnancy, puerperium and perinatal conditions  |                 |                 |                 |
| Abortion Spontaneous                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 2 / 176 (1.14%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| General disorders and administration site conditions |                 |                 |                 |
| Non-Cardiac Chest Pain                               |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyrexia  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                              |                 |                 |                 |
| Anaphylactic Reaction                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders             |                 |                 |                 |
| Benign Prostatic Hyperplasia                         |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Cyst   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostatitis  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                 |
| Acute Respiratory Failure                            |                 |                 |                 |
| subjects affected / exposed                          | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchiectasis                                       |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hyperventilation                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pleurisy  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Embolism                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Eosinophilia                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Confusional State                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mental Status Changes                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Suicidal Ideation                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Ankle Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bladder Injury                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Clavicle Fracture                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Fibula Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hip Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Jaw Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lumbar Vertebral Fracture                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Meniscus Injury                                 |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Procedural Intestinal Perforation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radius Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rib Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Spinal Compression Fracture                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tibia Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Traumatic Fracture                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Congenital, familial and genetic disorders      |                 |                 |                 |
| Hydrocele                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Acute Myocardial Infarction                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial Fibrillation                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac Arrest                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Coronary Artery Disease                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myocardial Infarction                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pericarditis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Aphasia   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cognitive Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Epilepsy  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Generalised Tonic-Clonic Seizure                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ischaemic Stroke                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Migraine  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Motor Dysfunction                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Optic Neuritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Presyncope                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Anaemia   |                 |                 |                 |
| subjects affected / exposed                     | 2 / 172 (1.16%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Autoimmune Haemolytic Anaemia                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Iron Deficiency Anaemia                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                 |                 |                 |
| Deafness Neurosensory                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Deafness Unilateral                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                 |                 |                 |
| Cataract  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Retinal Detachment                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Abdominal Pain                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Abdominal Pain Upper                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Anal Fissure                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anorectal Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Colitis Ulcerative                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 2 / 176 (1.14%) | 8 / 175 (4.57%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 2           | 0 / 8           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Colon Dysplasia                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diarrhoea Haemorrhagic                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Duodenal Ulcer                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enteritis                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enterovesical Fistula                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal Haemorrhage                    |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Inguinal Hernia                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Perforation                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Polyp                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mesenteric Fibrosis                             |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oesophageal Varices Haemorrhage                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pancreatitis Acute                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pseudopolyposis                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Small Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subileus  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Umbilical Hernia                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vomiting  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholecystitis Acute                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Drug-Induced Liver Injury                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Liver Disorder                                  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |
| Dermatitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyoderma Gangrenosum                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rash  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Acute Kidney Injury                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Calculus Bladder                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic Kidney Disease                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Glomerulonephritis Chronic                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nephrolithiasis                                 |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal Colic                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ureterolithiasis                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urinary Incontinence                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Enthesopathy                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intervertebral Disc Protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteoarthritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rotator Cuff Syndrome                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sacroiliitis                                    |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Infections and infestations</b>              |                 |                 |                 |
| <b>Anal Abscess</b>                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Appendicitis</b>                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cellulitis</b>                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Clostridium Difficile Infection</b>          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Complicated Appendicitis</b>                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cystitis</b>                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cytomegalovirus Colitis</b>                  |                 |                 |                 |
| subjects affected / exposed                     | 2 / 172 (1.16%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cytomegalovirus Infection</b>                |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diverticulitis                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis Salmonella                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis C                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Herpes Zoster                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Human Herpesvirus 6 Infection                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Influenza                                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Listeriosis                                     |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Neutropenic Sepsis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oral Herpes                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pelvic Inflammatory Disease                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Periorbital Cellulitis                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Perirectal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pharyngeal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Legionella                            |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Viral                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingitis                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingo-Oophoritis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subcutaneous Abscess                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tooth Abscess                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Diabetic Metabolic Decompensation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Failure to Thrive                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 172 (0.00%) | 0 / 176 (0.00%) | 0 / 175 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | IS: Ustekinumab<br>Nonresponders at<br>Week 8 | IS: Placebo-<br>Nonresponders at<br>Week 8 | MS: Placebo IV (IS –<br>Responders) to<br>Placebo SC |
|---|---|--|--|
| Total subjects affected by serious adverse events                   |   |  |  |
| subjects affected / exposed   | 12 / 233 (5.15%)                              | 7 / 184 (3.80%)                            | 8 / 103 (7.77%)                                      |
| number of deaths (all causes)                                       | 0   | 0  | 0  |
| number of deaths resulting from adverse events                      |   |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |  |  |
| Basal Cell Carcinoma  |   |  |  |
| subjects affected / exposed   | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                      | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                      | 0 / 0  |
| Bowen's Disease   |   |  |  |
| subjects affected / exposed   | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                      | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                      | 0 / 0  |
| Colon Adenoma   |   |  |  |
| subjects affected / exposed   | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                      | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                      | 0 / 0  |
| Colon Cancer  |   |  |  |
| subjects affected / exposed   | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                      | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                      | 0 / 0  |
| Colorectal Cancer   |   |  |  |
| subjects affected / exposed   | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                      | 0 / 0  |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                      | 0 / 0  |
| Hepatic Adenoma   |   |  |  |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intraductal Papilloma of Breast                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lentigo Maligna                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Adenoma                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pituitary Tumour Benign                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostate Cancer                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenocarcinoma                           |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Adenoma                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rectal Cancer                                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin Papilloma                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Testis Cancer                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vascular disorders                              |                 |                 |                 |
| Deep Vein Thrombosis                            |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Extremity Necrosis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Haemorrhage                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vasculitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pregnancy, puerperium and perinatal conditions  |                 |                 |                 |
| Abortion Spontaneous                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |



|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| General disorders and administration site conditions |                 |                 |                 |
| Non-Cardiac Chest Pain                               |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyrexia  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Immune system disorders                              |                 |                 |                 |
| Anaphylactic Reaction                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders             |                 |                 |                 |
| Benign Prostatic Hyperplasia                         |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Cyst   |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Prostatitis  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                 |
| Acute Respiratory Failure                            |                 |                 |                 |
| subjects affected / exposed                          | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Bronchiectasis                                       |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hyperventilation                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pleurisy  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Embolism                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pulmonary Eosinophilia                          |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Confusional State                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mental Status Changes                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Suicidal Ideation                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Ankle Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Bladder Injury                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Clavicle Fracture                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Fibula Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hip Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Jaw Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Lumbar Vertebral Fracture                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Meniscus Injury                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Procedural Intestinal Perforation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Radius Fracture                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rib Fracture                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Spinal Compression Fracture                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tibia Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Traumatic Fracture                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Congenital, familial and genetic disorders      |                 |                 |                 |
| Hydrocele                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Acute Myocardial Infarction                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Atrial Fibrillation                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac Arrest                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Coronary Artery Disease                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myocardial Infarction                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pericarditis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Aphasia   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cognitive Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Epilepsy  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Generalised Tonic-Clonic Seizure                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ischaemic Stroke                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Migraine  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Motor Dysfunction                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Optic Neuritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Presyncope                                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Anaemia   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Autoimmune Haemolytic Anaemia                   |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Iron Deficiency Anaemia                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ear and labyrinth disorders                     |                 |                 |                 |
| Deafness Neurosensory                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Deafness Unilateral                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Eye disorders                                   |                 |                 |                 |
| Cataract  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Retinal Detachment                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Abdominal Pain                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Abdominal Pain Upper                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| Anal Fissure                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anorectal Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Colitis Ulcerative                              |                 |                 |                 |
| subjects affected / exposed                     | 4 / 233 (1.72%) | 5 / 184 (2.72%) | 3 / 103 (2.91%) |
| occurrences causally related to treatment / all | 0 / 4           | 0 / 5           | 3 / 5           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Colon Dysplasia                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diarrhoea Haemorrhagic                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Duodenal Ulcer                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enteritis                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Enterovesical Fistula                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal Haemorrhage                    |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Inguinal Hernia                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Perforation                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Large Intestine Polyp                           |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Mesenteric Fibrosis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oesophageal Varices Haemorrhage                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pancreatitis Acute                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pseudopolyposis                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Small Intestinal Obstruction                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subileus  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Umbilical Hernia                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vomiting  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholecystitis Acute                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Drug-Induced Liver Injury                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Liver Disorder                                  |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Skin and subcutaneous tissue disorders          |                 |                 |                 |
| Dermatitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyoderma Gangrenosum                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rash  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Acute Kidney Injury                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Calculus Bladder                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Chronic Kidney Disease                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Glomerulonephritis Chronic                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nephrolithiasis                                 |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 233 (0.43%) | 1 / 184 (0.54%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal Colic                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Ureterolithiasis                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Urinary Incontinence                            |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Enthesopathy                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Intervertebral Disc Protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Osteoarthritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Rotator Cuff Syndrome                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Sacroiliitis                                    |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Anal Abscess                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Appendicitis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cellulitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Clostridium Difficile Infection                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Complicated Appendicitis                        |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cystitis  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cytomegalovirus Colitis                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cytomegalovirus Infection                       |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Diverticulitis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastroenteritis Salmonella                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatitis C                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Herpes Zoster                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Human Herpesvirus 6 Infection                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Influenza                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Listeriosis                                     |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Neutropenic Sepsis                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Oral Herpes                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pelvic Inflammatory Disease                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Periorbital Cellulitis                          |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Perirectal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pharyngeal Abscess                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia                                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Legionella                            |                 |                 |                 |

|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pneumonia Viral                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingitis                                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Salpingo-Oophoritis                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Subcutaneous Abscess                            |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Tooth Abscess                                   |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Metabolism and nutrition disorders              |                 |                 |                 |
| Diabetic Metabolic Decompensation               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Failure to Thrive                               |                 |                 |                 |



|   |                 |                 |                 |
|---|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                       | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w | Long Term Extension (LTE): Placebo SC | LTE: Placebo SC to Ustekinumab SC 90 mg q8w |
|---|---|---------------------------------------|---|
| Total subjects affected by serious adverse events                   |   |                                       |   |
| subjects affected / exposed   | 11 / 157 (7.01%)  | 6 / 115 (5.22%)                       | 8 / 56 (14.29%)                             |
| number of deaths (all causes)                                       | 1   | 0                                     | 1   |
| number of deaths resulting from adverse events                      |   |                                       |   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |   |                                       |   |
| Basal Cell Carcinoma  |   |                                       |   |
| subjects affected / exposed   | 1 / 157 (0.64%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 2   | 0 / 0                                 | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| Bowen's Disease   |   |                                       |   |
| subjects affected / exposed   | 0 / 157 (0.00%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| Colon Adenoma   |   |                                       |   |
| subjects affected / exposed   | 0 / 157 (0.00%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| Colon Cancer  |   |                                       |   |
| subjects affected / exposed   | 0 / 157 (0.00%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| Colorectal Cancer   |   |                                       |   |
| subjects affected / exposed   | 0 / 157 (0.00%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences causally related to treatment / all                     | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| deaths causally related to treatment / all                          | 0 / 0   | 0 / 0                                 | 0 / 0                                       |
| Hepatic Adenoma   |   |                                       |   |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 1 / 115 (0.87%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Intraductal Papilloma of Breast                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Lentigo Maligna                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ovarian Adenoma                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pituitary Tumour Benign                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Prostate Cancer                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Adenocarcinoma                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Adenoma                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Cancer                                   |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Skin Papilloma                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Testis Cancer                                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vascular disorders                              |                 |                 |                |
| Deep Vein Thrombosis                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Extremity Necrosis                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Haemorrhage                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vasculitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pregnancy, puerperium and perinatal conditions  |                 |                 |                |
| Abortion Spontaneous                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

|  |                 |                 |                |
|--|-----------------|-----------------|----------------|
| General disorders and administration site conditions |                 |                 |                |
| Non-Cardiac Chest Pain                               |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyrexia  |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Immune system disorders                              |                 |                 |                |
| Anaphylactic Reaction                                |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Reproductive system and breast disorders             |                 |                 |                |
| Benign Prostatic Hyperplasia                         |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Ovarian Cyst   |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Prostatitis  |                 |                 |                |
| subjects affected / exposed                          | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                |
| Acute Respiratory Failure                            |                 |                 |                |
| subjects affected / exposed                          | 1 / 157 (0.64%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 1           | 0 / 0           | 0 / 0          |
| Bronchiectasis                                       |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hyperventilation                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pleurisy  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pulmonary Embolism                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pulmonary Eosinophilia                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Psychiatric disorders                           |                 |                 |                |
| Confusional State                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Mental Status Changes                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Suicidal Ideation                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications  |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Ankle Fracture                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Bladder Injury                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Clavicle Fracture                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Fibula Fracture                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hip Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Injury  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Jaw Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Lumbar Vertebral Fracture                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Meniscus Injury                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Procedural Intestinal Perforation               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Radius Fracture                                 |                 |                 |                |
| subjects affected / exposed                     | 1 / 157 (0.64%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rib Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Spinal Compression Fracture                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Tibia Fracture                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Traumatic Fracture                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Congenital, familial and genetic disorders      |                 |                 |                |
| Hydrocele                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Acute Myocardial Infarction                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Atrial Fibrillation                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cardiac Arrest                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1          |
| Coronary Artery Disease                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Myocardial Infarction                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pericarditis                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 1 / 115 (0.87%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                 |                 |                |
| Aphasia   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cognitive Disorder                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Epilepsy  |                 |                 |                |



|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Generalised Tonic-Clonic Seizure                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ischaemic Stroke                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Migraine  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Motor Dysfunction                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Optic Neuritis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 1 / 115 (0.87%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Presyncope                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Blood and lymphatic system disorders            |                 |                 |                |
| Anaemia   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Autoimmune Haemolytic Anaemia                   |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Iron Deficiency Anaemia                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ear and labyrinth disorders                     |                 |                 |                |
| Deafness Neurosensory                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Deafness Unilateral                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                 |                 |                |
| Cataract  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Retinal Detachment                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                 |                 |                |
| Abdominal Pain                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Abdominal Pain Upper                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Anal Fissure                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Anorectal Disorder                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Colitis Ulcerative                              |                 |                 |                |
| subjects affected / exposed                     | 7 / 157 (4.46%) | 3 / 115 (2.61%) | 2 / 56 (3.57%) |
| occurrences causally related to treatment / all | 0 / 8           | 0 / 3           | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Colon Dysplasia                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diarrhoea Haemorrhagic                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Duodenal Ulcer                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Enteritis                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Enterovesical Fistula                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastrointestinal Haemorrhage                    |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Inguinal Hernia                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestinal Obstruction                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestine Perforation                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestine Polyp                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Mesenteric Fibrosis                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Oesophageal Varices Haemorrhage                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pancreatitis Acute                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pseudopolyposis                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Small Intestinal Obstruction                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Subileus  |                 |                 |                |
| subjects affected / exposed                     | 1 / 157 (0.64%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Umbilical Hernia                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vomiting  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hepatobiliary disorders                         |                 |                 |                |
| Cholecystitis Acute                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cholelithiasis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Drug-Induced Liver Injury                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Liver Disorder                                  |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                 |                 |                |
| Dermatitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyoderma Gangrenosum                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rash  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Renal and urinary disorders                     |                 |                 |                |
| Acute Kidney Injury                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Calculus Bladder                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Chronic Kidney Disease                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Glomerulonephritis Chronic                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Nephrolithiasis                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Renal Colic                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ureterolithiasis                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Urinary Incontinence                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                 |                 |                |
| Enthesopathy                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Intervertebral Disc Protrusion                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Osteoarthritis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rotator Cuff Syndrome                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Sacroiliitis                                    |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                 |                 |                |
| Anal Abscess                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Appendicitis                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cellulitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Clostridium Difficile Infection                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Complicated Appendicitis                        |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cystitis  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 1 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cytomegalovirus Colitis                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cytomegalovirus Infection                       |                 |                 |                |



|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 2 / 56 (3.57%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 2 / 2          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diverticulitis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastroenteritis                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastroenteritis Salmonella                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hepatitis C                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Herpes Zoster                                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Human Herpesvirus 6 Infection                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Influenza                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Listeriosis                                     |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Neutropenic Sepsis                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Oral Herpes                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pelvic Inflammatory Disease                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Periorbital Cellulitis                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Perirectal Abscess                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pharyngeal Abscess                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia                                       |                 |                 |                |
| subjects affected / exposed                     | 1 / 157 (0.64%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia Legionella                            |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia Viral                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 1 / 115 (0.87%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 1 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyelonephritis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Salpingitis                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Salpingo-Oophoritis                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Subcutaneous Abscess                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Tooth Abscess                                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Metabolism and nutrition disorders              |                 |                 |                |
| Diabetic Metabolic Decompensation               |                 |                 |                |
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 0 / 56 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Failure to Thrive                               |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

| <b>Serious adverse events</b>                                       | LTE: Ustekinumab<br>90 mg SC q12w to<br>90 mg SC q8w | LTE: Ustekinumab<br>90 mg SC q12w | LTE: Ustekinumab<br>90 mg SC q8w to 90<br>mg SC q8w |
|---|--|-----------------------------------|---|
| Total subjects affected by serious adverse events                   |  |                                   |   |
| subjects affected / exposed   | 6 / 64 (9.38%)                                       | 13 / 141 (9.22%)                  | 3 / 37 (8.11%)                                      |
| number of deaths (all causes)                                       | 0  | 0                                 | 0   |
| number of deaths resulting from adverse events                      |  |                                   |   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |  |                                   |   |
| Basal Cell Carcinoma  |  |                                   |   |
| subjects affected / exposed   | 0 / 64 (0.00%)                                       | 1 / 141 (0.71%)                   | 0 / 37 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0  | 1 / 1                             | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0                             | 0 / 0   |
| Bowen's Disease   |  |                                   |   |
| subjects affected / exposed   | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 0 / 37 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0                             | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0                             | 0 / 0   |
| Colon Adenoma   |  |                                   |   |
| subjects affected / exposed   | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 0 / 37 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0                             | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0                             | 0 / 0   |
| Colon Cancer  |  |                                   |   |
| subjects affected / exposed   | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 0 / 37 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0                             | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0                             | 0 / 0   |
| Colorectal Cancer   |  |                                   |   |
| subjects affected / exposed   | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 0 / 37 (0.00%)                                      |
| occurrences causally related to treatment / all                     | 0 / 0  | 0 / 0                             | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0  | 0 / 0                             | 0 / 0   |
| Hepatic Adenoma   |  |                                   |   |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Intraductal Papilloma of Breast                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Lentigo Maligna                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Ovarian Adenoma                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pituitary Tumour Benign                         |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Prostate Cancer                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rectal Adenocarcinoma                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rectal Adenoma                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rectal Cancer                                   |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Skin Papilloma                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Testis Cancer                                   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Vascular disorders                              |                |                 |                |
| Deep Vein Thrombosis                            |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Extremity Necrosis                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Haemorrhage                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Vasculitis                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pregnancy, puerperium and perinatal conditions  |                |                 |                |
| Abortion Spontaneous                            |                |                 |                |
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

|  |                |                 |                |
|--|----------------|-----------------|----------------|
| General disorders and administration site conditions |                |                 |                |
| Non-Cardiac Chest Pain                               |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Pyrexia  |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Immune system disorders                              |                |                 |                |
| Anaphylactic Reaction                                |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Reproductive system and breast disorders             |                |                 |                |
| Benign Prostatic Hyperplasia                         |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Ovarian Cyst   |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Prostatitis  |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                |                 |                |
| Acute Respiratory Failure                            |                |                 |                |
| subjects affected / exposed                          | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0           | 0 / 0          |
| Bronchiectasis                                       |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Hyperventilation                                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pleurisy  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pulmonary Embolism                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pulmonary Eosinophilia                          |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Psychiatric disorders                           |                |                 |                |
| Confusional State                               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Mental Status Changes                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Suicidal Ideation                               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 1 / 37 (2.70%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications  |                |                 |                |



|   |                |                 |                |
|---|----------------|-----------------|----------------|
| Ankle Fracture                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Bladder Injury                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Clavicle Fracture                               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Fibula Fracture                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Hip Fracture                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Injury  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Jaw Fracture                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 1 / 37 (2.70%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Lumbar Vertebral Fracture                       |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Meniscus Injury                                 |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Procedural Intestinal Perforation               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Radius Fracture                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rib Fracture                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Spinal Compression Fracture                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Tibia Fracture                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Traumatic Fracture                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Congenital, familial and genetic disorders      |                |                 |                |
| Hydrocele                                       |                |                 |                |
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| Acute Myocardial Infarction                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Atrial Fibrillation                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cardiac Arrest                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Coronary Artery Disease                         |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Myocardial Infarction                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pericarditis                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                |                 |                |
| Aphasia   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cognitive Disorder                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Epilepsy  |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Generalised Tonic-Clonic Seizure                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Ischaemic Stroke                                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Migraine  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Motor Dysfunction                               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Optic Neuritis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Presyncope                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Blood and lymphatic system disorders            |                |                 |                |
| Anaemia   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Autoimmune Haemolytic Anaemia                   |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Iron Deficiency Anaemia                         |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 4           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Ear and labyrinth disorders                     |                |                 |                |
| Deafness Neurosensory                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Deafness Unilateral                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                |                 |                |
| Cataract  |                |                 |                |
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Retinal Detachment                              |                |                 |                |
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                |                 |                |
| Abdominal Pain                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Abdominal Pain Upper                            |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| Anal Fissure                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Anorectal Disorder                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Colitis Ulcerative                              |                |                 |                |
| subjects affected / exposed                     | 3 / 64 (4.69%) | 1 / 141 (0.71%) | 1 / 37 (2.70%) |
| occurrences causally related to treatment / all | 0 / 3          | 0 / 1           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Colon Dysplasia                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Diarrhoea Haemorrhagic                          |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Duodenal Ulcer                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Enteritis                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Enterovesical Fistula                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastrointestinal Haemorrhage                    |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Inguinal Hernia                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Large Intestinal Obstruction                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Large Intestine Perforation                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Large Intestine Polyp                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Mesenteric Fibrosis                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Oesophageal Varices Haemorrhage                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pancreatitis Acute                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pseudopolyposis                                 |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Small Intestinal Obstruction                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Subileus  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Umbilical Hernia                                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Vomiting  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Hepatobiliary disorders                         |                |                 |                |
| Cholecystitis Acute                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cholelithiasis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Drug-Induced Liver Injury                       |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Liver Disorder                                  |                |                 |                |



|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                |                 |                |
| Dermatitis                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pyoderma Gangrenosum                            |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rash  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Renal and urinary disorders                     |                |                 |                |
| Acute Kidney Injury                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Calculus Bladder                                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Chronic Kidney Disease                          |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Glomerulonephritis Chronic                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Nephrolithiasis                                 |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Renal Colic                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Ureterolithiasis                                |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Urinary Incontinence                            |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                 |                |
| Enthesopathy                                    |                |                 |                |
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Intervertebral Disc Protrusion                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Osteoarthritis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Rotator Cuff Syndrome                           |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Sacroiliitis                                    |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 1 / 64 (1.56%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                |                 |                |
| Anal Abscess                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Appendicitis                                    |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cellulitis                                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Clostridium Difficile Infection                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Complicated Appendicitis                        |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cystitis  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cytomegalovirus Colitis                         |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Cytomegalovirus Infection                       |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Diverticulitis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastroenteritis                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Gastroenteritis Salmonella                      |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Hepatitis C                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Herpes Zoster                                   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Human Herpesvirus 6 Infection                   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Influenza                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Listeriosis                                     |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Neutropenic Sepsis                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Oral Herpes                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pelvic Inflammatory Disease                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Periorbital Cellulitis                          |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Perirectal Abscess                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pharyngeal Abscess                              |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pneumonia                                       |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 1 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pneumonia Legionella                            |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pneumonia Viral                                 |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Pyelonephritis                                  |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Salpingitis                                     |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Salpingo-Oophoritis                             |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Subcutaneous Abscess                            |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Tooth Abscess                                   |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Metabolism and nutrition disorders              |                |                 |                |
| Diabetic Metabolic Decompensation               |                |                 |                |
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |
| Failure to Thrive                               |                |                 |                |

|   |                |                 |                |
|---|----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 64 (0.00%) | 0 / 141 (0.00%) | 0 / 37 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0           | 0 / 0          |

| <b>Serious adverse events</b>                                       | LTE: Ustekinumab<br>90 mg SC q8w | LTE: Ustekinumab<br>Delayed Responders<br>(IS) to UST 90mg<br>SC q8w | LTE: Placebo IV (IS<br>– Responders) to<br>Placebo SC |
|---|----------------------------------|--|---|
| Total subjects affected by serious adverse events                   |                                  |  |   |
| subjects affected / exposed   | 15 / 143 (10.49%)                | 14 / 116 (12.07%)  | 10 / 73 (13.70%)                                      |
| number of deaths (all causes)                                       | 0                                | 0  | 0   |
| number of deaths resulting from adverse events                      |                                  |  |   |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                  |  |   |
| Basal Cell Carcinoma  |                                  |  |   |
| subjects affected / exposed   | 0 / 143 (0.00%)                  | 2 / 116 (1.72%)  | 0 / 73 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0                            | 0 / 2  | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                            | 0 / 0  | 0 / 0   |
| Bowen's Disease   |                                  |  |   |
| subjects affected / exposed   | 0 / 143 (0.00%)                  | 1 / 116 (0.86%)  | 0 / 73 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0                            | 0 / 1  | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                            | 0 / 0  | 0 / 0   |
| Colon Adenoma   |                                  |  |   |
| subjects affected / exposed   | 0 / 143 (0.00%)                  | 1 / 116 (0.86%)  | 0 / 73 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0                            | 0 / 1  | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                            | 0 / 0  | 0 / 0   |
| Colon Cancer  |                                  |  |   |
| subjects affected / exposed   | 0 / 143 (0.00%)                  | 0 / 116 (0.00%)  | 0 / 73 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0                            | 0 / 0  | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                            | 0 / 0  | 0 / 0   |
| Colorectal Cancer   |                                  |  |   |
| subjects affected / exposed   | 0 / 143 (0.00%)                  | 1 / 116 (0.86%)  | 0 / 73 (0.00%)  |
| occurrences causally related to treatment / all                     | 0 / 0                            | 0 / 1  | 0 / 0   |
| deaths causally related to treatment / all                          | 0 / 0                            | 0 / 0  | 0 / 0   |
| Hepatic Adenoma   |                                  |  |   |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Intraductal Papilloma of Breast                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Lentigo Maligna                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ovarian Adenoma                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pituitary Tumour Benign                         |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Prostate Cancer                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Adenocarcinoma                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Adenoma                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rectal Cancer                                   |                 |                 |                |



|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Skin Papilloma                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Testis Cancer                                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vascular disorders                              |                 |                 |                |
| Deep Vein Thrombosis                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Extremity Necrosis                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Haemorrhage                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vasculitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pregnancy, puerperium and perinatal conditions  |                 |                 |                |
| Abortion Spontaneous                            |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

|  |                 |                 |                |
|--|-----------------|-----------------|----------------|
| General disorders and administration site conditions |                 |                 |                |
| Non-Cardiac Chest Pain                               |                 |                 |                |
| subjects affected / exposed                          | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyrexia  |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Immune system disorders                              |                 |                 |                |
| Anaphylactic Reaction                                |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Reproductive system and breast disorders             |                 |                 |                |
| Benign Prostatic Hyperplasia                         |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Ovarian Cyst   |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Prostatitis  |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                 |                 |                |
| Acute Respiratory Failure                            |                 |                 |                |
| subjects affected / exposed                          | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0          |
| Bronchiectasis                                       |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hyperventilation                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pleurisy  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pulmonary Embolism                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pulmonary Eosinophilia                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Psychiatric disorders                           |                 |                 |                |
| Confusional State                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Mental Status Changes                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Suicidal Ideation                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Injury, poisoning and procedural complications  |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Ankle Fracture                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Bladder Injury                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Clavicle Fracture                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Fibula Fracture                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hip Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Injury  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Jaw Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Lumbar Vertebral Fracture                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Meniscus Injury                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Procedural Intestinal Perforation               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Radius Fracture                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rib Fracture                                    |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Spinal Compression Fracture                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Tibia Fracture                                  |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Traumatic Fracture                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Congenital, familial and genetic disorders      |                 |                 |                |
| Hydrocele                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cardiac disorders                               |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Acute Myocardial Infarction                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Atrial Fibrillation                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cardiac Arrest                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Coronary Artery Disease                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Myocardial Infarction                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pericarditis                                    |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Nervous system disorders                        |                 |                 |                |
| Aphasia   |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cognitive Disorder                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Epilepsy  |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Generalised Tonic-Clonic Seizure                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ischaemic Stroke                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Migraine  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Motor Dysfunction                               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Optic Neuritis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Presyncope                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Blood and lymphatic system disorders            |                 |                 |                |
| Anaemia   |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Autoimmune Haemolytic Anaemia                   |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Iron Deficiency Anaemia                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ear and labyrinth disorders                     |                 |                 |                |
| Deafness Neurosensory                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Deafness Unilateral                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Eye disorders                                   |                 |                 |                |
| Cataract  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Retinal Detachment                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastrointestinal disorders                      |                 |                 |                |
| Abdominal Pain                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Abdominal Pain Upper                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |



|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| Anal Fissure                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Anorectal Disorder                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Colitis Ulcerative                              |                 |                 |                |
| subjects affected / exposed                     | 5 / 143 (3.50%) | 2 / 116 (1.72%) | 4 / 73 (5.48%) |
| occurrences causally related to treatment / all | 0 / 6           | 0 / 2           | 0 / 4          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Colon Dysplasia                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diarrhoea Haemorrhagic                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Duodenal Ulcer                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Enteritis                                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Enterovesical Fistula                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastrointestinal Haemorrhage                    |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Inguinal Hernia                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestinal Obstruction                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestine Perforation                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Large Intestine Polyp                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Mesenteric Fibrosis                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Oesophageal Varices Haemorrhage                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pancreatitis Acute                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pseudopolyposis                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Small Intestinal Obstruction                    |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Subileus  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Umbilical Hernia                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Vomiting  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hepatobiliary disorders                         |                 |                 |                |
| Cholecystitis Acute                             |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cholelithiasis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Drug-Induced Liver Injury                       |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Liver Disorder                                  |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                 |                 |                |
| Dermatitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyoderma Gangrenosum                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rash  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Renal and urinary disorders                     |                 |                 |                |
| Acute Kidney Injury                             |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Calculus Bladder                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Chronic Kidney Disease                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Glomerulonephritis Chronic                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Nephrolithiasis                                 |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Renal Colic                                     |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Ureterolithiasis                                |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 2 / 116 (1.72%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 2           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Urinary Incontinence                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                 |                 |                |
| Enthesopathy                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Intervertebral Disc Protrusion                  |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Osteoarthritis                                  |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Rotator Cuff Syndrome                           |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Sacroiliitis                                    |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Infections and infestations                     |                 |                 |                |
| Anal Abscess                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Appendicitis                                    |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cellulitis                                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Clostridium Difficile Infection                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Complicated Appendicitis                        |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cystitis  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cytomegalovirus Colitis                         |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Cytomegalovirus Infection                       |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Diverticulitis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastroenteritis                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Gastroenteritis Salmonella                      |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Hepatitis C                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Herpes Zoster                                   |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Human Herpesvirus 6 Infection                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Influenza                                       |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Listeriosis                                     |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Neutropenic Sepsis                              |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Oral Herpes                                     |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pelvic Inflammatory Disease                     |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Periorbital Cellulitis                          |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Perirectal Abscess                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pharyngeal Abscess                              |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia                                       |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia Legionella                            |                 |                 |                |



|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pneumonia Viral                                 |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Pyelonephritis                                  |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 1 / 116 (0.86%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Salpingitis                                     |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Salpingo-Oophoritis                             |                 |                 |                |
| subjects affected / exposed                     | 1 / 143 (0.70%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Subcutaneous Abscess                            |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Tooth Abscess                                   |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 1 / 73 (1.37%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Metabolism and nutrition disorders              |                 |                 |                |
| Diabetic Metabolic Decompensation               |                 |                 |                |
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |
| Failure to Thrive                               |                 |                 |                |

|   |                 |                 |                |
|---|-----------------|-----------------|----------------|
| subjects affected / exposed                     | 0 / 143 (0.00%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0          |

Frequency threshold for reporting non-serious adverse events: 3 %

| <b>Non-serious adverse events</b>                     | IS: Ustekinumab<br>130 milligram (mg)<br>IV | Induction Study(IS):<br>Placebo Intravenous<br>(IV) | IS: Ustekinumab<br>approximately<br>6mg/kg IV |
|---|---|---|---|
| Total subjects affected by non-serious adverse events |   |   |   |
| subjects affected / exposed                           | 100 / 321 (31.15%)                          | 91 / 319 (28.53%)                                   | 103 / 320 (32.19%)                            |
| Vascular disorders                                    |   |   |   |
| Hypertension  |   |   |   |
| subjects affected / exposed                           | 1 / 321 (0.31%)                             | 5 / 319 (1.57%)                                     | 0 / 320 (0.00%)                               |
| occurrences (all)                                     | 1   | 7   | 0   |
| General disorders and administration site conditions  |   |   |   |
| Fatigue   |   |   |   |
| subjects affected / exposed                           | 6 / 321 (1.87%)                             | 5 / 319 (1.57%)                                     | 8 / 320 (2.50%)                               |
| occurrences (all)                                     | 6   | 5   | 8   |
| Influenza Like Illness                                |   |   |   |
| subjects affected / exposed                           | 2 / 321 (0.62%)                             | 2 / 319 (0.63%)                                     | 1 / 320 (0.31%)                               |
| occurrences (all)                                     | 2   | 2   | 1   |
| Injection Site Erythema                               |   |   |   |
| subjects affected / exposed                           | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences (all)                                     | 0   | 0   | 0   |
| Injection Site Swelling                               |   |   |   |
| subjects affected / exposed                           | 0 / 321 (0.00%)                             | 0 / 319 (0.00%)                                     | 0 / 320 (0.00%)                               |
| occurrences (all)                                     | 0   | 0   | 0   |
| Pyrexia   |   |   |   |
| subjects affected / exposed                           | 4 / 321 (1.25%)                             | 6 / 319 (1.88%)                                     | 6 / 320 (1.88%)                               |
| occurrences (all)                                     | 4   | 6   | 8   |
| Respiratory, thoracic and mediastinal disorders       |   |   |   |
| Cough   |   |   |   |
| subjects affected / exposed                           | 4 / 321 (1.25%)                             | 3 / 319 (0.94%)                                     | 3 / 320 (0.94%)                               |
| occurrences (all)                                     | 4   | 3   | 3   |
| Oropharyngeal Pain                                    |   |   |   |

|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 1 / 321 (0.31%)<br>1 | 1 / 319 (0.31%)<br>1 | 8 / 320 (2.50%)<br>8 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 1 / 321 (0.31%)<br>1 | 4 / 319 (1.25%)<br>4 | 0 / 320 (0.00%)<br>0 |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 0 / 321 (0.00%)<br>0 | 2 / 319 (0.63%)<br>2 | 6 / 320 (1.88%)<br>7 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 321 (0.00%)<br>0 | 2 / 319 (0.63%)<br>2 | 3 / 320 (0.94%)<br>3 |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 321 (0.00%)<br>0 | 1 / 319 (0.31%)<br>1 | 2 / 320 (0.63%)<br>2 |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 321 (0.31%)<br>1 | 1 / 319 (0.31%)<br>1 | 1 / 320 (0.31%)<br>1 |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 0 / 320 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 1 / 321 (0.31%)<br>1 | 0 / 319 (0.00%)<br>0 | 2 / 320 (0.63%)<br>2 |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 0 / 320 (0.00%)<br>0 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 0 / 320 (0.00%)<br>0 |
| Nervous system disorders<br>Dizziness   |                      |                      |                      |

|  |                        |                        |                        |
|--|------------------------|------------------------|------------------------|
| subjects affected / exposed<br>occurrences (all)   | 2 / 321 (0.62%)<br>2   | 1 / 319 (0.31%)<br>1   | 4 / 320 (1.25%)<br>4   |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 22 / 321 (6.85%)<br>24 | 14 / 319 (4.39%)<br>17 | 13 / 320 (4.06%)<br>16 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)   | 0 / 321 (0.00%)<br>0   | 0 / 319 (0.00%)<br>0   | 0 / 320 (0.00%)<br>0   |
| Tremor<br>subjects affected / exposed<br>occurrences (all)   | 1 / 321 (0.31%)<br>1   | 0 / 319 (0.00%)<br>0   | 0 / 320 (0.00%)<br>0   |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)    | 7 / 321 (2.18%)<br>10  | 11 / 319 (3.45%)<br>11 | 8 / 320 (2.50%)<br>8   |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)   | 2 / 321 (0.62%)<br>2   | 1 / 319 (0.31%)<br>1   | 5 / 320 (1.56%)<br>5   |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 321 (0.00%)<br>0   | 1 / 319 (0.31%)<br>1   | 1 / 320 (0.31%)<br>1   |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 321 (0.00%)<br>0   | 0 / 319 (0.00%)<br>0   | 1 / 320 (0.31%)<br>1   |
| Gastrointestinal disorders<br>Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 2 / 321 (0.62%)<br>2   | 0 / 319 (0.00%)<br>0   | 0 / 320 (0.00%)<br>0   |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)                                     | 8 / 321 (2.49%)<br>9   | 9 / 319 (2.82%)<br>9   | 5 / 320 (1.56%)<br>5   |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all)                               | 4 / 321 (1.25%)<br>4   | 0 / 319 (0.00%)<br>0   | 1 / 320 (0.31%)<br>1   |
| Colitis Ulcerative   |                        |                        |                        |

|  |                 |                 |                 |
|--|-----------------|-----------------|-----------------|
| subjects affected / exposed            | 5 / 321 (1.56%) | 8 / 319 (2.51%) | 5 / 320 (1.56%) |
| occurrences (all)                      | 5               | 8               | 5               |
| Constipation                           |                 |                 |                 |
| subjects affected / exposed            | 1 / 321 (0.31%) | 1 / 319 (0.31%) | 1 / 320 (0.31%) |
| occurrences (all)                      | 1               | 1               | 1               |
| Diarrhoea                              |                 |                 |                 |
| subjects affected / exposed            | 3 / 321 (0.93%) | 1 / 319 (0.31%) | 1 / 320 (0.31%) |
| occurrences (all)                      | 3               | 1               | 2               |
| Frequent Bowel Movements               |                 |                 |                 |
| subjects affected / exposed            | 3 / 321 (0.93%) | 0 / 319 (0.00%) | 1 / 320 (0.31%) |
| occurrences (all)                      | 4               | 0               | 1               |
| Nausea                                 |                 |                 |                 |
| subjects affected / exposed            | 8 / 321 (2.49%) | 7 / 319 (2.19%) | 7 / 320 (2.19%) |
| occurrences (all)                      | 8               | 7               | 7               |
| Rectal Haemorrhage                     |                 |                 |                 |
| subjects affected / exposed            | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Vomiting                               |                 |                 |                 |
| subjects affected / exposed            | 3 / 321 (0.93%) | 1 / 319 (0.31%) | 4 / 320 (1.25%) |
| occurrences (all)                      | 3               | 1               | 9               |
| Hepatobiliary disorders                |                 |                 |                 |
| Hepatic Steatosis                      |                 |                 |                 |
| subjects affected / exposed            | 0 / 321 (0.00%) | 1 / 319 (0.31%) | 0 / 320 (0.00%) |
| occurrences (all)                      | 0               | 1               | 0               |
| Skin and subcutaneous tissue disorders |                 |                 |                 |
| Acne                                   |                 |                 |                 |
| subjects affected / exposed            | 1 / 321 (0.31%) | 3 / 319 (0.94%) | 2 / 320 (0.63%) |
| occurrences (all)                      | 1               | 3               | 4               |
| Eczema                                 |                 |                 |                 |
| subjects affected / exposed            | 1 / 321 (0.31%) | 5 / 319 (1.57%) | 2 / 320 (0.63%) |
| occurrences (all)                      | 2               | 5               | 2               |
| Papule                                 |                 |                 |                 |
| subjects affected / exposed            | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences (all)                      | 0               | 0               | 0               |
| Pruritus                               |                 |                 |                 |

|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)                    | 8 / 321 (2.49%)<br>8 | 4 / 319 (1.25%)<br>4 | 3 / 320 (0.94%)<br>3 |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 3 / 321 (0.93%)<br>3 | 1 / 319 (0.31%)<br>1 | 4 / 320 (1.25%)<br>6 |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 1 / 320 (0.31%)<br>1 |
| Musculoskeletal and connective tissue disorders                     |                      |                      |                      |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 4 / 321 (1.25%)<br>4 | 3 / 319 (0.94%)<br>3 | 6 / 320 (1.88%)<br>6 |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 2 / 321 (0.62%)<br>2 | 4 / 319 (1.25%)<br>5 | 4 / 320 (1.25%)<br>4 |
| Infections and infestations   |                      |                      |                      |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 0 / 321 (0.00%)<br>0 | 1 / 319 (0.31%)<br>1 | 2 / 320 (0.63%)<br>2 |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 0 / 320 (0.00%)<br>0 |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 1 / 321 (0.31%)<br>1 | 0 / 319 (0.00%)<br>0 | 0 / 320 (0.00%)<br>0 |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 2 / 321 (0.62%)<br>2 | 2 / 319 (0.63%)<br>2 | 1 / 320 (0.31%)<br>1 |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 0 / 321 (0.00%)<br>0 | 0 / 319 (0.00%)<br>0 | 2 / 320 (0.63%)<br>2 |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 2 / 321 (0.62%)<br>2 | 0 / 319 (0.00%)<br>0 | 1 / 320 (0.31%)<br>1 |
| Laryngitis  |                      |                      |                      |

|   |                  |                 |                  |
|---|------------------|-----------------|------------------|
| subjects affected / exposed             | 0 / 321 (0.00%)  | 1 / 319 (0.31%) | 0 / 320 (0.00%)  |
| occurrences (all)                       | 0                | 1               | 0                |
| Nasopharyngitis                         |                  |                 |                  |
| subjects affected / exposed             | 13 / 321 (4.05%) | 9 / 319 (2.82%) | 18 / 320 (5.63%) |
| occurrences (all)                       | 13               | 9               | 18               |
| Oral Herpes                             |                  |                 |                  |
| subjects affected / exposed             | 1 / 321 (0.31%)  | 5 / 319 (1.57%) | 3 / 320 (0.94%)  |
| occurrences (all)                       | 1                | 5               | 4                |
| Pharyngitis                             |                  |                 |                  |
| subjects affected / exposed             | 1 / 321 (0.31%)  | 1 / 319 (0.31%) | 0 / 320 (0.00%)  |
| occurrences (all)                       | 1                | 2               | 0                |
| Rhinitis                                |                  |                 |                  |
| subjects affected / exposed             | 3 / 321 (0.93%)  | 0 / 319 (0.00%) | 1 / 320 (0.31%)  |
| occurrences (all)                       | 3                | 0               | 1                |
| Sinusitis                               |                  |                 |                  |
| subjects affected / exposed             | 5 / 321 (1.56%)  | 1 / 319 (0.31%) | 1 / 320 (0.31%)  |
| occurrences (all)                       | 5                | 1               | 1                |
| Tonsillitis                             |                  |                 |                  |
| subjects affected / exposed             | 1 / 321 (0.31%)  | 0 / 319 (0.00%) | 1 / 320 (0.31%)  |
| occurrences (all)                       | 1                | 0               | 1                |
| Upper Respiratory Tract Infection       |                  |                 |                  |
| subjects affected / exposed             | 6 / 321 (1.87%)  | 4 / 319 (1.25%) | 5 / 320 (1.56%)  |
| occurrences (all)                       | 6                | 6               | 5                |
| Urinary Tract Infection                 |                  |                 |                  |
| subjects affected / exposed             | 3 / 321 (0.93%)  | 0 / 319 (0.00%) | 3 / 320 (0.94%)  |
| occurrences (all)                       | 3                | 0               | 3                |
| Viral Infection                         |                  |                 |                  |
| subjects affected / exposed             | 0 / 321 (0.00%)  | 0 / 319 (0.00%) | 0 / 320 (0.00%)  |
| occurrences (all)                       | 0                | 0               | 0                |
| Viral Upper Respiratory Tract Infection |                  |                 |                  |
| subjects affected / exposed             | 1 / 321 (0.31%)  | 0 / 319 (0.00%) | 0 / 320 (0.00%)  |
| occurrences (all)                       | 1                | 0               | 0                |
| Metabolism and nutrition disorders      |                  |                 |                  |
| Iron Deficiency                         |                  |                 |                  |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences (all)           | 0               | 0               | 0               |
| Vitamin D Deficiency        |                 |                 |                 |
| subjects affected / exposed | 0 / 321 (0.00%) | 0 / 319 (0.00%) | 0 / 320 (0.00%) |
| occurrences (all)           | 0               | 0               | 0               |

| <b>Non-serious adverse events</b>                        | MS: Ustekinumab<br>90mg SC every 12<br>weeks (q12w) | MS: Ustekinumab<br>90mg SC every 8<br>weeks (q8w) | Maintenance<br>study(MS): Placebo<br>Subcutaneous (SC) |
|--|---|---|--|
| Total subjects affected by non-serious<br>adverse events |   |   |  |
| subjects affected / exposed                              | 93 / 172 (54.07%)                                   | 118 / 176 (67.05%)                                | 121 / 175 (69.14%)                                     |
| Vascular disorders                                       |   |   |  |
| Hypertension   |   |   |  |
| subjects affected / exposed                              | 4 / 172 (2.33%)                                     | 3 / 176 (1.70%)                                   | 0 / 175 (0.00%)  |
| occurrences (all)  | 4   | 4   | 0  |
| General disorders and administration<br>site conditions  |   |   |  |
| Fatigue  |   |   |  |
| subjects affected / exposed                              | 4 / 172 (2.33%)                                     | 7 / 176 (3.98%)                                   | 4 / 175 (2.29%)  |
| occurrences (all)  | 4   | 10  | 6  |
| Influenza Like Illness                                   |   |   |  |
| subjects affected / exposed                              | 2 / 172 (1.16%)                                     | 2 / 176 (1.14%)                                   | 4 / 175 (2.29%)  |
| occurrences (all)  | 4   | 2   | 4  |
| Injection Site Erythema                                  |   |   |  |
| subjects affected / exposed                              | 1 / 172 (0.58%)                                     | 3 / 176 (1.70%)                                   | 1 / 175 (0.57%)  |
| occurrences (all)  | 1   | 3   | 1  |
| Injection Site Swelling                                  |   |   |  |
| subjects affected / exposed                              | 0 / 172 (0.00%)                                     | 0 / 176 (0.00%)                                   | 1 / 175 (0.57%)  |
| occurrences (all)  | 0   | 0   | 1  |
| Pyrexia  |   |   |  |
| subjects affected / exposed                              | 1 / 172 (0.58%)                                     | 8 / 176 (4.55%)                                   | 7 / 175 (4.00%)  |
| occurrences (all)  | 1   | 8   | 7  |
| Respiratory, thoracic and mediastinal<br>disorders       |   |   |  |
| Cough  |   |   |  |
| subjects affected / exposed                              | 2 / 172 (1.16%)                                     | 7 / 176 (3.98%)                                   | 5 / 175 (2.86%)  |
| occurrences (all)  | 3   | 8   | 7  |
| Oropharyngeal Pain                                       |   |   |  |



|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 4 / 172 (2.33%)<br>4 | 7 / 176 (3.98%)<br>8 | 5 / 175 (2.86%)<br>7 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 3 / 172 (1.74%)<br>3 | 3 / 176 (1.70%)<br>3 | 2 / 175 (1.14%)<br>2 |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 5 / 172 (2.91%)<br>5 | 6 / 176 (3.41%)<br>7 | 4 / 175 (2.29%)<br>5 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 5 / 172 (2.91%)<br>6 | 4 / 176 (2.27%)<br>4 | 4 / 175 (2.29%)<br>5 |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 1 / 172 (0.58%)<br>1 | 1 / 176 (0.57%)<br>1 | 1 / 175 (0.57%)<br>1 |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 172 (0.58%)<br>1 | 1 / 176 (0.57%)<br>1 | 1 / 175 (0.57%)<br>1 |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 172 (0.00%)<br>0 | 0 / 176 (0.00%)<br>0 | 0 / 175 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 2 / 172 (1.16%)<br>2 | 4 / 176 (2.27%)<br>5 | 0 / 175 (0.00%)<br>0 |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 172 (0.00%)<br>0 | 0 / 176 (0.00%)<br>0 | 0 / 175 (0.00%)<br>0 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 172 (0.00%)<br>0 | 0 / 176 (0.00%)<br>0 | 0 / 175 (0.00%)<br>0 |
| Nervous system disorders<br>Dizziness   |                      |                      |                      |

|  |                        |                         |                        |
|--|------------------------|-------------------------|------------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 172 (0.00%)<br>0   | 3 / 176 (1.70%)<br>3    | 0 / 175 (0.00%)<br>0   |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 11 / 172 (6.40%)<br>22 | 18 / 176 (10.23%)<br>27 | 7 / 175 (4.00%)<br>7   |
| Migraine<br>subjects affected / exposed<br>occurrences (all)   | 1 / 172 (0.58%)<br>1   | 2 / 176 (1.14%)<br>3    | 3 / 175 (1.71%)<br>3   |
| Tremor<br>subjects affected / exposed<br>occurrences (all)   | 0 / 172 (0.00%)<br>0   | 0 / 176 (0.00%)<br>0    | 0 / 175 (0.00%)<br>0   |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)    | 7 / 172 (4.07%)<br>8   | 7 / 176 (3.98%)<br>7    | 12 / 175 (6.86%)<br>13 |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)   | 2 / 172 (1.16%)<br>2   | 3 / 176 (1.70%)<br>3    | 3 / 175 (1.71%)<br>5   |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 1 / 172 (0.58%)<br>1   | 2 / 176 (1.14%)<br>3    | 1 / 175 (0.57%)<br>3   |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 2 / 172 (1.16%)<br>3   | 1 / 176 (0.57%)<br>1    | 1 / 175 (0.57%)<br>1   |
| Gastrointestinal disorders<br>Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 2 / 172 (1.16%)<br>2   | 5 / 176 (2.84%)<br>5    | 4 / 175 (2.29%)<br>4   |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)                                     | 6 / 172 (3.49%)<br>6   | 8 / 176 (4.55%)<br>9    | 4 / 175 (2.29%)<br>9   |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all)                               | 0 / 172 (0.00%)<br>0   | 4 / 176 (2.27%)<br>5    | 1 / 175 (0.57%)<br>1   |
| Colitis Ulcerative   |                        |                         |                        |

|  |                   |                  |                   |
|--|-------------------|------------------|-------------------|
| subjects affected / exposed            | 19 / 172 (11.05%) | 16 / 176 (9.09%) | 48 / 175 (27.43%) |
| occurrences (all)                      | 23                | 18               | 57                |
| Constipation                           |                   |                  |                   |
| subjects affected / exposed            | 0 / 172 (0.00%)   | 3 / 176 (1.70%)  | 6 / 175 (3.43%)   |
| occurrences (all)                      | 0                 | 3                | 6                 |
| Diarrhoea                              |                   |                  |                   |
| subjects affected / exposed            | 5 / 172 (2.91%)   | 7 / 176 (3.98%)  | 2 / 175 (1.14%)   |
| occurrences (all)                      | 5                 | 7                | 2                 |
| Frequent Bowel Movements               |                   |                  |                   |
| subjects affected / exposed            | 1 / 172 (0.58%)   | 1 / 176 (0.57%)  | 0 / 175 (0.00%)   |
| occurrences (all)                      | 1                 | 1                | 0                 |
| Nausea                                 |                   |                  |                   |
| subjects affected / exposed            | 4 / 172 (2.33%)   | 6 / 176 (3.41%)  | 4 / 175 (2.29%)   |
| occurrences (all)                      | 5                 | 9                | 4                 |
| Rectal Haemorrhage                     |                   |                  |                   |
| subjects affected / exposed            | 0 / 172 (0.00%)   | 1 / 176 (0.57%)  | 1 / 175 (0.57%)   |
| occurrences (all)                      | 0                 | 2                | 2                 |
| Vomiting                               |                   |                  |                   |
| subjects affected / exposed            | 1 / 172 (0.58%)   | 1 / 176 (0.57%)  | 5 / 175 (2.86%)   |
| occurrences (all)                      | 1                 | 1                | 5                 |
| Hepatobiliary disorders                |                   |                  |                   |
| Hepatic Steatosis                      |                   |                  |                   |
| subjects affected / exposed            | 1 / 172 (0.58%)   | 0 / 176 (0.00%)  | 1 / 175 (0.57%)   |
| occurrences (all)                      | 1                 | 0                | 1                 |
| Skin and subcutaneous tissue disorders |                   |                  |                   |
| Acne                                   |                   |                  |                   |
| subjects affected / exposed            | 2 / 172 (1.16%)   | 3 / 176 (1.70%)  | 0 / 175 (0.00%)   |
| occurrences (all)                      | 2                 | 3                | 0                 |
| Eczema                                 |                   |                  |                   |
| subjects affected / exposed            | 0 / 172 (0.00%)   | 3 / 176 (1.70%)  | 5 / 175 (2.86%)   |
| occurrences (all)                      | 0                 | 3                | 5                 |
| Papule                                 |                   |                  |                   |
| subjects affected / exposed            | 0 / 172 (0.00%)   | 0 / 176 (0.00%)  | 2 / 175 (1.14%)   |
| occurrences (all)                      | 0                 | 0                | 2                 |
| Pruritus                               |                   |                  |                   |

|   |                        |                        |                        |
|---|------------------------|------------------------|------------------------|
| subjects affected / exposed<br>occurrences (all)                    | 1 / 172 (0.58%)<br>1   | 2 / 176 (1.14%)<br>2   | 4 / 175 (2.29%)<br>4   |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 6 / 172 (3.49%)<br>8   | 6 / 176 (3.41%)<br>6   | 6 / 175 (3.43%)<br>7   |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 0 / 172 (0.00%)<br>0   | 0 / 176 (0.00%)<br>0   | 0 / 175 (0.00%)<br>0   |
| Musculoskeletal and connective tissue disorders                     |                        |                        |                        |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 16 / 172 (9.30%)<br>18 | 10 / 176 (5.68%)<br>16 | 17 / 175 (9.71%)<br>18 |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 1 / 172 (0.58%)<br>1   | 7 / 176 (3.98%)<br>8   | 7 / 175 (4.00%)<br>8   |
| Infections and infestations   |                        |                        |                        |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 5 / 172 (2.91%)<br>5   | 6 / 176 (3.41%)<br>6   | 6 / 175 (3.43%)<br>6   |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 0 / 172 (0.00%)<br>0   | 0 / 176 (0.00%)<br>0   | 0 / 175 (0.00%)<br>0   |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 1 / 172 (0.58%)<br>1   | 1 / 176 (0.57%)<br>2   | 0 / 175 (0.00%)<br>0   |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 5 / 172 (2.91%)<br>6   | 7 / 176 (3.98%)<br>7   | 5 / 175 (2.86%)<br>5   |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 0 / 172 (0.00%)<br>0   | 2 / 176 (1.14%)<br>2   | 4 / 175 (2.29%)<br>4   |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 5 / 172 (2.91%)<br>5   | 10 / 176 (5.68%)<br>11 | 8 / 175 (4.57%)<br>9   |
| Laryngitis  |                        |                        |                        |

|   |                   |                   |                   |
|---|-------------------|-------------------|-------------------|
| subjects affected / exposed             | 0 / 172 (0.00%)   | 0 / 176 (0.00%)   | 1 / 175 (0.57%)   |
| occurrences (all)                       | 0                 | 0                 | 1                 |
| Nasopharyngitis                         |                   |                   |                   |
| subjects affected / exposed             | 31 / 172 (18.02%) | 26 / 176 (14.77%) | 28 / 175 (16.00%) |
| occurrences (all)                       | 45                | 38                | 39                |
| Oral Herpes                             |                   |                   |                   |
| subjects affected / exposed             | 1 / 172 (0.58%)   | 3 / 176 (1.70%)   | 1 / 175 (0.57%)   |
| occurrences (all)                       | 2                 | 6                 | 1                 |
| Pharyngitis                             |                   |                   |                   |
| subjects affected / exposed             | 3 / 172 (1.74%)   | 2 / 176 (1.14%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 3                 | 2                 | 2                 |
| Rhinitis                                |                   |                   |                   |
| subjects affected / exposed             | 2 / 172 (1.16%)   | 4 / 176 (2.27%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 2                 | 4                 | 2                 |
| Sinusitis                               |                   |                   |                   |
| subjects affected / exposed             | 2 / 172 (1.16%)   | 7 / 176 (3.98%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 3                 | 11                | 2                 |
| Tonsillitis                             |                   |                   |                   |
| subjects affected / exposed             | 2 / 172 (1.16%)   | 1 / 176 (0.57%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 3                 | 1                 | 2                 |
| Upper Respiratory Tract Infection       |                   |                   |                   |
| subjects affected / exposed             | 5 / 172 (2.91%)   | 16 / 176 (9.09%)  | 8 / 175 (4.57%)   |
| occurrences (all)                       | 5                 | 21                | 9                 |
| Urinary Tract Infection                 |                   |                   |                   |
| subjects affected / exposed             | 3 / 172 (1.74%)   | 2 / 176 (1.14%)   | 4 / 175 (2.29%)   |
| occurrences (all)                       | 7                 | 2                 | 5                 |
| Viral Infection                         |                   |                   |                   |
| subjects affected / exposed             | 2 / 172 (1.16%)   | 3 / 176 (1.70%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 2                 | 3                 | 2                 |
| Viral Upper Respiratory Tract Infection |                   |                   |                   |
| subjects affected / exposed             | 1 / 172 (0.58%)   | 1 / 176 (0.57%)   | 2 / 175 (1.14%)   |
| occurrences (all)                       | 1                 | 1                 | 2                 |
| Metabolism and nutrition disorders      |                   |                   |                   |
| Iron Deficiency                         |                   |                   |                   |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 172 (0.58%) | 0 / 176 (0.00%) | 1 / 175 (0.57%) |
| occurrences (all)           | 1               | 0               | 1               |
| Vitamin D Deficiency        |                 |                 |                 |
| subjects affected / exposed | 0 / 172 (0.00%) | 1 / 176 (0.57%) | 0 / 175 (0.00%) |
| occurrences (all)           | 0               | 1               | 0               |

| <b>Non-serious adverse events</b>                        | IS: Ustekinumab<br>Nonresponders at<br>Week 8 | IS: Placebo-<br>Nonresponders at<br>Week 8 | MS: Placebo IV (IS –<br>Responders) to<br>Placebo SC |
|--|---|--|--|
| Total subjects affected by non-serious<br>adverse events |   |  |  |
| subjects affected / exposed                              | 30 / 233 (12.88%)                             | 27 / 184 (14.67%)                          | 69 / 103 (66.99%)                                    |
| Vascular disorders                                       |   |  |  |
| Hypertension   |   |  |  |
| subjects affected / exposed                              | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 1 / 103 (0.97%)                                      |
| occurrences (all)  | 0   | 0  | 1  |
| General disorders and administration<br>site conditions  |   |  |  |
| Fatigue  |   |  |  |
| subjects affected / exposed                              | 1 / 233 (0.43%)                               | 0 / 184 (0.00%)                            | 3 / 103 (2.91%)                                      |
| occurrences (all)  | 1   | 0  | 3  |
| Influenza Like Illness                                   |   |  |  |
| subjects affected / exposed                              | 1 / 233 (0.43%)                               | 1 / 184 (0.54%)                            | 0 / 103 (0.00%)                                      |
| occurrences (all)  | 1   | 1  | 0  |
| Injection Site Erythema                                  |   |  |  |
| subjects affected / exposed                              | 1 / 233 (0.43%)                               | 1 / 184 (0.54%)                            | 0 / 103 (0.00%)                                      |
| occurrences (all)  | 1   | 1  | 0  |
| Injection Site Swelling                                  |   |  |  |
| subjects affected / exposed                              | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 0 / 103 (0.00%)                                      |
| occurrences (all)  | 0   | 0  | 0  |
| Pyrexia  |   |  |  |
| subjects affected / exposed                              | 0 / 233 (0.00%)                               | 1 / 184 (0.54%)                            | 5 / 103 (4.85%)                                      |
| occurrences (all)  | 0   | 1  | 6  |
| Respiratory, thoracic and mediastinal<br>disorders       |   |  |  |
| Cough  |   |  |  |
| subjects affected / exposed                              | 0 / 233 (0.00%)                               | 0 / 184 (0.00%)                            | 4 / 103 (3.88%)                                      |
| occurrences (all)  | 0   | 0  | 4  |
| Oropharyngeal Pain                                       |   |  |  |

|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 233 (0.00%)<br>0 | 1 / 184 (0.54%)<br>1 | 1 / 103 (0.97%)<br>1 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 233 (0.00%)<br>0 | 1 / 184 (0.54%)<br>1 | 4 / 103 (3.88%)<br>4 |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 3 / 103 (2.91%)<br>3 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 4 / 103 (3.88%)<br>4 |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 233 (0.43%)<br>1 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0 |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Nervous system disorders<br>Dizziness   |                      |                      |                      |

|  |                      |                      |                      |
|--|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0 |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 2 / 233 (0.86%)<br>2 | 2 / 184 (1.09%)<br>2 | 4 / 103 (3.88%)<br>4 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0 |
| Tremor<br>subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)    | 1 / 233 (0.43%)<br>1 | 4 / 184 (2.17%)<br>4 | 9 / 103 (8.74%)<br>9 |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)   | 1 / 233 (0.43%)<br>1 | 0 / 184 (0.00%)<br>0 | 4 / 103 (3.88%)<br>5 |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 3 / 103 (2.91%)<br>3 |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Gastrointestinal disorders<br>Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 1 / 233 (0.43%)<br>1 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 3 / 103 (2.91%)<br>3 |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all)                               | 2 / 233 (0.86%)<br>2 | 0 / 184 (0.00%)<br>0 | 1 / 103 (0.97%)<br>1 |
| Colitis Ulcerative   |                      |                      |                      |



|  |                 |                 |                   |
|--|-----------------|-----------------|-------------------|
| subjects affected / exposed            | 3 / 233 (1.29%) | 1 / 184 (0.54%) | 25 / 103 (24.27%) |
| occurrences (all)                      | 3               | 1               | 30                |
| Constipation                           |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 1 / 103 (0.97%)   |
| occurrences (all)                      | 0               | 1               | 2                 |
| Diarrhoea                              |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 2 / 103 (1.94%)   |
| occurrences (all)                      | 0               | 0               | 2                 |
| Frequent Bowel Movements               |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%)   |
| occurrences (all)                      | 0               | 0               | 0                 |
| Nausea                                 |                 |                 |                   |
| subjects affected / exposed            | 3 / 233 (1.29%) | 3 / 184 (1.63%) | 3 / 103 (2.91%)   |
| occurrences (all)                      | 3               | 3               | 3                 |
| Rectal Haemorrhage                     |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%)   |
| occurrences (all)                      | 0               | 0               | 1                 |
| Vomiting                               |                 |                 |                   |
| subjects affected / exposed            | 3 / 233 (1.29%) | 0 / 184 (0.00%) | 0 / 103 (0.00%)   |
| occurrences (all)                      | 3               | 0               | 0                 |
| Hepatobiliary disorders                |                 |                 |                   |
| Hepatic Steatosis                      |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%)   |
| occurrences (all)                      | 0               | 0               | 1                 |
| Skin and subcutaneous tissue disorders |                 |                 |                   |
| Acne                                   |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 4 / 103 (3.88%)   |
| occurrences (all)                      | 0               | 0               | 4                 |
| Eczema                                 |                 |                 |                   |
| subjects affected / exposed            | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 2 / 103 (1.94%)   |
| occurrences (all)                      | 1               | 0               | 2                 |
| Papule                                 |                 |                 |                   |
| subjects affected / exposed            | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%)   |
| occurrences (all)                      | 0               | 0               | 1                 |
| Pruritus                               |                 |                 |                   |

|   |                      |                      |                       |
|---|----------------------|----------------------|-----------------------|
| subjects affected / exposed<br>occurrences (all)                    | 0 / 233 (0.00%)<br>0 | 1 / 184 (0.54%)<br>1 | 3 / 103 (2.91%)<br>3  |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 2 / 233 (0.86%)<br>3 | 1 / 184 (0.54%)<br>1 | 2 / 103 (1.94%)<br>2  |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0  |
| Musculoskeletal and connective tissue disorders                     |                      |                      |                       |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 2 / 233 (0.86%)<br>2 | 1 / 184 (0.54%)<br>1 | 9 / 103 (8.74%)<br>13 |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 1 / 233 (0.43%)<br>1 | 0 / 184 (0.00%)<br>0 | 3 / 103 (2.91%)<br>3  |
| Infections and infestations   |                      |                      |                       |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 0 / 233 (0.00%)<br>0 | 1 / 184 (0.54%)<br>1 | 5 / 103 (4.85%)<br>5  |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0  |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 0 / 103 (0.00%)<br>0  |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 0 / 233 (0.00%)<br>0 | 0 / 184 (0.00%)<br>0 | 2 / 103 (1.94%)<br>2  |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 0 / 233 (0.00%)<br>0 | 1 / 184 (0.54%)<br>1 | 0 / 103 (0.00%)<br>0  |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 2 / 233 (0.86%)<br>2 | 0 / 184 (0.00%)<br>0 | 6 / 103 (5.83%)<br>6  |
| Laryngitis  |                      |                      |                       |

|   |                 |                 |                   |
|---|-----------------|-----------------|-------------------|
| subjects affected / exposed             | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 0 / 103 (0.00%)   |
| occurrences (all)                       | 0               | 0               | 0                 |
| Nasopharyngitis                         |                 |                 |                   |
| subjects affected / exposed             | 1 / 233 (0.43%) | 7 / 184 (3.80%) | 13 / 103 (12.62%) |
| occurrences (all)                       | 1               | 7               | 18                |
| Oral Herpes                             |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 2 / 103 (1.94%)   |
| occurrences (all)                       | 0               | 0               | 4                 |
| Pharyngitis                             |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 4 / 103 (3.88%)   |
| occurrences (all)                       | 0               | 1               | 4                 |
| Rhinitis                                |                 |                 |                   |
| subjects affected / exposed             | 1 / 233 (0.43%) | 1 / 184 (0.54%) | 0 / 103 (0.00%)   |
| occurrences (all)                       | 1               | 1               | 0                 |
| Sinusitis                               |                 |                 |                   |
| subjects affected / exposed             | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 1 / 103 (0.97%)   |
| occurrences (all)                       | 1               | 0               | 1                 |
| Tonsillitis                             |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 2 / 103 (1.94%)   |
| occurrences (all)                       | 0               | 0               | 2                 |
| Upper Respiratory Tract Infection       |                 |                 |                   |
| subjects affected / exposed             | 5 / 233 (2.15%) | 2 / 184 (1.09%) | 4 / 103 (3.88%)   |
| occurrences (all)                       | 5               | 2               | 5                 |
| Urinary Tract Infection                 |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 1 / 184 (0.54%) | 2 / 103 (1.94%)   |
| occurrences (all)                       | 0               | 1               | 2                 |
| Viral Infection                         |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 2 / 184 (1.09%) | 1 / 103 (0.97%)   |
| occurrences (all)                       | 0               | 2               | 1                 |
| Viral Upper Respiratory Tract Infection |                 |                 |                   |
| subjects affected / exposed             | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 2 / 103 (1.94%)   |
| occurrences (all)                       | 0               | 0               | 2                 |
| Metabolism and nutrition disorders      |                 |                 |                   |
| Iron Deficiency                         |                 |                 |                   |

|                             |                 |                 |                 |
|-----------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed | 1 / 233 (0.43%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences (all)           | 1               | 0               | 1               |
| Vitamin D Deficiency        |                 |                 |                 |
| subjects affected / exposed | 0 / 233 (0.00%) | 0 / 184 (0.00%) | 1 / 103 (0.97%) |
| occurrences (all)           | 0               | 0               | 1               |

| <b>Non-serious adverse events</b>                     | MS: Ustekinumab Delayed Responders(IS) to UST 90mg SC q8w | Long Term Extension (LTE): Placebo SC | LTE: Placebo SC to Ustekinumab SC 90 mg q8w |
|---|---|---------------------------------------|---|
| Total subjects affected by non-serious adverse events |   |                                       |   |
| subjects affected / exposed                           | 93 / 157 (59.24%)   | 68 / 115 (59.13%)                     | 48 / 56 (85.71%)                            |
| Vascular disorders                                    |   |                                       |   |
| Hypertension  |   |                                       |   |
| subjects affected / exposed                           | 3 / 157 (1.91%)   | 1 / 115 (0.87%)                       | 2 / 56 (3.57%)                              |
| occurrences (all)                                     | 3   | 1                                     | 2   |
| General disorders and administration site conditions  |   |                                       |   |
| Fatigue   |   |                                       |   |
| subjects affected / exposed                           | 3 / 157 (1.91%)   | 4 / 115 (3.48%)                       | 1 / 56 (1.79%)                              |
| occurrences (all)                                     | 4   | 4                                     | 1   |
| Influenza Like Illness                                |   |                                       |   |
| subjects affected / exposed                           | 0 / 157 (0.00%)   | 1 / 115 (0.87%)                       | 0 / 56 (0.00%)                              |
| occurrences (all)                                     | 0   | 1                                     | 0   |
| Injection Site Erythema                               |   |                                       |   |
| subjects affected / exposed                           | 3 / 157 (1.91%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences (all)                                     | 4   | 0                                     | 0   |
| Injection Site Swelling                               |   |                                       |   |
| subjects affected / exposed                           | 1 / 157 (0.64%)   | 0 / 115 (0.00%)                       | 0 / 56 (0.00%)                              |
| occurrences (all)                                     | 2   | 0                                     | 0   |
| Pyrexia   |   |                                       |   |
| subjects affected / exposed                           | 5 / 157 (3.18%)   | 2 / 115 (1.74%)                       | 3 / 56 (5.36%)                              |
| occurrences (all)                                     | 5   | 2                                     | 3   |
| Respiratory, thoracic and mediastinal disorders       |   |                                       |   |
| Cough   |   |                                       |   |
| subjects affected / exposed                           | 4 / 157 (2.55%)   | 5 / 115 (4.35%)                       | 5 / 56 (8.93%)                              |
| occurrences (all)                                     | 4   | 5                                     | 5   |
| Oropharyngeal Pain                                    |   |                                       |   |

|   |                      |                      |                      |
|---|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)  | 1 / 157 (0.64%)<br>1 | 0 / 115 (0.00%)<br>0 | 1 / 56 (1.79%)<br>1  |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 157 (0.00%)<br>0 | 0 / 115 (0.00%)<br>0 | 1 / 56 (1.79%)<br>1  |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 1 / 157 (0.64%)<br>1 | 0 / 115 (0.00%)<br>0 | 7 / 56 (12.50%)<br>7 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 3 / 157 (1.91%)<br>4 | 0 / 115 (0.00%)<br>0 | 5 / 56 (8.93%)<br>5  |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 2 / 157 (1.27%)<br>2 | 0 / 115 (0.00%)<br>0 | 2 / 56 (3.57%)<br>2  |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 1 / 157 (0.64%)<br>1 | 0 / 115 (0.00%)<br>0 | 0 / 56 (0.00%)<br>0  |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 0 / 157 (0.00%)<br>0 | 0 / 115 (0.00%)<br>0 | 4 / 56 (7.14%)<br>6  |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 1 / 157 (0.64%)<br>2 | 0 / 115 (0.00%)<br>0 | 2 / 56 (3.57%)<br>3  |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 1 / 157 (0.64%)<br>1 | 0 / 115 (0.00%)<br>0 | 2 / 56 (3.57%)<br>2  |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 1 / 157 (0.64%)<br>1 | 1 / 115 (0.87%)<br>1 | 0 / 56 (0.00%)<br>0  |
| Nervous system disorders<br>Dizziness   |                      |                      |                      |

|  |                       |                       |                     |
|--|-----------------------|-----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 2 / 157 (1.27%)<br>2  | 1 / 115 (0.87%)<br>1  | 1 / 56 (1.79%)<br>1 |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 9 / 157 (5.73%)<br>21 | 7 / 115 (6.09%)<br>10 | 4 / 56 (7.14%)<br>5 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)   | 2 / 157 (1.27%)<br>3  | 0 / 115 (0.00%)<br>0  | 0 / 56 (0.00%)<br>0 |
| Tremor<br>subjects affected / exposed<br>occurrences (all)   | 0 / 157 (0.00%)<br>0  | 0 / 115 (0.00%)<br>0  | 0 / 56 (0.00%)<br>0 |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)    | 9 / 157 (5.73%)<br>9  | 1 / 115 (0.87%)<br>1  | 3 / 56 (5.36%)<br>3 |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)   | 5 / 157 (3.18%)<br>7  | 0 / 115 (0.00%)<br>0  | 2 / 56 (3.57%)<br>2 |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 4 / 157 (2.55%)<br>6  | 1 / 115 (0.87%)<br>1  | 2 / 56 (3.57%)<br>3 |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 3 / 157 (1.91%)<br>4  | 0 / 115 (0.00%)<br>0  | 0 / 56 (0.00%)<br>0 |
| Gastrointestinal disorders<br>Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 1 / 157 (0.64%)<br>1  | 0 / 115 (0.00%)<br>0  | 3 / 56 (5.36%)<br>3 |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)                                     | 5 / 157 (3.18%)<br>7  | 2 / 115 (1.74%)<br>2  | 1 / 56 (1.79%)<br>1 |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all)                               | 1 / 157 (0.64%)<br>2  | 3 / 115 (2.61%)<br>3  | 2 / 56 (3.57%)<br>2 |
| Colitis Ulcerative   |                       |                       |                     |

|  |                   |                   |                  |
|--|-------------------|-------------------|------------------|
| subjects affected / exposed            | 23 / 157 (14.65%) | 23 / 115 (20.00%) | 11 / 56 (19.64%) |
| occurrences (all)                      | 27                | 27                | 12               |
| Constipation                           |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 1 / 115 (0.87%)   | 1 / 56 (1.79%)   |
| occurrences (all)                      | 0                 | 1                 | 1                |
| Diarrhoea                              |                   |                   |                  |
| subjects affected / exposed            | 6 / 157 (3.82%)   | 2 / 115 (1.74%)   | 1 / 56 (1.79%)   |
| occurrences (all)                      | 6                 | 2                 | 1                |
| Frequent Bowel Movements               |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 1 / 56 (1.79%)   |
| occurrences (all)                      | 0                 | 0                 | 1                |
| Nausea                                 |                   |                   |                  |
| subjects affected / exposed            | 5 / 157 (3.18%)   | 2 / 115 (1.74%)   | 1 / 56 (1.79%)   |
| occurrences (all)                      | 5                 | 2                 | 1                |
| Rectal Haemorrhage                     |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 2 / 56 (3.57%)   |
| occurrences (all)                      | 0                 | 0                 | 2                |
| Vomiting                               |                   |                   |                  |
| subjects affected / exposed            | 3 / 157 (1.91%)   | 3 / 115 (2.61%)   | 2 / 56 (3.57%)   |
| occurrences (all)                      | 3                 | 3                 | 2                |
| Hepatobiliary disorders                |                   |                   |                  |
| Hepatic Steatosis                      |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 1 / 115 (0.87%)   | 2 / 56 (3.57%)   |
| occurrences (all)                      | 0                 | 1                 | 2                |
| Skin and subcutaneous tissue disorders |                   |                   |                  |
| Acne                                   |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 0 / 56 (0.00%)   |
| occurrences (all)                      | 0                 | 0                 | 0                |
| Eczema                                 |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 2 / 56 (3.57%)   |
| occurrences (all)                      | 0                 | 0                 | 2                |
| Papule                                 |                   |                   |                  |
| subjects affected / exposed            | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 2 / 56 (3.57%)   |
| occurrences (all)                      | 0                 | 0                 | 2                |
| Pruritus                               |                   |                   |                  |

|   |                         |                      |                      |
|---|-------------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all)                    | 2 / 157 (1.27%)<br>2    | 1 / 115 (0.87%)<br>1 | 1 / 56 (1.79%)<br>1  |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 2 / 157 (1.27%)<br>2    | 0 / 115 (0.00%)<br>0 | 1 / 56 (1.79%)<br>1  |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 0 / 157 (0.00%)<br>0    | 0 / 115 (0.00%)<br>0 | 2 / 56 (3.57%)<br>2  |
| Musculoskeletal and connective tissue disorders                     |                         |                      |                      |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 16 / 157 (10.19%)<br>19 | 6 / 115 (5.22%)<br>6 | 4 / 56 (7.14%)<br>5  |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 5 / 157 (3.18%)<br>5    | 5 / 115 (4.35%)<br>5 | 6 / 56 (10.71%)<br>8 |
| Infections and infestations   |                         |                      |                      |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 6 / 157 (3.82%)<br>7    | 2 / 115 (1.74%)<br>2 | 3 / 56 (5.36%)<br>5  |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 0 / 157 (0.00%)<br>0    | 0 / 115 (0.00%)<br>0 | 0 / 56 (0.00%)<br>0  |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 0 / 157 (0.00%)<br>0    | 0 / 115 (0.00%)<br>0 | 0 / 56 (0.00%)<br>0  |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 5 / 157 (3.18%)<br>6    | 1 / 115 (0.87%)<br>1 | 2 / 56 (3.57%)<br>3  |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 0 / 157 (0.00%)<br>0    | 0 / 115 (0.00%)<br>0 | 0 / 56 (0.00%)<br>0  |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 7 / 157 (4.46%)<br>7    | 4 / 115 (3.48%)<br>4 | 4 / 56 (7.14%)<br>4  |
| Laryngitis  |                         |                      |                      |



|   |                   |                   |                  |
|---|-------------------|-------------------|------------------|
| subjects affected / exposed             | 0 / 157 (0.00%)   | 1 / 115 (0.87%)   | 2 / 56 (3.57%)   |
| occurrences (all)                       | 0                 | 1                 | 2                |
| Nasopharyngitis                         |                   |                   |                  |
| subjects affected / exposed             | 19 / 157 (12.10%) | 17 / 115 (14.78%) | 13 / 56 (23.21%) |
| occurrences (all)                       | 20                | 21                | 28               |
| Oral Herpes                             |                   |                   |                  |
| subjects affected / exposed             | 0 / 157 (0.00%)   | 0 / 115 (0.00%)   | 1 / 56 (1.79%)   |
| occurrences (all)                       | 0                 | 0                 | 1                |
| Pharyngitis                             |                   |                   |                  |
| subjects affected / exposed             | 2 / 157 (1.27%)   | 1 / 115 (0.87%)   | 0 / 56 (0.00%)   |
| occurrences (all)                       | 2                 | 1                 | 0                |
| Rhinitis                                |                   |                   |                  |
| subjects affected / exposed             | 1 / 157 (0.64%)   | 2 / 115 (1.74%)   | 2 / 56 (3.57%)   |
| occurrences (all)                       | 1                 | 2                 | 2                |
| Sinusitis                               |                   |                   |                  |
| subjects affected / exposed             | 3 / 157 (1.91%)   | 3 / 115 (2.61%)   | 2 / 56 (3.57%)   |
| occurrences (all)                       | 3                 | 3                 | 3                |
| Tonsillitis                             |                   |                   |                  |
| subjects affected / exposed             | 0 / 157 (0.00%)   | 1 / 115 (0.87%)   | 1 / 56 (1.79%)   |
| occurrences (all)                       | 0                 | 1                 | 1                |
| Upper Respiratory Tract Infection       |                   |                   |                  |
| subjects affected / exposed             | 7 / 157 (4.46%)   | 6 / 115 (5.22%)   | 4 / 56 (7.14%)   |
| occurrences (all)                       | 9                 | 6                 | 5                |
| Urinary Tract Infection                 |                   |                   |                  |
| subjects affected / exposed             | 4 / 157 (2.55%)   | 2 / 115 (1.74%)   | 2 / 56 (3.57%)   |
| occurrences (all)                       | 5                 | 2                 | 2                |
| Viral Infection                         |                   |                   |                  |
| subjects affected / exposed             | 1 / 157 (0.64%)   | 2 / 115 (1.74%)   | 0 / 56 (0.00%)   |
| occurrences (all)                       | 1                 | 2                 | 0                |
| Viral Upper Respiratory Tract Infection |                   |                   |                  |
| subjects affected / exposed             | 1 / 157 (0.64%)   | 0 / 115 (0.00%)   | 1 / 56 (1.79%)   |
| occurrences (all)                       | 1                 | 0                 | 1                |
| Metabolism and nutrition disorders      |                   |                   |                  |
| Iron Deficiency                         |                   |                   |                  |

|                             |                 |                 |                |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 157 (0.64%) | 1 / 115 (0.87%) | 1 / 56 (1.79%) |
| occurrences (all)           | 1               | 1               | 1              |
| Vitamin D Deficiency        |                 |                 |                |
| subjects affected / exposed | 0 / 157 (0.00%) | 0 / 115 (0.00%) | 1 / 56 (1.79%) |
| occurrences (all)           | 0               | 0               | 1              |

| <b>Non-serious adverse events</b>                     | LTE: Ustekinumab<br>90 mg SC q12w to<br>90 mg SC q8w | LTE: Ustekinumab<br>90 mg SC q12w | LTE: Ustekinumab<br>90 mg SC q8w to 90<br>mg SC q8w |
|---|--|-----------------------------------|---|
| Total subjects affected by non-serious adverse events |  |                                   |   |
| subjects affected / exposed                           | 38 / 64 (59.38%)                                     | 98 / 141 (69.50%)                 | 27 / 37 (72.97%)                                    |
| Vascular disorders                                    |  |                                   |   |
| Hypertension  |  |                                   |   |
| subjects affected / exposed                           | 1 / 64 (1.56%)                                       | 5 / 141 (3.55%)                   | 3 / 37 (8.11%)                                      |
| occurrences (all)                                     | 1  | 5                                 | 3   |
| General disorders and administration site conditions  |  |                                   |   |
| Fatigue   |  |                                   |   |
| subjects affected / exposed                           | 2 / 64 (3.13%)                                       | 0 / 141 (0.00%)                   | 1 / 37 (2.70%)                                      |
| occurrences (all)                                     | 2  | 0                                 | 2   |
| Influenza Like Illness                                |  |                                   |   |
| subjects affected / exposed                           | 0 / 64 (0.00%)                                       | 2 / 141 (1.42%)                   | 0 / 37 (0.00%)                                      |
| occurrences (all)                                     | 0  | 2                                 | 0   |
| Injection Site Erythema                               |  |                                   |   |
| subjects affected / exposed                           | 0 / 64 (0.00%)                                       | 1 / 141 (0.71%)                   | 1 / 37 (2.70%)                                      |
| occurrences (all)                                     | 0  | 1                                 | 2   |
| Injection Site Swelling                               |  |                                   |   |
| subjects affected / exposed                           | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 2 / 37 (5.41%)                                      |
| occurrences (all)                                     | 0  | 0                                 | 3   |
| Pyrexia   |  |                                   |   |
| subjects affected / exposed                           | 0 / 64 (0.00%)                                       | 0 / 141 (0.00%)                   | 0 / 37 (0.00%)                                      |
| occurrences (all)                                     | 0  | 0                                 | 0   |
| Respiratory, thoracic and mediastinal disorders       |  |                                   |   |
| Cough   |  |                                   |   |
| subjects affected / exposed                           | 2 / 64 (3.13%)                                       | 2 / 141 (1.42%)                   | 1 / 37 (2.70%)                                      |
| occurrences (all)                                     | 2  | 3                                 | 1   |
| Oropharyngeal Pain                                    |  |                                   |   |

|   |                     |                      |                     |
|---|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 0 / 64 (0.00%)<br>0 | 7 / 141 (4.96%)<br>7 | 0 / 37 (0.00%)<br>0 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 0 / 64 (0.00%)<br>0 | 0 / 141 (0.00%)<br>0 | 0 / 37 (0.00%)<br>0 |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 3 / 64 (4.69%)<br>4 | 3 / 141 (2.13%)<br>5 | 1 / 37 (2.70%)<br>1 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 3 / 64 (4.69%)<br>3 | 1 / 141 (0.71%)<br>2 | 1 / 37 (2.70%)<br>1 |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 64 (0.00%)<br>0 | 1 / 141 (0.71%)<br>2 | 0 / 37 (0.00%)<br>0 |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 2 / 64 (3.13%)<br>2 | 0 / 141 (0.00%)<br>0 | 1 / 37 (2.70%)<br>1 |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 1 / 64 (1.56%)<br>1 | 1 / 141 (0.71%)<br>1 | 2 / 37 (5.41%)<br>2 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 0 / 64 (0.00%)<br>0 | 1 / 141 (0.71%)<br>1 | 0 / 37 (0.00%)<br>0 |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 64 (0.00%)<br>0 | 0 / 141 (0.00%)<br>0 | 0 / 37 (0.00%)<br>0 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 1 / 64 (1.56%)<br>1 | 1 / 141 (0.71%)<br>1 | 2 / 37 (5.41%)<br>2 |
| Nervous system disorders<br>Dizziness   |                     |                      |                     |

|  |                     |                      |                     |
|--|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                         | 2 / 64 (3.13%)<br>2 | 2 / 141 (1.42%)<br>2 | 1 / 37 (2.70%)<br>1 |
| Headache<br>subjects affected / exposed<br>occurrences (all)             | 2 / 64 (3.13%)<br>2 | 9 / 141 (6.38%)<br>9 | 2 / 37 (5.41%)<br>3 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)             | 2 / 64 (3.13%)<br>2 | 0 / 141 (0.00%)<br>0 | 0 / 37 (0.00%)<br>0 |
| Tremor<br>subjects affected / exposed<br>occurrences (all)               | 0 / 64 (0.00%)<br>0 | 0 / 141 (0.00%)<br>0 | 2 / 37 (5.41%)<br>2 |
| Blood and lymphatic system disorders                                     |                     |                      |                     |
| Anaemia<br>subjects affected / exposed<br>occurrences (all)              | 3 / 64 (4.69%)<br>4 | 4 / 141 (2.84%)<br>4 | 1 / 37 (2.70%)<br>1 |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)           | 0 / 64 (0.00%)<br>0 | 3 / 141 (2.13%)<br>4 | 0 / 37 (0.00%)<br>0 |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)          | 0 / 64 (0.00%)<br>0 | 1 / 141 (0.71%)<br>1 | 0 / 37 (0.00%)<br>0 |
| Eye disorders  |                     |                      |                     |
| Cataract<br>subjects affected / exposed<br>occurrences (all)             | 2 / 64 (3.13%)<br>2 | 1 / 141 (0.71%)<br>1 | 0 / 37 (0.00%)<br>0 |
| Gastrointestinal disorders   |                     |                      |                     |
| Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 0 / 64 (0.00%)<br>0 | 2 / 141 (1.42%)<br>2 | 0 / 37 (0.00%)<br>0 |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)       | 2 / 64 (3.13%)<br>2 | 2 / 141 (1.42%)<br>3 | 1 / 37 (2.70%)<br>1 |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all) | 1 / 64 (1.56%)<br>1 | 4 / 141 (2.84%)<br>4 | 1 / 37 (2.70%)<br>1 |
| Colitis Ulcerative   |                     |                      |                     |

|  |                  |                   |                  |
|--|------------------|-------------------|------------------|
| subjects affected / exposed            | 20 / 64 (31.25%) | 34 / 141 (24.11%) | 13 / 37 (35.14%) |
| occurrences (all)                      | 26               | 40                | 19               |
| Constipation                           |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 1 / 141 (0.71%)   | 1 / 37 (2.70%)   |
| occurrences (all)                      | 0                | 1                 | 1                |
| Diarrhoea                              |                  |                   |                  |
| subjects affected / exposed            | 3 / 64 (4.69%)   | 6 / 141 (4.26%)   | 2 / 37 (5.41%)   |
| occurrences (all)                      | 3                | 7                 | 2                |
| Frequent Bowel Movements               |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 1 / 141 (0.71%)   | 2 / 37 (5.41%)   |
| occurrences (all)                      | 0                | 1                 | 2                |
| Nausea                                 |                  |                   |                  |
| subjects affected / exposed            | 1 / 64 (1.56%)   | 5 / 141 (3.55%)   | 1 / 37 (2.70%)   |
| occurrences (all)                      | 1                | 6                 | 1                |
| Rectal Haemorrhage                     |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 0 / 141 (0.00%)   | 3 / 37 (8.11%)   |
| occurrences (all)                      | 0                | 0                 | 3                |
| Vomiting                               |                  |                   |                  |
| subjects affected / exposed            | 1 / 64 (1.56%)   | 0 / 141 (0.00%)   | 0 / 37 (0.00%)   |
| occurrences (all)                      | 1                | 0                 | 0                |
| Hepatobiliary disorders                |                  |                   |                  |
| Hepatic Steatosis                      |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 0 / 141 (0.00%)   | 0 / 37 (0.00%)   |
| occurrences (all)                      | 0                | 0                 | 0                |
| Skin and subcutaneous tissue disorders |                  |                   |                  |
| Acne                                   |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 0 / 141 (0.00%)   | 1 / 37 (2.70%)   |
| occurrences (all)                      | 0                | 0                 | 1                |
| Eczema                                 |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 1 / 141 (0.71%)   | 1 / 37 (2.70%)   |
| occurrences (all)                      | 0                | 1                 | 1                |
| Papule                                 |                  |                   |                  |
| subjects affected / exposed            | 0 / 64 (0.00%)   | 0 / 141 (0.00%)   | 0 / 37 (0.00%)   |
| occurrences (all)                      | 0                | 0                 | 0                |
| Pruritus                               |                  |                   |                  |

|   |                     |                      |                     |
|---|---------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                    | 2 / 64 (3.13%)<br>2 | 1 / 141 (0.71%)<br>1 | 0 / 37 (0.00%)<br>0 |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 1 / 64 (1.56%)<br>1 | 2 / 141 (1.42%)<br>3 | 1 / 37 (2.70%)<br>1 |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 0 / 64 (0.00%)<br>0 | 0 / 141 (0.00%)<br>0 | 0 / 37 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                     |                     |                      |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 5 / 64 (7.81%)<br>6 | 9 / 141 (6.38%)<br>9 | 2 / 37 (5.41%)<br>3 |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 3 / 64 (4.69%)<br>3 | 7 / 141 (4.96%)<br>8 | 2 / 37 (5.41%)<br>2 |
| Infections and infestations   |                     |                      |                     |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 2 / 64 (3.13%)<br>2 | 7 / 141 (4.96%)<br>9 | 0 / 37 (0.00%)<br>0 |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 0 / 64 (0.00%)<br>0 | 0 / 141 (0.00%)<br>0 | 1 / 37 (2.70%)<br>1 |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 0 / 64 (0.00%)<br>0 | 1 / 141 (0.71%)<br>1 | 2 / 37 (5.41%)<br>2 |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 0 / 64 (0.00%)<br>0 | 4 / 141 (2.84%)<br>4 | 3 / 37 (8.11%)<br>3 |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 2 / 64 (3.13%)<br>2 | 0 / 141 (0.00%)<br>0 | 0 / 37 (0.00%)<br>0 |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 3 / 64 (4.69%)<br>3 | 6 / 141 (4.26%)<br>6 | 3 / 37 (8.11%)<br>4 |
| Laryngitis  |                     |                      |                     |

|   |                  |                   |                  |
|---|------------------|-------------------|------------------|
| subjects affected / exposed             | 0 / 64 (0.00%)   | 0 / 141 (0.00%)   | 0 / 37 (0.00%)   |
| occurrences (all)                       | 0                | 0                 | 0                |
| Nasopharyngitis                         |                  |                   |                  |
| subjects affected / exposed             | 10 / 64 (15.63%) | 29 / 141 (20.57%) | 12 / 37 (32.43%) |
| occurrences (all)                       | 16               | 51                | 14               |
| Oral Herpes                             |                  |                   |                  |
| subjects affected / exposed             | 1 / 64 (1.56%)   | 3 / 141 (2.13%)   | 2 / 37 (5.41%)   |
| occurrences (all)                       | 2                | 4                 | 2                |
| Pharyngitis                             |                  |                   |                  |
| subjects affected / exposed             | 1 / 64 (1.56%)   | 3 / 141 (2.13%)   | 2 / 37 (5.41%)   |
| occurrences (all)                       | 1                | 4                 | 3                |
| Rhinitis                                |                  |                   |                  |
| subjects affected / exposed             | 1 / 64 (1.56%)   | 2 / 141 (1.42%)   | 0 / 37 (0.00%)   |
| occurrences (all)                       | 2                | 3                 | 0                |
| Sinusitis                               |                  |                   |                  |
| subjects affected / exposed             | 1 / 64 (1.56%)   | 5 / 141 (3.55%)   | 4 / 37 (10.81%)  |
| occurrences (all)                       | 1                | 7                 | 4                |
| Tonsillitis                             |                  |                   |                  |
| subjects affected / exposed             | 0 / 64 (0.00%)   | 3 / 141 (2.13%)   | 1 / 37 (2.70%)   |
| occurrences (all)                       | 0                | 6                 | 2                |
| Upper Respiratory Tract Infection       |                  |                   |                  |
| subjects affected / exposed             | 4 / 64 (6.25%)   | 12 / 141 (8.51%)  | 2 / 37 (5.41%)   |
| occurrences (all)                       | 5                | 14                | 2                |
| Urinary Tract Infection                 |                  |                   |                  |
| subjects affected / exposed             | 3 / 64 (4.69%)   | 0 / 141 (0.00%)   | 3 / 37 (8.11%)   |
| occurrences (all)                       | 4                | 0                 | 3                |
| Viral Infection                         |                  |                   |                  |
| subjects affected / exposed             | 0 / 64 (0.00%)   | 3 / 141 (2.13%)   | 2 / 37 (5.41%)   |
| occurrences (all)                       | 0                | 3                 | 2                |
| Viral Upper Respiratory Tract Infection |                  |                   |                  |
| subjects affected / exposed             | 2 / 64 (3.13%)   | 0 / 141 (0.00%)   | 0 / 37 (0.00%)   |
| occurrences (all)                       | 2                | 0                 | 0                |
| Metabolism and nutrition disorders      |                  |                   |                  |
| Iron Deficiency                         |                  |                   |                  |

|                             |                |                 |                |
|-----------------------------|----------------|-----------------|----------------|
| subjects affected / exposed | 1 / 64 (1.56%) | 1 / 141 (0.71%) | 2 / 37 (5.41%) |
| occurrences (all)           | 1              | 1               | 2              |
| Vitamin D Deficiency        |                |                 |                |
| subjects affected / exposed | 0 / 64 (0.00%) | 1 / 141 (0.71%) | 0 / 37 (0.00%) |
| occurrences (all)           | 0              | 1               | 0              |

| <b>Non-serious adverse events</b>                        | LTE: Ustekinumab<br>90 mg SC q8w | LTE: Ustekinumab<br>Delayed Responders<br>(IS) to UST 90mg<br>SC q8w | LTE: Placebo IV (IS<br>– Responders) to<br>Placebo SC |
|--|----------------------------------|--|---|
| Total subjects affected by non-serious<br>adverse events |                                  |  |   |
| subjects affected / exposed                              | 105 / 143 (73.43%)               | 91 / 116 (78.45%)  | 45 / 73 (61.64%)                                      |
| Vascular disorders                                       |                                  |  |   |
| Hypertension   |                                  |  |   |
| subjects affected / exposed                              | 5 / 143 (3.50%)                  | 3 / 116 (2.59%)  | 3 / 73 (4.11%)  |
| occurrences (all)  | 5                                | 4  | 3   |
| General disorders and administration<br>site conditions  |                                  |  |   |
| Fatigue  |                                  |  |   |
| subjects affected / exposed                              | 5 / 143 (3.50%)                  | 2 / 116 (1.72%)  | 1 / 73 (1.37%)  |
| occurrences (all)  | 5                                | 2  | 1   |
| Influenza Like Illness                                   |                                  |  |   |
| subjects affected / exposed                              | 4 / 143 (2.80%)                  | 5 / 116 (4.31%)  | 1 / 73 (1.37%)  |
| occurrences (all)  | 5                                | 5  | 1   |
| Injection Site Erythema                                  |                                  |  |   |
| subjects affected / exposed                              | 5 / 143 (3.50%)                  | 3 / 116 (2.59%)  | 0 / 73 (0.00%)  |
| occurrences (all)  | 7                                | 5  | 0   |
| Injection Site Swelling                                  |                                  |  |   |
| subjects affected / exposed                              | 1 / 143 (0.70%)                  | 0 / 116 (0.00%)  | 0 / 73 (0.00%)  |
| occurrences (all)  | 1                                | 0  | 0   |
| Pyrexia  |                                  |  |   |
| subjects affected / exposed                              | 1 / 143 (0.70%)                  | 7 / 116 (6.03%)  | 2 / 73 (2.74%)  |
| occurrences (all)  | 1                                | 7  | 4   |
| Respiratory, thoracic and mediastinal<br>disorders       |                                  |  |   |
| Cough  |                                  |  |   |
| subjects affected / exposed                              | 7 / 143 (4.90%)                  | 4 / 116 (3.45%)  | 1 / 73 (1.37%)  |
| occurrences (all)  | 7                                | 6  | 1   |
| Oropharyngeal Pain                                       |                                  |  |   |



|   |                      |                      |                     |
|---|----------------------|----------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)  | 5 / 143 (3.50%)<br>5 | 3 / 116 (2.59%)<br>3 | 1 / 73 (1.37%)<br>1 |
| Psychiatric disorders<br>Anxiety<br>subjects affected / exposed<br>occurrences (all)                            | 2 / 143 (1.40%)<br>2 | 1 / 116 (0.86%)<br>1 | 0 / 73 (0.00%)<br>0 |
| Investigations<br>Alanine Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)        | 3 / 143 (2.10%)<br>3 | 4 / 116 (3.45%)<br>8 | 0 / 73 (0.00%)<br>0 |
| Aspartate Aminotransferase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 4 / 143 (2.80%)<br>4 | 3 / 116 (2.59%)<br>5 | 0 / 73 (0.00%)<br>0 |
| Blood Alkaline Phosphatase Increased<br>subjects affected / exposed<br>occurrences (all)                        | 0 / 143 (0.00%)<br>0 | 0 / 116 (0.00%)<br>0 | 0 / 73 (0.00%)<br>0 |
| Blood Phosphorus Decreased<br>subjects affected / exposed<br>occurrences (all)                                  | 0 / 143 (0.00%)<br>0 | 0 / 116 (0.00%)<br>0 | 0 / 73 (0.00%)<br>0 |
| Stool Analysis Abnormal<br>subjects affected / exposed<br>occurrences (all)                                     | 3 / 143 (2.10%)<br>3 | 1 / 116 (0.86%)<br>1 | 0 / 73 (0.00%)<br>0 |
| Injury, poisoning and procedural complications<br>Contusion<br>subjects affected / exposed<br>occurrences (all) | 3 / 143 (2.10%)<br>3 | 2 / 116 (1.72%)<br>2 | 0 / 73 (0.00%)<br>0 |
| Heat Illness<br>subjects affected / exposed<br>occurrences (all)  | 0 / 143 (0.00%)<br>0 | 1 / 116 (0.86%)<br>1 | 0 / 73 (0.00%)<br>0 |
| Ligament Sprain<br>subjects affected / exposed<br>occurrences (all)   | 0 / 143 (0.00%)<br>0 | 2 / 116 (1.72%)<br>2 | 0 / 73 (0.00%)<br>0 |
| Nervous system disorders<br>Dizziness   |                      |                      |                     |

|  |                         |                        |                     |
|--|-------------------------|------------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)   | 0 / 143 (0.00%)<br>0    | 1 / 116 (0.86%)<br>1   | 0 / 73 (0.00%)<br>0 |
| Headache<br>subjects affected / exposed<br>occurrences (all)   | 11 / 143 (7.69%)<br>15  | 11 / 116 (9.48%)<br>14 | 4 / 73 (5.48%)<br>4 |
| Migraine<br>subjects affected / exposed<br>occurrences (all)   | 2 / 143 (1.40%)<br>6    | 2 / 116 (1.72%)<br>16  | 1 / 73 (1.37%)<br>1 |
| Tremor<br>subjects affected / exposed<br>occurrences (all)   | 0 / 143 (0.00%)<br>0    | 0 / 116 (0.00%)<br>0   | 0 / 73 (0.00%)<br>0 |
| Blood and lymphatic system disorders<br>Anaemia<br>subjects affected / exposed<br>occurrences (all)    | 2 / 143 (1.40%)<br>2    | 4 / 116 (3.45%)<br>6   | 3 / 73 (4.11%)<br>3 |
| Leukopenia<br>subjects affected / exposed<br>occurrences (all)   | 0 / 143 (0.00%)<br>0    | 3 / 116 (2.59%)<br>4   | 2 / 73 (2.74%)<br>3 |
| Neutropenia<br>subjects affected / exposed<br>occurrences (all)  | 2 / 143 (1.40%)<br>2    | 3 / 116 (2.59%)<br>4   | 0 / 73 (0.00%)<br>0 |
| Eye disorders<br>Cataract<br>subjects affected / exposed<br>occurrences (all)                          | 0 / 143 (0.00%)<br>0    | 1 / 116 (0.86%)<br>1   | 0 / 73 (0.00%)<br>0 |
| Gastrointestinal disorders<br>Abdominal Distension<br>subjects affected / exposed<br>occurrences (all) | 5 / 143 (3.50%)<br>5    | 3 / 116 (2.59%)<br>4   | 0 / 73 (0.00%)<br>0 |
| Abdominal Pain<br>subjects affected / exposed<br>occurrences (all)                                     | 15 / 143 (10.49%)<br>24 | 5 / 116 (4.31%)<br>5   | 4 / 73 (5.48%)<br>5 |
| Abdominal Pain Upper<br>subjects affected / exposed<br>occurrences (all)                               | 2 / 143 (1.40%)<br>2    | 2 / 116 (1.72%)<br>2   | 1 / 73 (1.37%)<br>1 |
| Colitis Ulcerative   |                         |                        |                     |

|  |                   |                   |                  |
|--|-------------------|-------------------|------------------|
| subjects affected / exposed            | 37 / 143 (25.87%) | 30 / 116 (25.86%) | 27 / 73 (36.99%) |
| occurrences (all)                      | 43                | 39                | 31               |
| Constipation                           |                   |                   |                  |
| subjects affected / exposed            | 5 / 143 (3.50%)   | 2 / 116 (1.72%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 5                 | 2                 | 0                |
| Diarrhoea                              |                   |                   |                  |
| subjects affected / exposed            | 13 / 143 (9.09%)  | 9 / 116 (7.76%)   | 4 / 73 (5.48%)   |
| occurrences (all)                      | 17                | 12                | 4                |
| Frequent Bowel Movements               |                   |                   |                  |
| subjects affected / exposed            | 0 / 143 (0.00%)   | 2 / 116 (1.72%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 0                 | 2                 | 0                |
| Nausea                                 |                   |                   |                  |
| subjects affected / exposed            | 9 / 143 (6.29%)   | 5 / 116 (4.31%)   | 1 / 73 (1.37%)   |
| occurrences (all)                      | 11                | 6                 | 1                |
| Rectal Haemorrhage                     |                   |                   |                  |
| subjects affected / exposed            | 2 / 143 (1.40%)   | 0 / 116 (0.00%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 2                 | 0                 | 0                |
| Vomiting                               |                   |                   |                  |
| subjects affected / exposed            | 6 / 143 (4.20%)   | 2 / 116 (1.72%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 7                 | 2                 | 0                |
| Hepatobiliary disorders                |                   |                   |                  |
| Hepatic Steatosis                      |                   |                   |                  |
| subjects affected / exposed            | 0 / 143 (0.00%)   | 1 / 116 (0.86%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 0                 | 1                 | 0                |
| Skin and subcutaneous tissue disorders |                   |                   |                  |
| Acne                                   |                   |                   |                  |
| subjects affected / exposed            | 1 / 143 (0.70%)   | 0 / 116 (0.00%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 1                 | 0                 | 0                |
| Eczema                                 |                   |                   |                  |
| subjects affected / exposed            | 2 / 143 (1.40%)   | 3 / 116 (2.59%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 4                 | 3                 | 0                |
| Papule                                 |                   |                   |                  |
| subjects affected / exposed            | 0 / 143 (0.00%)   | 0 / 116 (0.00%)   | 0 / 73 (0.00%)   |
| occurrences (all)                      | 0                 | 0                 | 0                |
| Pruritus                               |                   |                   |                  |

|   |                        |                        |                     |
|---|------------------------|------------------------|---------------------|
| subjects affected / exposed<br>occurrences (all)                    | 2 / 143 (1.40%)<br>2   | 3 / 116 (2.59%)<br>4   | 0 / 73 (0.00%)<br>0 |
| Rash<br>subjects affected / exposed<br>occurrences (all)            | 5 / 143 (3.50%)<br>5   | 3 / 116 (2.59%)<br>3   | 6 / 73 (8.22%)<br>7 |
| Skin Lesion<br>subjects affected / exposed<br>occurrences (all)     | 1 / 143 (0.70%)<br>2   | 0 / 116 (0.00%)<br>0   | 0 / 73 (0.00%)<br>0 |
| Musculoskeletal and connective tissue disorders                     |                        |                        |                     |
| Arthralgia<br>subjects affected / exposed<br>occurrences (all)      | 11 / 143 (7.69%)<br>13 | 10 / 116 (8.62%)<br>12 | 4 / 73 (5.48%)<br>4 |
| Back Pain<br>subjects affected / exposed<br>occurrences (all)       | 7 / 143 (4.90%)<br>9   | 6 / 116 (5.17%)<br>7   | 5 / 73 (6.85%)<br>6 |
| Infections and infestations   |                        |                        |                     |
| Bronchitis<br>subjects affected / exposed<br>occurrences (all)      | 4 / 143 (2.80%)<br>7   | 6 / 116 (5.17%)<br>7   | 0 / 73 (0.00%)<br>0 |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)        | 3 / 143 (2.10%)<br>3   | 4 / 116 (3.45%)<br>4   | 0 / 73 (0.00%)<br>0 |
| Ear Infection<br>subjects affected / exposed<br>occurrences (all)   | 4 / 143 (2.80%)<br>4   | 2 / 116 (1.72%)<br>2   | 0 / 73 (0.00%)<br>0 |
| Gastroenteritis<br>subjects affected / exposed<br>occurrences (all) | 5 / 143 (3.50%)<br>5   | 8 / 116 (6.90%)<br>9   | 2 / 73 (2.74%)<br>4 |
| Herpes Zoster<br>subjects affected / exposed<br>occurrences (all)   | 3 / 143 (2.10%)<br>3   | 5 / 116 (4.31%)<br>6   | 0 / 73 (0.00%)<br>0 |
| Influenza<br>subjects affected / exposed<br>occurrences (all)       | 10 / 143 (6.99%)<br>12 | 3 / 116 (2.59%)<br>5   | 6 / 73 (8.22%)<br>6 |
| Laryngitis  |                        |                        |                     |

|   |                   |                   |                |
|---|-------------------|-------------------|----------------|
| subjects affected / exposed             | 1 / 143 (0.70%)   | 0 / 116 (0.00%)   | 0 / 73 (0.00%) |
| occurrences (all)                       | 1                 | 0                 | 0              |
| Nasopharyngitis                         |                   |                   |                |
| subjects affected / exposed             | 27 / 143 (18.88%) | 32 / 116 (27.59%) | 5 / 73 (6.85%) |
| occurrences (all)                       | 52                | 55                | 10             |
| Oral Herpes                             |                   |                   |                |
| subjects affected / exposed             | 6 / 143 (4.20%)   | 0 / 116 (0.00%)   | 4 / 73 (5.48%) |
| occurrences (all)                       | 9                 | 0                 | 6              |
| Pharyngitis                             |                   |                   |                |
| subjects affected / exposed             | 3 / 143 (2.10%)   | 0 / 116 (0.00%)   | 3 / 73 (4.11%) |
| occurrences (all)                       | 3                 | 0                 | 3              |
| Rhinitis                                |                   |                   |                |
| subjects affected / exposed             | 2 / 143 (1.40%)   | 1 / 116 (0.86%)   | 0 / 73 (0.00%) |
| occurrences (all)                       | 2                 | 1                 | 0              |
| Sinusitis                               |                   |                   |                |
| subjects affected / exposed             | 8 / 143 (5.59%)   | 4 / 116 (3.45%)   | 1 / 73 (1.37%) |
| occurrences (all)                       | 15                | 5                 | 1              |
| Tonsillitis                             |                   |                   |                |
| subjects affected / exposed             | 3 / 143 (2.10%)   | 6 / 116 (5.17%)   | 1 / 73 (1.37%) |
| occurrences (all)                       | 4                 | 6                 | 2              |
| Upper Respiratory Tract Infection       |                   |                   |                |
| subjects affected / exposed             | 17 / 143 (11.89%) | 10 / 116 (8.62%)  | 4 / 73 (5.48%) |
| occurrences (all)                       | 26                | 17                | 4              |
| Urinary Tract Infection                 |                   |                   |                |
| subjects affected / exposed             | 6 / 143 (4.20%)   | 3 / 116 (2.59%)   | 1 / 73 (1.37%) |
| occurrences (all)                       | 9                 | 3                 | 1              |
| Viral Infection                         |                   |                   |                |
| subjects affected / exposed             | 3 / 143 (2.10%)   | 0 / 116 (0.00%)   | 0 / 73 (0.00%) |
| occurrences (all)                       | 3                 | 0                 | 0              |
| Viral Upper Respiratory Tract Infection |                   |                   |                |
| subjects affected / exposed             | 0 / 143 (0.00%)   | 3 / 116 (2.59%)   | 1 / 73 (1.37%) |
| occurrences (all)                       | 0                 | 3                 | 1              |
| Metabolism and nutrition disorders      |                   |                   |                |
| Iron Deficiency                         |                   |                   |                |

|                             |                 |                 |                |
|-----------------------------|-----------------|-----------------|----------------|
| subjects affected / exposed | 4 / 143 (2.80%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences (all)           | 4               | 0               | 0              |
| Vitamin D Deficiency        |                 |                 |                |
| subjects affected / exposed | 5 / 143 (3.50%) | 0 / 116 (0.00%) | 0 / 73 (0.00%) |
| occurrences (all)           | 6               | 0               | 0              |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date          | Amendment  |
|---------------|--|
| 14 July 2015  | To address health authority feedback and provide additional clarifications.  |
| 20 April 2016 | To address health authority requests for additional data collection as well as to address investigator feedback and to provide further clarifications on the protocol. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported